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ABSTRACT 
The purpose of this research was to examine the effects of mu (µ), 
kappa (K) and sigma (o) agents namely, morphine (µ), ethylketo-
cyclazocine ( K), SKF 10,047 ( o), pentazocine (K, o), cyclazocine (K, 
o) and the mu antagonists, naloxone and naltrexone on dopamine 
mediated behaviors and the development of haloperidol-induced 
dopaminergic supersensitivity (DA-SS) in the mouse. Three behavioral 
paradigms were utilized which are predictive of mesolimbic and/or 
striatal dopaminergic effects: locomotor activity (mesol imbic); 
apomorphine-induced stereotyped behavior (striatal) and apomorphine-
induced climbing behavior (mesolimbic/striatal). Morphine, SKF 10,047, 
pentazocine and cyclazocine produced increases in locomotor activity 
suggesting increased dopaminergic activity, while naloxone and 
naltrexone had no effect on locomotion. Ethylketocyclazocine (EKC) 
induced a biphasic effect of sedation followed by an increase in 
locomotor activity at three hours postadmi ni strati on. EKC and SKF 
10,047 antagonized apomorphine-induced climbing because of motor 
deficits, sedation and ataxia, respectively, while the other opiates 
had no effect. Only EKC inhibited apomorphine-induced stereotypy, due 
to initial motor deficits and sedation. Thus, these compounds were 
not dopamine antagonists, insofar as apomorphine-induced behaviors 
were only antagonized at debilitating doses which incapacitated mice. 
Furthermore, both EKC and SKF 10,047 increased locomotion, unlike 
neuroleptics which generally cause motor depression. 
The stimulant properties of the K and a opiates warranted further 
investigation. EKC at 5 mg/kg sc produced a biphasic effect over time 
with a peak effect from 180 to 210 minutes. EKC ( 5 mg/kg) hyper-
activity was dependent upon catecholamine synthesis and transmission 
since a -MPT (300 mg/kg), reserpine (5 mg/kg), tetrabenazine (5, 40 
mg/kg), haloperidol (1 mg/kg), apomorphine (0.1 mg/kg), muscimol (1 
mg/kg) and prazosin (2.5 mg/kg) blocked EKC-induced locomotor 
activity. SKF 10,047 at 40 mg/kg sc not only increased locomotor 
activity but also induced stereotypy and climbing behavior with an 
ED50 for climbing at 90 minutes equal to 14.6 mg/kg sc. SKF 10,047 
(40 mg/kg) -induced climbing was dependent on catecholamine trans-
mission and a direct serotonin receptor interaction since a -MPT (300 
mg/kg), tetrabenazine (5, 40 mg/kg), haloperidol (1 mg/kg), 
apomorphine (0.1 mg/kg), muscimol (1 mg/kg), prazosin (2.5 mg/kg) and 
methysergi de ( 10 mg/kg) antagonized this behavior. Both EKC-i nduced 
hyperactivity and SKF 10,047-induced climbing were not antagonized by 
naloxone (10, 100 mg/kg). Furthermore, naloxone, EKC and SKF 10,047 
potentiated apomorphine-induced climbing. 
The µ, 1c:;, CJ and mixed K, CJ agents all produced effects suggesting 
dopaminergic activity, i.e., locomotion, stereotypy, climbing and 
potentiation of apomorphine effects. Therefore, each was tested for 
its ability to attenuate haloperidol-induced DA-SS in the climbing and 
stereotyped behavior paradigms. In the acute climbing paradigm, 
haloperidol-induced DA-SS was dose-dependently attenuated by SKF 
10,047, EKC, cyclazocine, pentazocine, naloxone and naltrexone, with 
morphine inactive. In the chronic (5-day) climbing and stereotypy 
models, only the concomitant administration of either SKF 10,047 or 
cyclazocine and haloperidol inhibited the development of DA-SS, while 
morphine alone produced DA-SS. 
opiate modulation of DA-SS in 
These results suggest differential 
the acute vs. chronic paradigms. 
Furthermore, sigma 
haloperidol-induced 
properties. 
agonists were most effective in attenuating 
DA-SS, presumably through dopamine agonist 
ACKNOWLEDGMENTS 
I wish to express my appreciation and graditude to Hoechst-Roussel 
Pharmaceuticals, Inc. and the University of Rhode Island for the 
opportunity to continue my education and attain a Ph.D. in 
Pharmacology. Also, a special thanks to Ors. H. Lal, S. Fielding, D. 
Valentino and J. DeFeo for their encouragement, help and guidance. 
In addition, my thanks to Ms. Wendy Parker for her excellent 
secretarial assistance in the preparation of this dissertation. And 
above all, my most warm and sincere gratitude to Dr. Nancy Hutchinson-
Dunn for her devoted inspiration and understanding. 
v 
TABLE OF CONTENTS 
Abstract ... 
Acknowledgments 
Table of Contents 
List of Figures 
List of Tables 
I. General Introduction 
I I. Introduction - Literature Survey 
A. Nigrostriatal and Mesolimbic Dopamine Pathway 
1. The Nigrostriatal System 
2. The Mesolimbic System 
B. Functional Differentiation: Mesolimbic 
vs. Striatal ...... . 
i i 
v 
vi 
ix 
xi 
1 
4 
4 
4 
5 
5 
C. Dopaminergic Supersensitivity 14 
I I I. 
D. Opiate Receptor Subtypes 22 
E. Similarities of Opiate and Dopaminergic Agents -
Modulation of Dopaminergic Nigrostriatal and 
Mesolimbic Systems by Opiates 28 
F. Hypotheses 32 
Materials and Methods 
A. Acute Studies 
B. Acute Supersensitivity Studies 
c. Chronic Supersensitivity Studies 
D. Locomotor Activity Experiments 
E. Apomorphine-Induced Stereotypy 
F. Apomorphine-Induced Climbing 
G. SKF 10,047-Induced Climbing 
vi 
34 
34 
34 
34 
34 
35 
36 
37 
IV. 
H. Ethylketocyclazocine-Induced Hyperactivity 
I. Drugs 
Results 
A. Apomorphine-Induced Behaviors 
1. Locomotor Activity 
2. Stereotyped Behavior 
3. Climbing Behavior 
Page 
37 
38 
39 
39 
39 
39 
39 
B. Locomotor Activity •)f Opiate Subtypes in Mice 39 
C. Effects of Opiate Subtypes on Apomorphine-Induced 
Climbing and Stereotypy . . . . . . . . . . . . . 40 
D. The Effect of 72-Hour Pretreatment of Haloperidol 
(1.25 mg/kg): 
1. on Apomorphine-Induced Locomotor Activity 
2. on Apomorphine-Induced Stereotypy 
3. on Apomorphine-Induced Climbing . 
41 
41 
41 
E. The Effects of Simultaneous Administration of Opiate 
Agents and Haloperidol 72 Hours Prior to Apomorphine 
at 0.4 mg/kg sc in the Climbing Mouse Assay . . . 42 
F. The Effects of Chronic (5-Day) Haloperidol 
(1.25 mg/kg) Administration on Apomorphine-Induced 
Locomotor Activity . . . . . . . . . . . 43 
G. The Effects of Chronic (5-Day) Simultaneous 
Administration of Opiate Agents and Haloperidol 
72 Hours Prior to Apomorphine at 0.4 mg/kg sc on 
Stereotyped Behavior . . . . . . . . . . . . . 44 
H. The Effects of Chronic (5-Day) Simultaneous 
Administration of Opiate Agents and Haloperidol 
72 Hours Prior to Apomorphine at 0.4 mg/kg sc 
in the Climbing Mouse Assay . . . . . . . . . . 45 
I. Acute Interaction Effects of Apomorphine (0.4 mg/kg) and 
Either Naloxone, EKC or SKF 10,047 on Climbing Behavior 
in Mice . . . . . . . . . . . . . . . . . . . . . . . 46 
vii 
J. Ethylketocyclazocine-Induced Hyperactivity 
in Mice .............. . 47 
K. Effects of Various Blocking Agents on EKC-
Induced Hyperactivity . . . . . . . . . . . 47 
L. SKF 10,047-Induced Climbing Behavior in Mice 48 
M. Effects of Various Blocking Agents on SKF 10,047-
Induced Climbing Behavior 48 
V. Discussion 
VI. Conclusions 
VII. Figure Legends 1-20 
VIII. Figures 1-20 
IX. Tables 1-46 
X. References 
viii 
49 
77 
80 
84 
104 
161 
No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
List of Figures 
Mesolimbic and Nigrostriatal Dopamine Pathways 
Opiate Receptor Subtypes 
Prototypical Agonists, Antagonists and Mixed 
Page 
84 
Agonist-Antagonists . . . . . . . . . 85 
Chemical Structures of Morphine and its 
Antagonists ..... . 
Chemical Structures of Benzomorphans 
Opiate Receptor Subtypes 
Antinociceptive Activity - Behavioral Excitation 
Activity in Mice . . . . . . . . . . ... 
Effects of Apomorphine on Locomotor Activity 
Effects of Morphine on Locomotor Activity 
Effects of Naloxone on Locomotor Activity 
Effects of Naltrexone on Locomotor Activity 
Effects of Ethylketocyclazocine on Locomotor 
Activity . . . . . . . . . 
Effects of Pentazocine on Locomotor Activity 
Effects of Cyclazocine on Locomotor Activity 
Effects of SKF 10,047 on Locomotor Activity 
Effects of Acute Haloperidol Administration 
72 Hours Prior to Apomorphine on Locomotor Activity 
Effects of Chronic Haloperidol Administration 
72 Hours Prior to Apomorphine on Locomotor Activity 
Effects of Chronic Simultaneous Administration of 
Morphine and Haloperidol on Apomorphine-Induced 
Stereotyped Behavior ............. . 
Effects of Chronic Simultaneous Administration of 
Naltrexone and Haloperidol on Apomorphine-Induced 
Stereotyped Behavior ............. . 
ix 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
18. 
19. 
20. 
Effects of Chronic Simultaneous Administration 
of Ethylketocyclazocine and Haloperidol on 
Apomorphine-Induced Stereotyped Behavior ... 
Effects of Chronic Simultaneous Administration 
of Cyclazocine and Haloperidol on Apomorphine-
Induced Stereotyped Behavior . . . . . . . . . 
Effects of Chronic Simultaneous Administration 
of SKF 10,047 and Haloperidol on Apomorphine-
Induced Stereotyped Behavior . . . · · · · · · 
x 
101 
102 
103 
List of Tables 
No. 
1., la. Effects of Apomorphine on Locomotor Activity 104 
2. Apomorphine-Induced Stereotyped Behavior in Mice 106 
3. Apomorphine-Induced Climbing Behavior in Mice 107 
4., 4a. Effects of Morphine on Locomotor Activity 108 
5., Sa. Effects of Morphine on Locomotor Activity 110 
6., 6a. Effects of Naloxone on Locomotor Activity 112 
7., 7a. Effects of Naltrexone on Locomotor Activity 114 
8., 8a. Effects of Ethylketocyclazocine on Locomotor 
Activity . . . . . . . . . . . . 116 
9., 9a. Effects of Pentazocine on Locomotor Activity 118 
10., lOa. Effects of Cyclazocine on Locomotor Activity 120 
11., lla. Effects of SKF 10,047 on Locomotor Activity 122 
12. Effects of Acute Administration of Opiate 
Agonists, Antagonists and Mixed Agonist-Antagonists 
on Apomorphine-Induced Climbing in Mice . . 124 
13. Effects of SKF 10,047 and EKC on Apomorphine-
Induced Stereotypy . . . . . 125 
14., 14a. Effects of Acute Haloperidol Treatment on Apomorphine 
(0.4 mg/kg) -Induced Locomotor Activity . . . . 126 
15. Apomorphine-Induced Stereotyped Behavior Effects 
of Haloperidol (1.25 mg/kg) 72 Hours Pretreatment 128 
16. Haloperidol-Induced Supersensitivity in the Climbing 
Mice Assay . . . . . 129 
17. Climbing Mice Supersensitivity 
Simultaneous Administration of Vehicle and Opiate 
Agonists, Antagonists and Mixed Agonist-Antagonists 130 
xi 
No. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25., 25a. 
26. 
27. 
28. 
29. 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol 
and Opiate Agonists, Antagonists and Mixed 
Agonist-Antagonists . 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol 
and Naloxone . . . . . ... 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol 
and Naltrexone . . . . . . . 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol 
and EKC . . · · · · · 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol 
and Pentazocine . . . · . · · · · · 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol 
and Cyclazocine ............ . 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol 
and SKF 10 ,047 . . . . . · · · · · · · · · 
Effects of Chronic Haloperidol Treatment on 
Apomorphine (0.4 mg/kg) -Induced Locomotor 
Activity .. · · · · · · · · · · · · · · 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of Morphine 
(10 mg/kg sc) and Haloperidol (1.25 mg/kg ip) 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of Naltrexone 
(40 mg/kg sc) and Haloperidol (1.25 mg/kg ip) 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of EKC 
(20 mg/kg sc) and Haloperidol (1.25 mg/kg ip) . 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of Cyclazocine 
(2.5 mg/kg sc) and Haloperidol (1.25 mg/kg ip) 
xii 
131 
132 
133 
134 
135 
136 
137 
138 
140 
141 
142 
143 
No. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40. 
41. 
42. 
43. 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of SKF 10,047 
(40 mg/kg sc) and Haloperidol (1.25 mg/kg ip) . 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of Morphine 
and Haloperidol .............. . 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of Naloxone 
and Haloperidol .............. . 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of Naltrexone 
and Haloperidol ............ . 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of EKC 
and Haloperidol ............ . 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of Pentazocine 
and Haloperidol ................ . 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of Cyclazocine 
and Haloperidol ............... . 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of SKF 10,047 
and Haloperidol ........... . 
The Effects of Naloxone on Apomorphine-Induced 
Climbing Behavior ............. . 
The Effects of Ethylketocyclazocine on Apomorphine-
lnduced Climbing Behavior .......... . 
The Effects of SKF 10,047 on Apomorphine-Induced 
Climbing Behavior .............. . 
Induction of Hyperactivity in Mice by 
Ethylketocyclazocine at 5 mg/kg sc 
Ethylketocyclazocine-Induced Hyperactivity in Mice 
Ethylketocyclazocine-Induced Hyperactivity in Mice: 
Effects of Various Blocking Agents ..... 
xiii 
144 
145 
146 
147 
148 
149 
150 
151 
152 
153 
154 
155 
156 
157 
44. 
45. 
46. 
Induction of Climbing Behavior in Mice by 
SKF 10,047 at 40 mg/kg SC ..... 
SKF 10,047-Induced Climbing in Mice 
SKF 10,047-Induced Climbing in Mice: 
Effects of Various Blocking Agents ....... . 
xiv 
158 
159 
160 
1 
I. .GENERAL INTRODUCTION 
Schizophrenia is a psychosis which is characterized by dis-
ordered thinking and emotions while often accompanied by delusions and 
auditory hallucinations. The schizophrenic fluctuates rapidly between 
contradictory affects, thoughts and actions (Bleuler, 1950). The 
original theory of schizophrenia was the dopamine hypothesis which 
states that schizophrenia is related to dopamine hyperactivity in the 
central nervous system. This theory was based on the fact that 
phenothiazines and butyrophenones which have effective antipsychotic 
and tranquilizing effects in the clinic, are dopamine-receptor 
blockers (Carlsson and Linquist, 1963). Furthermore, amphetamine, 
which releases norepinephrine and dopamine and blocks catecholamine 
reuptake, can elicit psychotic symptoms in chronic schizophrenics 
(Janowsky and Davis, 1974) and also produces a paranoid psychosis in 
normal individuals which closely resembles paranoid schizophrenia 
(Angrist and Gershon, 1970). 
In recent years, experimental evidence in man and animals has 
shown that there is more to schizophrenia than simply an excess of 
dopamine activity. Studies of the neuroanatomy and physiology of the 
brain have revealed the dopamine system to be regulated by its own 
feedback mechanisms as well as by more complex interactions between 
this system and other neurotransmitters and neuromodul a tors. Recent-
ly, it was suggested that dopaminergic instability in psychosis may 
develop from an excess amount of feedback and modulation (King et al., 
1982). 
2 
An inherent problem with chronic neuroleptic treatment in the 
clinic and in animal experimentation is that it leads to dopamine 
receptor supersensitivity, manifest as extrapyramidal side effects and 
tardive dyskinesias in man and enhanced responsiveness to dopamine and 
its analogues in animals. Many strategies have been employed in an 
attempt to enhance the efficacy of neuroleptic therapy while mini-
mizing side effect liability and, in particular, the development of 
dopami nergi c supersens it i vity. Of particular interest are the reports 
that combined administration of antipsychotics and lithium (Gallager 
et al., 1978; Pert et al., 1978; Verimer et al., 1980; Seeger et al., 
1981), L-dopa and other dopamine agonists (Friedhoff et al., 1977; 
Ezrin-Waters and Seeman, 1978; Christensen and Nielsen, 1979; List and 
Seeman, 1979; Seeger et al., 1981; Reches et al., 1982) and naloxone 
(Seeger et al., 1980) have attenuated dopaminergic supersensitivity to 
varying degrees. 
It is possible that schizophrenia is not only associated with 
the dopaminergic system but may also be influenced by the opiate sys-
tem. There are many dynamic interrelationships both functionally and 
anatomically between the dopaminergic and opiate systems (Lal, 1975). 
Although the endorphinergic system may not play a primary role in the 
etiology of schizophrenia, the opiate receptor-antagonist naloxone has 
no deleterious effect and may possibly improve some symptoms of this 
disease in the clinic (Verebey et al., 1978; Watson et al., 1978; 
Pickar et al., 1982; Lo et al., 1983; Blum et al., 1984). Van Ree and 
De Wied (1981) proposed that dopamine overactivity or imbalance in 
schizophrenia may be linked to a disturbance in endorphinergic 
3 
homeostasis. Moreover, extra pyramidal movement disorders may be 
associated with either increases or decreases in endogenous opioid 
activity (Sandyk, 1985). If psychosis is a result of an instability 
of both dopamine and endogenous opiate systems, it is of interest to 
investigate the effects of combined treatment of haloperidol and 
various opiate receptor subtype agents, namely, mu, kappa and sigma 
(Martin et al., 1976) on the development of dopaminergic super-
sensitivity. The results of the studies in this dissertation may be 
relevant for the clinical treatment of schizophrenia, i.e., the 
amelioration of psychotic symptoms and side effects, as well as a 
better understanding of the nature of the interactions of dopamine and 
opiate systems in the development of dopaminergic supersensitivity. 
4 
II. INTRODUCTION - LITERATURE SURVEY 
A. The Nigrostriatal and Mesolimbic Dopamine Pathways 
The major pathways of dopaminergic neurons in the central ner-
vous system, namely, the nigrostriatal, mesolimbic and tubero-
infundibular systems, were originally mapped by histofluorescence 
and anterograde or retrograde degeneration techniques (Anden et 
al., 1965; Ungerstedt, 1971). In the study of schizophrenia, the 
nigrostriatal and mesol imbic areas appear to be primarily 
responsible for the extrapyramidal effects and the antipsychotic 
effects, respectively (Costall and Naylor, 1976; Crow et al., 
1977). 
1. The Nigrostriatal System (Figure 1) 
Anatomical and histochemical studies have shown that the 
nigrostriatal dopaminergic cell bodies originate in the A9 DA 
cell group in the zona compacta of the substantia nigra and 
its rostromedial extension in the ventral tegmental area, 
ascend adjacent to the lateral hypothalamus and terminate in 
the neostriatum or corpus striatum, i.e., the caudate nucleus 
and putamen (Anden et al., 1966; Ungerstedt, 1971; Cooper et 
al., 1978). Also, the axons from the A8 DA cell bodies caudal 
to the substantia nigra join the nigrostriatal system since 
they show retrograde degeneration after lesions of the corpus 
striatum (Ungerstedt, 1971). 
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2. The Mesolimbic System (Figure 1) 
Cell bodies in this pathway originate in the AlO cell 
group dorsocranial to the interpenducular nucleus of the 
ventral tegmental region and ascend closely but more medially 
with the axons of the ni grostri ata 1 system and terminate in 
the nucleus accumbens, the olfactory tubercle and the 
prefrontal cortical area (Anden et al., 1966; Ungerstedt, 
1971; Cooper et al., 1978). 
B. Functional Differentiation: Mesolimbic vs. Striatal 
In recent years, a generalized approach to antipsychotic 
effectiveness has been based on the relative effects of dopamine 
antagonists on the nigrostriatal and mesolimbic areas. Many of 
the extrapyrami da 1 effects of neural epti c treatment may be 
mediated by the effects in the basal ganglia, namely, the caudate, 
putamen and globus pallidus, while the antipsychotic effects may 
be mediated by the antidopaminergic effects in the mesolimbic and 
mesocortical areas. Although it is an oversimplification to state 
that psychosis is due to dopamine overactivity in a particular 
brain region such as the mesolimbic system, much research has been 
generated in an attempt to qualify and quantify the activity and 
adaptation of mesolimbic and striatal areas to dopaminergic 
agents. 
In general, animal studies have followed two approaches: ef-
fects following either intracerebrally or extracerebrally-adminis-
tered drugs. Dopamine appears to function as a mediator of 
various motor activities, in particular, locomotor and stereotyped 
6 
behavior. Pijnenburg and Van Rossum (1973) originally discovered 
that dopaminergic mechanisms within the nucleus accumbens regulate 
locomotor activity. Bilateral injection of dopamine (5 µg) into the 
nucleus accumbens of nialamide- (a monoamine oxidase inhibitor) 
pretreated rats resulted in a significant increase in locomotor 
activity compared to saline controls while noradrenaline- (5 µg) 
treated rats showed a slight enhancement of locomotion. On the other 
hand, bilateral injection of dopamine (25-100 µg) into the caudate-
putamen of nialamide-pretreated rats elicited strong stereotypy, 
especially chewing, biting and licking, whereas lower doses (6.25, 
12.5 µg) showed less intense behavior characterized by repetitive 
head and front limb movement and some chewing and biting (Costall et 
al., 1974). Furthermore, noradrenaline (100 µg) did not show 
hyperactivity or stereotypy in this paradigm. 
Further investigations revealed subtle functional differences 
between structures within the mesolimbic and striatal regions. 
Costall and Naylor (1975) showed that bilateral injection of dopa-
mine (1-200 µg) into the nucleus accumbens septi increased locomotor 
activity and caused stereotyped sniffing behavior while injections 
into the olfactory tubercle produced periodic hyperactivity but no 
stereotypy. Following pretreatment with nialamide, these effects 
were enhanced and biting and gnawing were observed in the olfactory 
tubercle-injected group. In addition, although there is a structural 
resemblance between the hydroxyl and nitrogen substituents of the 
dopamine agonist apomorphine and dopamine itself, apomorphine, which 
induced stereotyped biting following direct injection into the 
7 
caudate-putamen (Ernst and Smel ick, 1966), did not induce 
hyperactivity or stereotypy following intraaccumbens injection 
(Pijnenberg et al., 1976; Costall et al., 1977). These results 
suggested differential dopaminergic mediation of stereotyped 
responses emanating from the nucleus accumbens versus the caudate 
putamen. 
Additional evidence for predominant dopamine receptor mediation 
of hyperactivity and stereotyped be ha vi or in the nucleus accumbens 
and caudate-putamen (respectively) was reported by Costall et al. 
(1977). lntracerebral dopamine (6.25-50 µg) dose dependently 
increased these behaviors in their respective areas while 
intraperitoneal injections of haloperidol (0.2-0.8 mg/kg) blocked 
these effects and 10 mg/kg of either aceperone (an alpha-adrenergic 
antagonist) or propranolol (a beta-adrenergic antagonist) had no 
effect. Interestingly, intraaccumbens injections of alpha- and/or 
beta-adrenergic receptor agonists such as adrenaline, noradrenaline, 
which augments dopamine release (Rei sine et al., 1982), and 
isoprenaline were potent inducers of hyperactivity but to a lesser 
extent than dopamine (Costall et al., 1976; Vance and Blumberg, 
1983) and were inhibited only by intracerebral injection of the 
dopamine antagonist fluphenazine and not by either the alpha 
antagonist, piperoxan, or the beta antagonist, propranolol (Costall 
et al., 1976). It was concluded that hyperactivity mediated by the 
nucleus accumbens may not be specific for dopamine agonists; 
however, this behavior is specifically antagonized by dopamine 
blockade. 
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A copious amount of data related to mesol imbic versus striatal 
functioning has been generated by extracerebral administration of 
dopaminergic agents. Since metabolic breakdown and inability to 
penetrate the blood-brain barrier prevents systemic administration 
of endogenous amines, dopamine agonists and releasers such as apo-
morphine and amphetamine, respectively, serve as classical drugs in 
animal research. 
Following systemic administration, apomorphine and amphetamine 
induced a series of behaviora 1 effects characterized by stereotypy 
and hyperactivity (Randrup and Munkvad, 1967; Costall and Naylor, 
1977; Ljungberg and Ungerstedt, 1978). Drug interaction experi-
ments were employed to ascertain the relative importance of 
endogenous amines in amphetamine-induced locomotor activity and 
stereotyped behaviors. The tyrosine-hydroxalase inhibitor, alpha-
methyl-p-tyrosine, depletes brain noradrenaline and dopamine through 
synthesis inhibition and antagonizes amphetamine behavioral 
responses (Weissman et al., 1966; Stolz and Rech, 1970). However, 
if noradrenaline is selectively depleted by dopamine-beta-
hydroxylase inhibitors, there is little or no effect on amphetamine-
induced hyperactivity or stereotypy (Scheel-Kruger and Randrup, 
1967; Thornburg and Moore, 1973). Furthermore, following either 
systemic or intraaccumbens (but not intracaudate) injection, 
dopamine antagonists were more efficacious than noradrenaline 
antagonists in blocking amphetamine-induced locomotor activity in 
rodents (Rolinski and Scheel-Kruger, 1973; Pijnenburg et al., 1974). 
Also, systemic administration of neuroleptics dose-dependently 
antagonized 
and Naylor, 
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intraaccumbens dopamine-induced hyperactivity (Costall 
1976). In addition to antagonizing amphetamine and 
dopamine effects, dopamine antagonists have been shown to inhibit 
apomorphi ne-induced locomotion and gnawing ( Ljungberg and 
Ungerstedt, 1978). 
Although drug interaction experiments have provided valuable 
information concerning dopaminergic involvement in locomotion and 
stereotypy, lesioning techniques have been used to further delineate 
the brain areas which are functionally significant in the 
manifestation of these drug-induced behaviors. Basically, striatal 
or mesol imbic structures are destroyed by either electrolesions or 
6-hydroxydopamine (6-0HDA), a chemical analog of the catecholamines 
which selectively destroys dopaminergic and noradrenergic nerve 
fibers (Uretsky and Iversen, 1970). Interpretation of lesioning 
studies must be guarded because varying the size of a lesion in 
particular areas may yield diverse results as well as varying 
amounts of depletion of dopamine and norepinephrine. 
There is much evidence that dopaminergic neurons in the corpus 
striatum mediate amphetamine-induced stereotypy. Bilateral electro-
lytic lesions of the caudate (Divac, 1972; Fog, 1972) or globus 
pallidus (Costall and Naylor, 1975) and 6-0HDA lesions of either the 
caudate (Asher and Aghajanian, 1974; Creese and Iversen, 1974; 
Kelley et al., 1975), the globus pallidus (Costall and Naylor, 1977) 
or the substantia nigra (Creese and Iversen, 1972; 1973) all 
attentuate amphetamine stereotypy. On the other hand, both electro-
1 es ions and 6-0HDA lesions of the nucleus accumbens (Asher and 
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Aghananian, 1974; Kelley et al., 1975; Costall et al., 1979) and 
olfactory tubercle (Asher and Aghajanian, 1974; Costall and Naylor, 
1977) had no effect on the intense forms of amphetamine stereotypy, 
i.e., biting, gnawing, while slightly attenuating the sniffing 
component of this behavior. These studies suggested a striatal 
mediation of amphetamine-stereotyped behavior with little or no 
involvement of mesolimbic structures. 
The functional integrity of the mesolimbic system was essential 
for the expression of amphetamine hyperactivity. Both electrolytic 
and 6-0HDA lesions of the nucleus accumbens effectively reduced 
amphetamine-induced hyperactivity (Iversen et al., 1975; Kelley et 
al., 1975; Costall et al., 1979). By contrast, striatal lesions had 
little or no effect on this behavior. Electrolesions of the sub-
stantia nigra and caudate, as well as 6-0HDA lesions of the caudate, 
did not effect amphetamine hyperactivity (Costall and Naylor, 1973; 
Kelley et al., 1975; Costall et al., 1979). However, 6-0HDA lesions 
of the substantia nigra yielded apparently confusing results in that 
some groups reported no effect (Creese and Iversen, 1972; Brook and 
Iversen, 1975) wh i1 e others found a reduction in amphetamine hyper-
activity (Creese and Iversen, 1975; Roberts et al., 1975). The 
reduction of activity was most likely due to a dopaminergic 
disruption in the mesolimbic system since intranigral 6-0HDA not 
only reduced nigrostriatal dopamine but also mesolimbic dopamine due 
to the probable diffusion of drug into the AlO area following 
injection into the A9 cells, two areas of close proximity (Kelley et 
al., 1975; Costall and Naylor, 1977). 
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The interpretation of apomorphine-induced behaviors differs from 
amphetamine behaviors due to the difference in physiological 
responses to these drugs. Amphetamine acts presynaptically to 
release catecholamines and block reuptake, whereas apomorphine acts 
directly as an agonist at postsynaptic dopamine receptors {Ernst, 
1967). 6-0HDA lesions in the nigrostriatal system may result in an 
enhanced or "supersensitive" response to low intensity stereotypy, 
i.e., sniffing but not biting induced by peripherally-administered 
apomorphine, although contradictory findings have been reported. 6-
0HDA lesions of the caudate nucleus and substantia nigra resulted in 
an enhanced apomorphine-induced stereotyped behavior due to a super-
sensitivity of remaining intact dopamine receptors (Creese and 
Iversen, 1975; Kelley et al., 1975). On the other hand, 6-0HDA or 
electrolesions of the caudate have been reported to have no effect 
on apomorphine-induced stereotypy (Divac, 1972; Costall and Naylor, 
1973; 1977; Asher and Aghajanian, 1974) while lesions of the sub-
stantia nigra actually reduced this behavior (Baum et al., 1971; 
Costall et al., 1972; Loew and Vigouret, 1975). Also, both electro-
lytic and 6-0HDA lesions of the globus pallidus markedly reduced 
apomorphine stereotypy (Costall and Naylor, 1975; 1977; Loew and 
Vigouret, 1975). However, when 6-0HDA was administered intraven-
tricuarly to neonatal rats, a greater destruction of the nigrostri-
atal pathway resulted in an enhanced responsiveness to apomorphine-
induced locomotor activity and stereotypy while amphetamine 
responses were abolished (Creese and Iversen, 1973). These results 
suggested a supersensitivity to remaining intact dopamine receptors. 
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Experiments involving apomorphine-induced hyperactivity follow-
ing peripheral administration are even more debatable. Some 
investigators have reported hyperactivity following apomorphine 
administration (Maj et al., 1972; Iversen et al., 1975) while others 
showed no marked increase in locomotor activity (Costall and Naylor, 
1977). Differences in the equipment used to measure hyperactivity, 
i.e., photocell chambers vs. electromechanical sensors, may yield 
conflicting results. Additionally, apomorphine has narrow dose-
response and time-course "windows" for differentiating between 
locomotor vs. stereotyped behavior where stereotypy becomes the pre-
dominant apomorphine-induced behavior at higher dose levels. 
6-0HDA lesions of the nucleus accumbens (Iversen et al., 1975; 
Kelley et al., 1975) and olfactory tubercle (Costall and Naylor, 
1977) enhanced locomotor activity following apomorphine adminis-
tration. However, Kelley et al. (1975) reported that intraaccumbens 
lesions resulted in a significant reduction in dopamine levels in 
the olfactory tubercle. Furthermore, following a more selective 
intraaccumbens lesion, Costall and Naylor (1977) reported no change 
in apomorphine-induced hyperactivity. And lastly, whereas direct 
injection of apomorphine into the nucleus accumbens failed to 
initiate hyperactivity (Pijnenberg et al., 1976), direct injection 
into the olfactory tubercle increased locomotor activity in rats 
(Pijnenberg et al., 1976; Costall and Naylor, 1977). Therefore, 
apomorphine-induced hyperactivity depends upon the integrity of at 
least the olfactory tubercle and probably to some extent an intact 
nucleus accumbens within the mesolimbic system. 
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An alternative means for measuring apomorphine effects is the 
climbing mouse assay. Peripheral administration of apomorphine 
initiated rearing and cage climbing in mice (Hester et al., 1970; 
Costentin et al., 1975; Protais et al., 1976; Costall et al., 1978). 
This behavior is specific for apomorphine since other dopamine 
agonists such as d-amphetamine, piribedil, amatadine and L-dopa do 
not induce climbing behavior (Protais et al., 1976; Nohria, 1983). 
Apomorphine-induced climbing is mediated by dopaminergic receptors 
since this behavior is specifically antagonized by neuroleptics 
(Protais et al., 1976; Costall et al., 1978) and GABA agonists (Dunn 
et al., 1980) but not by alpha- or beta-adrenergic antagonists 
(Costal l et al., 1978). 
Lesions of mesol imbic and striatal areas have generated con-
flicting results. Costall and associates (1979) showed that elec-
trolytic lesions of the nucleus accumbens attenuated apomorphine-
induced climbing while Protais et al. (1976) showed no effect with 
the same lesion (although the extent of these lesions may have dif-
fered). In contrast, intraaccumbens 6-0HDA which decreased dopamine 
in the nucleus accumbens and olfactory tubercle, enhanced apo-
morphine climbing, probably due to a supersensitive response at in-
tact dopamine receptors in these areas (Costall et al., 1979b; 
1980). Similar disagreements between these investigators were 
observed following lesions of the striatum. Electrolytic striatal 
lesions either decreased (Protais et al., 1976) or had no effect 
(Costall et al., 1979) on apomorphine-induced climbing while 
intrastriatal 6-0HDA either enhanced this behavior (Protais et al., 
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1976) or had no effect (Costall et al., 1979b; 1980). Furthermore, 
spontaneous climbing behavior, like spontaneous locomotor activity, 
is reduced by either low doses of apomorphine (less than or equal to 
0.1 mg/kg) which act via presynaptic autoreceptors to decrease 
dopamine release (Strombom, 1975; Di Chiara et al., 1976; Costall et 
al., 1982) or by electrolesions of the caudate-putamen, nucleus 
accumbens or olfactory tubercle (Costall et al., 1982). Most 
probably, climbing behavior is modulated through mesolimbic as well 
as striatal dopaminergic neurons. 
C. Dopaminergic Supersensitivity 
Dopami nergi c supersens it i vity (DA-SS), i.e., enhanced respon-
siveness to dopamine or its analogues, is a well-established bio-
chemical and pharmacological phenomenon following either chronic 
neuroleptic treatment or lesioning of dopaminergic nerve tracts 
(for reviews, see Owen, 1980; Rupniak et al., 1983). In man, 
chronic blockade of dopamine receptors in patients treated with 
classical neuroleptics may lead to the appearance of tardive 
dyskinesias (Klawans and Rubovits, 1972). Tardive dyskinesias, 
believed to be the result of overactive dopaminergic systems, are 
characterized by stereotyped, repetitive and involuntary movements 
of the mouth, lips and tongue, occasionally accompanied by 
choreiform movements of the limbs and trunk (Burki, 1979b). 
Various biochemical and behavioral animal models have proved to be 
predictive of an antipsychotic's liability for producing DA-SS. 
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Biochemical indices for DA-SS include receptor binding studies 
and the measurement of dopamine metabolites. Chronic neuro l ept i c 
treatment results in an increase in striatal dopamine receptor popu-
lations (Bmax) labelled by the tritiated dopamine antagonists 3H-
haloperidol and 3H-spiperone in rats (Burt et al., 1977; Hitri et 
al., 1978; Theodorou et al., 1981) and by 3H-pimozide in mice 
(Schwartz et al., 1978). However, changes in affinity (Ko) for the 
dopamine receptor was controversial (probably due to differing 
methodologies) with a reported no change (Burt et al., 1977), 
decrease (Schwartz et al., 1978; Theodorou et al., 1981) and in-
crease (Hitri et al., 1978). Also, some investigators have reported 
either no effect (Hitri et al., 1978) or increases (Theodorou et 
al., 1981; Hall et al., 1983) in mesolimbic dopamine receptor popu-
lations following chronic neuroleptic treatment. Likewise, 6-0HDA 
lesions of the nigrostriatal (Creese et al., 1977; Goldstein et al., 
1980) and mesol imbic (Goldstein et al., 1980) systems resulted in 
increases of dopamine receptors in these regions. 
Increase in dopamine receptor population following chronic anti-
psychotic treatment is directly related to compensatory changes in 
dopamine synthesis and release. The major indices of dopamine turn-
over are its principle metabolites, 4-hydroxy-3-methoxyphenylacetic 
acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), indicative of 
extraneuronal enzymatic degradation by catechol-o-methyl transferase 
and intraneuronal metabolism by monoamine oxidase, respectively 
(Roffler-Tarlov et al., 1971). Acute neuroleptic administration 
produced a biphasic effect in metabolite levels where initial in-
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creases in striatal HVA and DOPAC levels are followed by a return to 
control levels at 2 to 3 days and then an eventual decrease in 
metabolic concentrations {Hyttel, 1977; Martres et al., 1977). In 
addition, 72 hours after the administration of 4 mg/kg haloperidol, 
there was an increased ability of apomorphine to lower HVA levels 
{Martres et al., 1977). 
Chronic haloperidol treatment resulted in tolerance to striatal 
dopamine turnover as reflected by an attenuation of the large in-
creases in HVA and DOPAC levels seen following acute treatment 
{Lerner et al., 1977; Burki, 1979a; Meller et al., 1980; Nicolaou, 
1980; Melamed et al., 1983). However, 7 days after chronic haloper-
i do 1 treatment, apomorphine still showed an increased ability to 
lower HVA levels {Smith et al., 1977) similar to acute treatment 
{Martres et al., 1977). These metabolic effects following acute and 
chronic haloperidol treatment have also been observed in mesolimbic 
areas, i.e., nucleus accumbens and olfactory tubercle {Matsumoto et 
al., 1983). Although, neuroleptic treatment enhances dopamine turn-
over, it appears that dopamine concentration remains the same due to 
corresponding increases in the rates of synthesis and release 
{Melamed et al., 1983); however, decreases in dopamine concentra-
tions have also been reported {Hyttel, 1975). 
The increase in dopamine turnover following acute neuroleptic 
administration is attributable to a blockade of presynaptic auto-
receptors which regulate dopamine rel ease and/or postsynapt i c 
receptor blockade as well as negative feedback mechanisms or loops 
{Snyder et al., 1974; Iversen et al., 1976). Tolerance following 
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chronic neuroleptic treatment may be due to adaptational processes 
at neuroleptic sites which result from an incomplete blockade of the 
increased number of dopamine receptors, decreased negative feedback 
and effects on tyrosine hydroxylase kinetics (Lerner et al., 1977; 
Meller et al., 1980; Melamed et al., 1983). 
The findings and conclusions of these metabolic studies were 
further substantiated by electrophysiological studies. Following 
acute neuroleptic administration, extracellular recordings of neur-
onal activity in the A9 (substantia nigra) and AlO (ventral tegmen-
tal area) areas of the rat brain showed an increase in both the fir-
ing rate of dopamine neurons and the number of active neurons that 
could be identified (Bunney et al., 1973). This increased firing 
rate correlates with an increase in dopamine turnover. It was post-
ulated, similar to the metabolic studies, that this increase was due 
to autoreceptor blockade, postsynaptic blockade and the nigrostri-
atal feedback loop's attempt to maintain homeostasis. On the other 
hand, chronic neural epti c treatment resulted in an al most complete 
absence of spontaneous firing of dopamine neurons, a silence due to 
the gradual development of a depolarization block (Bunney and Grace, 
1978). This tonic depolarization block appeared to be mediated by 
the nigrostriatal feedback pathways and caused by the initial in-
creases in the activity of dopamine neurons. 
While these biochemical and electrophysiological events are oc-
curring at the neuronal level, corresponding behavioral activities 
can be observed which are predictive of DA-SS. The most commonly 
used methods for assessing dopamine receptor hypersensitivity 
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involve measurement of increased locomotor activity and stereotyped 
behavior following administration of dopamine agonists. As earlier 
described, increased locomotor activity and stereotypy following 
chronic neuroleptic administration would be indicative of DA-SS in 
mesolimbic and striatal areas, respectively. 
The results of supersens i ti vity experiments involving locomotor 
activity are controversial. Animals were chronically administered 
neuroleptics and following withdrawal, spontaneous locomotor activi-
ty and/or dopamine agonist-induced motor activity were measured. 
While some investigators reported increases in spontaneous motor ac-
tivity in rats or mice after termination of chronic administration 
of "typical" neuroleptics such as haloperidol, chlorpromazine, 
penfluridol and alpha-flupenthixol (Jackson et al., 1975; Von 
Voigtlander et al., 1975; Shakian et al., 1976; Gianutsos and Moore, 
1977; Gianutsos et al., 1978; Hulperin et al., 1983), others report-
ed no difference compared to controls (Tarsy and Baldessarini, 1974; 
Smith and Davis, 1976; Dunstan and Jackson, 1977; Costall and 
Naylor, 1978; Davis et al., 1978). Also, chronic administration of 
the atypical neuroleptics, clozapine and thioridazine, has either 
enhanced (Smith and Davis, 1976) or had no effect ( Gi anutsos and 
Moore, 1977) on spontaneous motor activity. 
Equally as confusing were the results when dopamine agonists or 
releasers were peripherally administered following chronic neurolep-
ti c treatment. Whereas some groups found either increased apomor-
phine-i nduced locomotion (Gianutsos and Moore, 1977; Gianutsos et 
al., 1978; Montanaro et al., 1982; Fayle et al., 1985) or increased 
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ct-amphetamine-induced locomotion (Von Voigtlander et al., 1975; 
Dunstan and Jackson, 1977; Gianutsos et al., 1978), others reported 
either no difference or slight decreases compared to controls 
(Sahakian et al., 1976; Smith and Davis, 1976; Dunstan and Jackson, 
1977; Costall et al., 1978; Rupniak et al., 1983). 
The most reliable model for studying locomotor activity involved 
direct injection of dopamine through cannulae into the nucleus ac-
cumbens. This procedure consistently showed increased locomotion in 
animals treated chronically with neuroleptics (Jackson et al., 1975; 
Davis et al., 1978; Moore et al., 1980; Halperin et al., 1983). 
Direct injection of dopamine yielded site-specific activity (meso-
1 imbic supersensitivity) while peripheral injection of dopamine ag-
onists results in a whole spectrum of peripheral as well as central 
nervous system effects which may mask or interfere with locomotor 
activity per se. 
On the other hand, enhanced stereotyped behavior in response to 
systemic administration of dopamine agonists following chronic 
neuroleptic treatment showed a more consistent and robust effect re-
ported by numerous laboratories (Klawans and Rubovits, 1972; Tarsy 
and Baldessarini, 1974; Sahakian et al., 1976; Costall et al., 1978; 
Gianutsos et al., 1978; Nielsen et al., 1978; Waddington and Gamble, 
1980; Montanaro et al., 1982). In addition, Christensen and his 
associates (1976) reported DA-SS as measured by methylphenidate- and 
apomorphine-induced gnawing after a single administration of various 
neuroleptics. The high intensity components of apomorphine-induced 
stereotyped behavior included gnawing, licking and biting while the 
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lower intensity responses included sniffing and some locomotion. 
Direct injection of dopamine into the striatum and in particular, 
the caudate putamen, after chronic neuroleptic administration also 
resulted in an enhanced stereotypic response compared to controls 
(Jackson et al., 1975; Moore et al., 1980; Halperin et al., 1983). 
In comparison, striatal DA-SS as measured by apomorphine-induced 
stereotyped behavior is a more consistent and reliable model than 
mesolimbic supersensitivity as measured by locomotor activity fol-
lowing chronic antipsychotic treatment. Direct injection of dopa-
mine into either the striatum or nucleus accumbens proved to be 
reliable models for detection of striatal and mesolimbic DA-SS, 
respectively. However, these models are somewhat tedious and cumber-
some. 
DA-SS, as measured by the apomorphine-induced climbing mouse as-
say, has been shown to be a predictive model. Enhanced responsive-
ness to apomorphine as measured by climbing behavior was observed in 
all reported studies 48-72 hours following either acute (Costentin 
et al., 1975; Protais et al., 1976; Martres et al., 1977) or chronic 
(Von Voigtlander et al., 1975; Protais et al., 1976; Day and 
Greenblatt, 1979; Wilcox et al., 1980) neuroleptic treatment. The 
climbing mouse assay appears to be particularly sensitive for meas-
urement of DA-SS since both acute and chronic dopamine receptor 
blockade resu1ts in an increased dopamine receptor sensitivity 
whereas neither locomotor activity nor stereotyped behavior has con-
sistently shown DA-SS after acute treatment. 
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Thus, it appears that a consequence of neuroleptic treatment is 
the development of dopamine receptor supersensitivity as measured by 
various behavioral or biochemical techniques in animals and the 
physical manifestation of tardive dyskinesias in man. It was of in-
terest to various laboratories to attempt to attenuate DA-SS by 
means of a concurrent treatment of certain compounds in combination 
with anti psychotics. It was demonstrated that chronic admi n i stra-
ti on of either direct or indirect dopaminergic agonists such as apo-
morphine, L-dopa/carbidopa, amantadine and bromocriptine, in combin-
ation with haloperidol, significantly reversed the increase in 3H-
neuroleptic binding in the striatum (Friedhoff et al., 1977; List 
and Seeman, 1979; Allen et al., 1980; Reches et al., 1982), the 
increase in adenylate cyclase activity (Friedhoff et al., 1977) and 
the enhanced stereotyped activity induced by apomorphine 
(Christensen and Nielsen, 1979; Allen et al., 1980). It was also 
reported that the combination of L-dopa and haloperidol partially 
prevented the development of ventral tegmental intracranial self-
stimulation (ICSS) supersensitivity (Seeger et al., 1981). There-
fore, the administration of dopamine agonists counteracted the abil-
ity of dopamine antagonists to induce DA-SS. 
In addition, chronic lithium in combination with haloperidol was 
reported to either attenuate (Pert et al., 1978) or have no effect 
(Staunton et al., 1982a) on the haloperidol-induced increase in 3H-
spi roperi dol binding, decreased the enhanced effect of apomorphi ne-
i nduced stereotyped behavior (Pert et al., 1978; Staunton et al., 
1982b), partially prevented the development of ventral tegmental 
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ICSS supersensitivity (Seeger et al., 1981) and blocked the 
development of presynaptic DA-SS as measured either 
electrophysiologically (Gallager et al., 1978) or behaviorally by 
the low dose apomorphine-induced inhibition of locomotor activity 
(Verimer et al., 1980). 
It has been demonstrated that neuroleptic-induced DA-SS can be 
attenuated by concomitant administration of dopamine agonists or 
lithium. Knowing that opiate systems share certain anatomical and 
functional properties with dopaminergic systems, might 
simultaneous treatment of an opiate agent with haloperidol be 
prophylactic in the development of DA-SS? 
D. Opiate Receptor Subtypes 
The concept of multiple opiate receptors {summarized in Figure 
2; structures Figures 3, 4) has evolved over the years from 
pharmacological observations of differences seen between the 
various analgesic agents. The landmark studies in this area were 
performed by Martin and his coworkers {Gilbert and Martin, 1976; 
Martin et al., 1976). On the basis of neurophysiological and 
behavioral evidence in the dog, Dr. Martin postulated that there 
were three different opiate receptors in the central nervous 
system, namely, µ {mu), K {kappa) and a {sigma) receptors, repre-
sented by the prototype drugs, morphine, ketocycl azoc i ne and N-
a 11 yl normetazoc i ne {SKF 10,047), respectively. Although there are 
other endogenous opiate receptors which preferentially interact 
with enkephalins and endorphins, namely, delta {o) and epsilon {E) 
receptors; they will not be covered in this dissertation. 
23 
The morphine syndrome (µ) was characterized by miosis, 
bradycardia, hypothermia and analgesia. The ketocyclazocine and 
ethylketocyclazocine syndrome (K) was associated with pupillary con-
striction, decreased flexor reflexes and sedation. SKF 10,047 (er) 
caused mydriasis, tachypnea, tachycardia and mania or "canine 
delirium" which was proposed to be the equivalent of psychotomimetic 
effects in man. 
Martin's group extended these studies and observed the ability 
of these agents to precipitate and suppress signs of abstinence in 
both morphine- and cyclazocine-dependent, chronic spinal dogs. 
Antagonists were 1/20 to 1/60 as potent in precipitating abstinence 
in the cyclazocine-, compared to the morphine-dependent dog. It was 
also observed that the ketocyclazocine and cyclazocine (K, er agon-
ist; µ antagonist) precipitated abstinence syndromes were qualita-
tively similar to each other but different from the morphine 
abstinence syndrome. SKF 10,047 precipitated (suggesting antagonist 
activity at the µ receptor) while morphine suppressed the abstinence 
syndrome in morphine-dependent dogs. On the other hand, ethylketo-
cycl azocine neither suppressed nor precipitated wi thdrawa 1 in 
morphine-dependent dogs; however, it did suppress the cyclazocine 
abstinence syndrome. On the basis of these findings, ethylketo-
cyclazocine could not be an agonist, partial agonist or competitive 
antagonist at the morphine receptor. It was inferred that both 
ethylketocyclazocine and cyclazocine must produce their agonistic 
action at another receptor. Furthermore, ethylketocyclazocine's 
actions were different from those of N-allylnormetazocine. 
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Therefore, Martin postulated the existence of 3 separate opiate 
receptors. 
Recently, much evidence has been generated which supports this 
3-receptor theory while some findings are to the contrary. In-vivo 
evidence obtained from antinociceptive testing in rats and mice show 
that when chemical agents were the nociceptive stimuli, bothµ and K 
agonists were effective (Tyers, 1980; Ward and Takemori, 1983). 
However, K -agonists were more potent against pressure nociception 
than against heat nociception while the converse was true for µ-
agonists (Tyers, 1980; Sewell et al., 1981; Upton et al., 1982; 
1983). SKF 10,047 (CJ agonist) had potent antinociceptive activity 
in chemically-induced writhing (Pasternak et al., 1981; Aceto and 
May, 1983) but was inactive against heat (Aceto and May, 1983) and 
pressure nociception (Dunn, unpublished observation). 
The prototypic opiate compounds also have differential effects 
on locomotor activity. Morphine (µ-agonist), pentazocine ( K , CJ -
agonist, µ-antagonist), cyclazocine (K, CJ -agonist, µ-antagonist) and 
SKF 10,047 (CJ-agonist, µ-antagonist) increased locomotor activity 
(Rethy et al., 1971; Holtzman and Jewett, 1972; 1973; Iwamoto, 1981) 
whereas ketocyclazocine and ethylketocyclazocine ( K -agonist, µ-
antagonists) decreased 1 ocomot ion (Tepper and Woods, 1978; Iwamoto 
1981). Naloxone and naltrexone either had no effect (Parker, 1974) 
or slightly decreased locomotor activity (Castellano and Puglisi-
Allegra, 1982). Only morphine-induced locomotion was antagonized by 
naloxone or naltrexone (Rethy et al., 1971; Iwamoto, 1981) while the 
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other agents were insensitive to the µ antagonists (Holtzman and 
Jewett, 1972; 1973; Iwamoto, 1981). 
Interestingly, decreased brain catecholamine levels were noted 
following morphine-, pentazocine- and cyclazocine-induced locomotion 
(Rethy et al., 1971; Holtzman and Jewett, 1972; 1973). Furthermore, 
the catecholamine synthesis inhibitor, alpha-methyltyrosine, blocked 
the increased locomotor activity induced by these compounds (Buxbaum 
et al., 1973; Holtzman and Jewett, 1972; 1973). Also, spiperone 
(0.03 mg/kg), a postsynaptic dopamine-receptor blocker and apomor-
phine (0.1 mg/kg), a presynaptic dopamine inhibitor at this dose, 
attenuated morphine- and SKF 10,047-induced locomotor activity 
(Iwamoto, 1981). These results suggested that mu- and sigma-agonist-
induced locomotor activity may be dependent on catecholamine 
transmission and, more specifically, dopaminergic transmission 
(antinociceptive and locomotor activity for opiate subtypes are 
summarized in Figure 5). 
Characterization of three receptor subtypes was possible by 
concomitant testing of two in-vivo models. In the flurothyl-induced 
seizure test in rats, µ and cr agonists raised seizure thresholds, K 
agonists had no effect, while in the rat Y-maze test, the behavioral 
profiles of µ and K agonists could be differentiated from SKF 10,047 
(cr) and cyclazocine (K/ cr ) (Cowan, 1981). In drug discrimination 
models measuring generalization and antagonism, rat and monkey data 
generally support the three-receptor theory (Teal and Holtzman, 
1980; Herling and Woods, 1981). Finally, cortical EEG spectral 
analysis has been employed as a sensitive tool to delineate 
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qualitative and quantitative similarities and differences between 
theµ, and opiate agents (Young et al., 1981). 
Perhaps some of the more compelling evidence for the existence 
ofµ, K and cr receptors can be found in the in-vitro studies. In 
the last few years, there has been considerable controversy concern-
ing theµ, K and cr receptors. The type of tissue used in the assay 
is of utmost importance. It has been shown that rabbit vas deferens 
contains K receptors exclusively and does not respond to µ or cr 
agonists (Oka et al., 1980). It was originally thought that the 
guinea pig ileum contained mainly µ receptors and the mouse vas 
deferens contained mainly µ and o (delta) opiate receptors (Lord et 
al., 1977). It has now been shown that ethylketocyclazocine is a 
pure agoni st in the guinea pig ileum and mouse vas deferens and 
effectively antagonizes selective µ agonists in the rat vas deferens 
(Gillan et al., 1981). 
Receptor binding studies using CNS tissues have provided more 
concrete results. Initial sudies using 3H-ethylketocyclazocine in 
competitive binding assays concluded there were no distinct K 
receptors (Chang et al., 1980; Hiller and Simon, 1980). Chang et 
al. (1980) suggested that K agonists have agonistic activity toward 
µ and o receptors whereas cr agonists were agonists at cr receptors 
and antagonists at µ receptors. In a 1 ater study, when ( D-Al a2, D-
LeuS) enkephalin and morphiceptin were added in concentrations which 
occupied 98% of the enkephalin (o ) and morphine (µ) receptors, 3H-
diprenorphin binding was only partially inhibited (Chang et al., 
1981). Therefore, a third binding site exhibited high affinity for 
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several benzomorphan drugs (cyclazocine, ethylketocyclazocine, SKF 
10,047, etc.). Wood and coworkers (1981) i dentified a K receptor in 
rat brain where 3H-ethylketocyclazocine binding was potently dis-
placed by ~, partial µ and agonist-antagonist analgesics while µ, 6 , 
and a receptor agonists were much less active at this binding site. 
In a study using 3H-cyclazocine, 3H-ethylketocyclazocine and 3H-
SKF 10,047 and various other agents, competitive displacement and 
kinetic analysis revealed 3 cyclazocine binding sites (in order of 
decreasing affinity): 1) µreceptor, 2) a non-µ, non- a binding site 
(which may represent the K receptor) and 3) a putative a receptor 
(Zukin and Zukin, 198la). Other displacement studies in rat brain 
suggested the existence of distinct binding sites for K - and a -
opiates which differed from morphine (µ) and enkephalin (6 ) binding 
sites (Wolozin et al., 1982). In another series of studies, it was 
suggested that the a receptor and the PCP {phencyclidine) binding 
site may be one in the same (Zukin and Zukin, 198lb) with the (+)-
isomers of N-allylnormetazocine and cyclazocine being highly 
specific sigma opiate/PCP ligands (Zukin et al., 1984; Mendelsohn et 
al., 1985; Sircar et al., 1986). This may explain why behaviorally 
PCP and sigma agonists produce similar psychotomimetic effects. 
However, other investigators have shown a distinction between sigma 
and PCP binding sites in mice, rat and guinea pig brains (Su, 1982; 
Tam, 1983; Martin et al., 1984; Gundlach, 1985; Downes et al., 
1986). 
Behavioral and biochemical data suggest the existence of 
multiple opiate receptors. Discovery and development of specific 
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1 igand antagonists for each receptor subtype would be beneficial 
in clarifying the presence, both functionally and anatomically, of 
specific mu, kappa and sigma receptors. 
E. Similarities of Opiate and Dopaminergic Agents - Modulation of 
Dopaminergic Nigrostriatal and Mesolimbic Systems by Opiates 
The opiate and dopaminergic systems share certain 
interrelationships, both functionally and anatomically, 
dynamic 
in the 
central nervous system and, especially in the nigrostriatal and 
mesolimbic systems. Functionally, both morphine and haloperidol 
induce catalepsy in rats which can be antagonized by apomorphine 
or benztropine (Lal et al., 1975). However, there was a qual ita-
tive difference in the catatonia; neuroleptic-induced catalepsy 
was marked by muscular hypotoni a whereas hyperton i a characterized 
narcotic-induced catatonia (Wauquier et al., 1974). Likewise, the 
endogenous opiates, 13 -endorphi n, met-enkephal in and 1 eu-enkepha-
1 in, produced sedation and catalepsy following microinjection into 
the periaqueductal gray in rats (Jacquet and Marks, 1976). 
Narcotics and neuroleptics effectively block either apomorphine or 
amphetamine-induced stereotypy in the rat and L-dopa and ampheta-
mine-induced jumping in mice, as well as apomorphine-induced 
emesis in dogs (Lal et al., 1975). Moreover, morphine and 
haloperdol antagonized apomorphine-induced aggression in the rat, 
apomorphine- and amphetamine-induced aggression in mice and 
morphine withdrawal aggression in rats (Lal et al., 1975). 
Motivational behavior such as lateral hypothalmic self-stimulation 
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in rats was also effectively blocked by haloperidol and morphine 
(Wauquier et al., 1974). 
On the other hand, whereas opiate agonists as well as 
neuroleptics antagonized dopamine-dependent behaviors, opiate 
antagonists such as naloxone potentiated apomorphine- and 
amphetamine-induced behaviors. Naloxone has been reported to 
potentiate apomorphine-induced hyperthermia in rabbits (Quock, 
1977), the anticataleptic effect of L-dopa in reserpinized mice 
(Namba et al., 1980), the antitremor effect of L-dopa in 
oxotremorine-treated mice (Quock and Lucas, 1983), apomorphine-
induced turning in rats with unilateral electrocoagulation lesion of 
the substantia nigra (Quock and Welsh, 1980), apomorphine-induced 
climbing in mice (Quock and Lucas, 1981; Quock et al., 1983) and 
apomorphine- and cl-amphetamine-induced stereotypy in rats (Adams et 
al., 1981). 
Biochemical binding techniques have shown these behaviors are 
probably not a result of the direct action of opiate agents on 
dopamine receptors since the acute administration of opiates had no 
effect on 3H-neuroleptic binding (Burt et al., 1976; Puri et al., 
1978; Carlson and Seeger, 1981; 1982). Conversely, acute haloperi-
dol showed competitive binding to the opiate receptor similar to an 
opiate agonist while other butyrophenones bind and resembled 
antagonists or mixed agonist-antagonists (Creese et al., 1976). 
Hence, opiates do not directly act as antagonists at dopamine 
receptor sites but neuroleptics may act at opiate receptor sites. 
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These opiate receptor sites were biochemically demonstrated by 
3H-naloxone binding to be located in large amounts in rat brain with 
the greatest concentration in the corpus striatum (Pert and Snyder, 
1973). Opiate and enkephalin receptors have been located 
presynaptically on dopamine neurons in the mesolimbic (Pollard et 
al., 1977a) and striatal (Pollard et al., 1977b) systems, respec-
tively. In fact, the highest concentration of enkephalins was found 
in the globus pallidus followed by the caudate nucleus and the 
nucleus accumbens (Hong et al., 1977). Furthermore, biochemical 
(Pollard et al., 1978) and autoradiographic techniques (Murrin et 
al., 1980) have shown that one-third of the striatal opiate recep-
tors are located presynaptically on dopamine neurons while two-
thirds of the opiate receptors are located on intrinsic neurons with 
the majority of these making postsynaptic contact with dopamine 
neurons. Since opiate and enkephal in receptors and neurons are in 
close proximity and contact with dopamine neurons in the striatal 
and mesolimbic systems, they may serve to modulate dopaminergic 
transmission in these areas. 
Additional evidence for opiate regulation of dopaminergic 
processes was reported following chronic morphine administration. 
Iwamoto and his associates (1973) found that following chronic 
morphine pellet implantation in mice, naloxone-induced withdrawal 
jumping behavior was accompanied by an increase in dopamine levels 
with the greatest elevation occurring in the corpus striatum while 
norepinephrine and serotonin levels remained relatively constant. 
Chronic morphine treatment has also led to the development of 
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postsynaptic DA-SS as measured by apomorphine-induced stereotyped 
behavior in rats (Cox et al., 1976) and guinea pigs (Carlson and 
Almasi, 1978); apomorphine-induced aggression in rats (Puri and Lal, 
1973; Gianutsos et al., 1974); apomorphine-induced locomotion in 
rats (Bhargava, 1980) and apomorphine-induced climbing in mice 
(Baume et al., 1979; Martin and Takemori, 1986). Also, repeated 
intraventricular injections of beta-endorphin in rats resulted in 
the development of DA-SS (Bhargava, 1°Sl). 
Biochemically, chronic administration of morphine was similar to 
haloperidol in that an initial rise in HVA levels was followed by a 
significant decrease for severa 1 days (Bau me et al • , 1979). One 
explanation for the diminished activity of dopamine neurons was due 
to the increased activity of the feedback loop when the postsynaptic 
receptors became hypersensitive to dopamine (Martres et al., 1977). 
Also, apomorphine caused a greater reduction in dopamine turnover in 
morphine-dependent rats (Kuschinsky, 1975; Gianutoss et al., 1974; 
Puri et al., 1977) suggesting DA-SS and probable supersensitive 
presynaptic dopamine autoreceptors (Kuschinsky, 1975). Unlike 
haloperidol-induced DA-SS where there was an increase in dopamine 
receptors (Burt et al., 1977), chronic morphine treatment was 
reported to either decrease (Puri et al., 1978), slightly increase 
(Baume et al., 1979) or have no effect (Carlson and Seeger, 1982) on 
3H-neuroleptic binding. However, a recent study showed that chronic 
morphine administration in mice resulted in a significant increase 
in 3H-spiroperidol binding sites in whole brain (Martin and 
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Takemori, 1986). Also, there may be an increase in affinity, 
although fewer binding sites (Puri et al., 1978; Bhargava, 1983). 
It would appear that dopaminergic transmission is modulated to 
some extent by the opiate system, especially in the nigrostriatal 
and mesolimbic areas. Since morphine and haloperidol display some 
similar behavioral and biochemical effects with each capable of 
eliciting DA-SS, might dopamine metabolism be modified by mu 
antagonists and/or non-mu opiates in such a way to down regulate 
the dopamine system? Namely, since naloxone has been shown to 
potentiate certain dopaminergic mediated behaviors and because 
simultaneous administration of dopamine agonists with dopamine 
antagonists compensates for the development of DA-SS, would the 
concomitant administration of mu antagonists with the dopamine 
antagonist, haloperidol, attenuate DA-SS? What effects would the 
kappa agonist, ethylketocyclazocine or the sigma agonist, SKF 
10,047 (agents which also possess mu antagonistic properties) have 
on the development of haloperidol-induced DA-SS? This disseration 
investigates these possibilities using both acute and chronic 
behavioral paradigms predictive of mesolimbic and striatal 
dopaminergic activity, namely locomotor activity and stereotyped 
behavior, respectively, as well as the climbing mouse model. 
F. Hypotheses 
The following hypotheses will be investigated concerning the 
mediation of the dopamine receptor by the opiate receptor subtype 
agents, particularly concerning the development of haloperidol-
induced dopaminergic supersensitivity (DA-SS). The opiate receptor 
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subtype agents specifically investigated include: the mu agonist, 
morphine; the mu antagonists, naloxone and naltrexone; the mixed 
kappa, sigma agonists and mu antagonists, pentazocine and 
cyclazocine; the kappa agonist and mu antagonist, ethylketo-
cyclazocine; and the sigma agonist and mu antagonist, N-
allylnormetazocine (SKF 10,047). 
1. Opiates are not dopamine-receptor antagonists and therefore, 
will not attenuate apomorphine-induced climbing and stereotyped 
behaviors in mice. 
2. Opiates which stimulate catecholamine neuronal activity will 
cause either increased locomotor activity (indicative of 
mesolimbic activity), stereotypy (indicative of striatal 
activity) or climbing behavior (indicative of mesol imbic and/or 
striatal activity) in mice. 
3. The acute and/or chronic simultaneous administration of the 
opiate receptor subtype agents and haloperidol will attenuate 
the development of dopaminergic supersensitivity as measured by 
apomorphine-induced climbing and stereotyped behavior in mice. 
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MATERIALS AND METHODS 
For all experiments, male C0-1 albino mice (Charles River) weigh-
ing 20-30 g were used. They were group housed (20 per cage) in a room 
where the temperature was 22 + 10 C with lights on between 6 a.m. and 
6 p.m. Food and water were available ad libitum. All experiments were 
carried out between 10 a.m. and 4 p.m. 
Acute Studies. 
Following a one-hour acclimation period, compounds were adminis-
tered to male mice (C0-1) and tested for their effects on either 
locomotor activity, stereotypy or climbing behavior. 
Acute Supersensitivity Studies. 
Each opiate agent was simultaneously administered sc with 
haloperidol ip to male mice (C0-1) 72 hours before testing. Controls 
were given appropriate treatments. Mice were then group housed (9 per 
cage) until test day under the standard laboratory conditions detailed 
above. 
Chronic Supersensitivity Studies. 
Each opiate agent was simultaneously administered sc with 
haloperidol ip to male mice (C0-1) for 5 days. Controls were given 
appropriate treatments. Mice were group housed (9 per cage) until 
test day, 72 hours after 1 ast dosing under the standard 1 abora tory 
condtions detailed above. 
Locomotor Activity Experiments. 
Locomotor activity was measured on electromagnetic sensors 
(Stoelting Co. #13404) in sound-attenuated chambers. C0-1 male mice 
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were placed in opaque plastic cages (2 mice per cage) measuring 10.5" 
x 8" x 6" which rested upon each sensor. Fa 11 owing a one-hour 
adaptation or exploratory period where mice became acclimated to their 
cages, each animal was administered drug and testing commenced. 
To measure the effects of individual opiate agents, mice were 
administered drug sc, then activity was assessed immediately after 
injection for 6 hours. To measure supersensitivity effects of acute 
and chronic pretreatment of haloperidol, apomorphine HCl was 
administered sc, then activity was measured for 2 hours. The combined 
activity of each pair of mice provided activity counts. The counts 
were recorded by a Data General Nova 2/10 computer within 15-minute 
intervals over the first 2 hours of testing, then at hourly intervals 
for the remaining 4 hours during the 6-hour test. These counts were 
transformed into square-root values to normalize the data and to make 
the means and variances independent, with the resulting variances 
homogeneous. Contra 1 scores were com pa red with scores from compound-
treated subjects using a one-way analysis of variance (ANOVA) followed 
by a Dunnet's multiple comparison (Kirk, 1968) on a DEC (Digital 
Equipment Corporation) PDP 11/10 computer. 
Apomorphine-lnduced Stereotypy. 
Prior to injection, CD-1 male mice were placed in clear plastic 
cages (2 mice per cage) measuring 10.5" x 8" x 6" and were allowed to 
acclimate for 60 minutes. For antagonism studies, compounds were 
administered ip 30 minutes before apomorphine at 1.5 mg/kg sc. For 
acute and chronic supersensitivity studies, 72 hours following 
appropriate treatments (and one hour after cage acclimation), mice 
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received apomorphine at 0.4 mg/kg sc. In both designs, mice were 
scored for stereotypy during 2-minute observation periods at 10, 20 
and 30 minutes after injection. Scores were assigned according to the 
following rating scale modified from Costall et al. (1972): 0 -normal 
behavior, mice essentially the same as before injection; 1 -locomotor 
activity and sniffing; 2 - discontinuous locomotor activity, rearing, 
intense, continuous sniffing, licking and gnawing. 
Stereotypy scores were individually totaled (maximum score = 6 per 
mouse over 3 readings) and tranformed into square-root values to 
normalize the data and to make the means and variances independent, 
with the resulting variances homogeneous. Control scores were compared 
to scores from compound-treated subjects by a one-way ANOVA fo 11 owed 
by the Duncan's multiple range test by using a SAS (Statistical 
Analysis System) program on an IBM 3033 computer. 
Apomorphine-Induced Climbing. 
Prior to injection, CD-1 male mice were placed individually in 
wire mesh test cages measuring 4" x 4" x 10" and were a 11 owed to 
acclimate for 60 minutes. For antagonism studies, compounds were 
administered 30 minutes before apomorphine at 1.5 mg/kg sc. For 
potentiation studies, compounds were administered prior to apomorphine 
at either 0.4 or 0.8 mg/kg sc. For acute and chronic supersensitivity 
studies, 72 hours following appropriate treatments (and one hour after 
cage acclimation), mice received apomorphine at 0.4 mg/kg sc. In both 
designs, mice were scored for climbing activity during observation 
periods at 10, 20 and 30 minutes after injection. Scores were 
assigned according to the following rating scale (Protais et al., 
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1976): 0 - no climbing, 4 paws on bottom of cage; 1 - rearing, 2 paws 
clinging to the side of the cage; 2 - full climbing, 4 paws clinging 
to the side or top of the cage. 
Climbing scores were individually totaled (maximum score = 6 per 
mouse over 3 readings) and transformed into square-root values to 
normalize the data and to make the means and variances independent, 
with the resulting variances homogeneous. Control scores were compared 
to scores from compound-treated subjects by a one-way ANOVA followed 
by the Duncan's multiple range test by using a SAS program on an IBM 
3033 computer. 
SKF 10,047-Induced Climbing Behavior. 
Same as above for apomorphine-induced climbing where SKF 10,047 
was administered sc. ED50 values with 95% confidence limits were 
calculated by linear regression analysis. For antagonism studies, SKF 
10,047 at 40 mg/kg sc was administered 90 minutes before testing. 
Compounds were administered at appropriate pretreatment times. 
Ethylketocyclazocine-Induced Hyperactivity. 
Same as above for apomorphine-induced climbing where 
ethylketocyclazocine was administered sc and hyperactivity, not 
climbing, was measured. Hyperactivity scores were assigned according 
to the following rating scale: 0 - no locomotor activity, animal in 
resting position on the bottom of the cage; 1 - locomotion and 
circling, confined to the bottom of the cage; 2 - more continuous 
locomotion on bottom and sides of cage. For antagonism studies, 
ethylketocyclazocine at 5 mg/kg sc was administered at 180 minutes 
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before testing. Compounds were administered at appropriate pretreat-
ment times. 
Drugs. 
The following drugs were used in these studies: apomorphine HCl 
(Merck), haloperidol (McNeil), alpha-methyl-para-tyrosine (Sigma), 
atropine (Sigma), bicuculline (Regis), clonidine HCl (Boehringer), 
cyclazocine (Sterling-Winthrop), ethyl ketocyclazocine (Sterling-
Winthrop), methyl sergide (Sandoz), :.iuscimol (Regis), N-allyl-
normetazocine (NIDA), naloxone (Endo), naltrexone (Endo), pentazocine 
(Sterling-Winthrop), dl-p-chlorophenylalanine methyl ester HCl 
(Sigma), propranolol HCl (Ayerst), phentolamine HCl (Ciba), prazosin 
(Pfizer), reserpine (Aldrich), tetrabenazine (Hoffman-La Roche) and 
yohimbine (Sigma). 
Drugs which were not water soluble were suspended in distilled 
water and one drop of Tween 80, i.e., haloperidol, ethylketo-
cyclazocine, dl-p-chlorophenylalanine methyl ester, prazosin and 
yohimbine. Cyclazocine, N-allyl-normetazocine and pentazocine were 
solubilized in distilled water with the addition of one drop of lactic 
acid and pH adjusted with 0.25 N NaOH. The final volume was prepared 
to account for the sa 1 t content and the dosage is expressed as 100% 
base. The injection volume was 10 ml/kg. 
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RESULTS 
Apomorphine-induced behaviors. Locomotor Activity. Genera 11 y, apo-
morphi ne at 1.5 and 5 mg/kg produced slight but not significant 
increases in locomotor activity in mice over the first hour (14% to 
21%) following subcutaneous administration with 1 ittl e or no effect 
during the second hour (Table 1, Fig. 6). 
Stereotyped behavior. Apomorphi ne dose-dependently increased stereo-
typed behavior in mice at doses from 0.3 mg/kg to 3.0 mg/kg with an 
ED50 equal to 0.80 (0.76-0.84) mg/kg sc (Table 2). At the lower 
doses, locomotion and sniffing were prevalent while at the higher 
doses, discontinuous activity was marked by intense sniffing, rearing, 
licking and gnawing. 
Climbing behavior. Apomorphine at doses from 0.3 to 3.0 mg/kg 
produced climbing beha vor in mice characterized by elongated, 
deliberate and sustained verticalization in the wire mesh stick cages. 
The ED50 value for climbing was 0.58 (0.55-0.61) mg/kg sc (Table 3). 
Locomotor activity of opiate subtype agents in mice. Morphine at 2.5, 
5 and 10 mg/kg produced dose-dependent increases from 23% to 41% in 
locomotor activity, during the first hour of testing and increases 
from 79% to 101% during the second hour where these increases were 
significant (Table 4, Fig. 7). These increases in locomotion were 
consistently seen at higher doses (Table 5) and would correspond to 
the characteristic "morphine mania" observed in rodents. In general, 
the mu antagonists, naloxone (Table 6, Fig. 8) and naltrexone (Table 
7, Fig. 9) at doses from 10 to 40 mg/kg had no effects on locomotor 
activity. The kappa agonist, mu antagonist ethylketocyclazocine (EKC) 
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at 5, 10 and 20 mg/kg showed an interesting biphasic effect on 
locomotor activity in mice (Table 8, Fig. 10). At 5 mg/kg, initial 
significant decreases in locomotion (with almost complete cessaton of 
activity at 30 minutes) over 75 minutes were followed by increases 
which peaked between three (+46%) to four hours (+85%). At the higher 
doses (10 and 20 mg/kg), decreased activity lasted for three hours 
followed by increases beginning at four hours and lasting throughout 
the six hours of testing. The mixed kappa and sigma agonists, mu 
antagonists, pentazocine and cyclazocine, enhanced locomotor activity 
beginning at about 30 minutes for the first two to three hours of 
testing (Table 9, Fig. 11 and Table 10, Fig. 12, respectively). 
Pentazocine at doses from 20 to 80 mg/kg increased activity by 27% to 
78% while cyclazocine at doses from 2.5 to 10 mg/kg augmented 
locomotion by 33% to 112% compared to controls. This hyperactivity 
was followed by slight decreases in activity at five hours for 
pentazocine and at four hours for cyclazocine. On the other hand, the 
prototype sigma agonist, SKF 10,047 at 10 to 40 mg/kg produced an 
increase in locomotor activity from 15 minutes through five hours 
(Table 11, Fig. 13). The hyperactivity ranged from 25% to 86% over 
control levels of locomotion. 
Effects of opiate subtype agents on apomorphine-induced climbing and 
stereotypy. It was of interest to determine the acute effects of 
opiate agents on the reliable and consistent apomorphine-induced 
behaviors (apomorphine did not produce reliable increases in 
locomotion), namely climbing and stereotypy. Morphine, naloxone, 
naltrexone, pentazocine and cyclazocine had no effect on apomorphine 
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(1.5 mg/kg) -induced climbing behavior. However, EKC at 20 mg/kg and 
SKF 10,047 at 40 mg/kg significantly decreased the maximal climbing 
induced by apomorphine at 1.5 mg/kg by 52% and 25%, respectively 
(Table 12). General depressive effects including ataxia and flaccidity 
were observed following EKC and SKF 10,047 administration, which may 
have interfered with the ability of the mice to climb. However, in 
both cases the lower doses of EKC and SKF 10,047, namely 5 and 10 
mg/kg, respectively, had no significant effects on climbing. EKC and 
SKF 10,047 at the doses which were active in attenuating apomorphine-
induced climbing, were then tested for their effects on apomorphi ne-
i nduced stereotyped behavior. EKC at 20 mg/kg significantly 
attenuated apomorphine-induced stereotypy while SKF 10,047 at 40 mg/kg 
had no effect {Table 13). 
The effect of 72-hour pretreatment of haloperidol (1.25 mg/kg) on 
apomorphine-induced locomotor activity. There was no significant 
effect of 72-hour haloperidol pretreatment on apomorphine-induced 
locomotor activity {Table 14, Fig. 14). 
The effect of 72-hour pretreatment of haloperidol (1.25 mg/kg) on 
apomorphine-induced stereotypy. There was no significant effect of 
72-hour haloperidol pretreatment on apomorphine-induced stereotyped 
behavior {Table 15). 
The effect of 72-hour pretreatment of haloperidol (1.25 mg/kg) on 
apomorphine-induced climbing. Ha 1 operi dol 72 hours prior to 
apomorphine at 0.4 mg/kg sc significantly increased climbing 
{approximate two-fold increase) compared to vehicle controls {Table 
16). 
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The effects of simultaneous administration of opiate agents and 
haloperidol 72 hours prior to apomorphine at 0.4 mg/kg sc in the 
climbing mouse assay. Since acute pretreatment (72 hours) of 
ha 1 operi do 1 produced an enhanced responsiveness or supersens it i vity to 
apomorphine-induced climbing (CMA-SS), the effects of various opiate 
agents on this behavior was investigated. The concurrent treatment of 
these agents and vehicle {72 hours pretreatment) had no significant 
effects on apomorphine-induced climbing behavior (Table 17). However, 
every agent except morphine had a significant effect on attenuating 
the enhanced responsiveness to ha l operi dol pretreatment on 
apomorphine-induced climbing (Table 18). Simultaneous administration 
of haloperidol at 1.25 mg/kg and either naloxone at 20 mg/kg, 
naltrexone at 20 mg/kg, EKC at 20 mg/kg, pentazocine at 80 mg/kg, 
cyclazocine at 1.25 and 5 mg/kg or SKF 10,047 at 10 and 40 mg/kg 
significantly reduced CMA-SS by 44%, 51%, 56%, 42%, 53% and 64%, or 
54% and 75%, respectively (Table 18). 
Dose-response relationships were assessed for those agents which 
effectively attenuated haloperidol-induced supersensitivity (Tables 19 
to 24). Generally, increasing doses of naloxone (Table 19), naltrexone 
(Table 20), EKC (Table 21), pentazocine (Table 22), cyclazocine (Table 
23) and SKF 10,047 (Table 24) resulted in an increased suppression of 
haloperidol-induced supersensitivity in the climbing mouse assay 
whereas these agents alone did not significantly effect this behavior 
(Tables 19 to 24). 
Increasing doses of naloxone (5 to 20 mg/kg) in combination with 
haloperidol, dose-dependently decreased {37% to 62%) the enhanced 
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responsiveness to apomorphi ne fo 11 owing ha 1 operi dol pretreatment 
(Table 19). Likewise, naltrexone at doses from 5 to 20 mg/kg dose-
dependently decreased CMA-SS by 34% to 59% (Table 20). The combina-
tion of EKC with haloperidol was also effective in attenuating the 
enhanced responsiveness to apomorphine following haloperidol treatment 
alone (Table 21). Although the effects of EKC at doses from 2.5 to 20 
mg/kg were variable, significant reduction of CMA-SS was seen at 5 
mg/kg (-35%) and 20 mg/kg (-57%) without any observed overt depressive 
effects. 
The mixed kappa and sigma agonists, pentazocine and cyclazocine 
each dose-dependently decreased haloperidol-induced CMA-SS although 
cyclazocine was more potent. Pentazocine at doses from 20 to 80 mg/kg 
decreased CMA-SS from 29% to 63% (Table 22) while cyclazocine 
attenuated CMA-SS at doses from 1.25 to 5 mg/kg by 32% to 55% (Table 
23). The prototype sigma agonist, SKF 10,047 also effectively reduced 
ha 1 operi do 1-i nduced CMA-SS by 39% to 75% at doses between 5 and 40 
mg/kg (Table 24). 
The effects of chronic (5-day) haloperidol (1.25 mg/kg) administration 
on apomorphine-induced locomotor activity. Although there was a 
slight increase (15%) in apomorphine (0.4 mg/kg) -induced locomotor 
activity during the first hour of testing following chronic 
haloperidol treatment, this effect was not statistically significant 
(Table 25, Fig. 15). 
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The effects of chronic (5-day) simultaneous administration of opiate 
agents and haloperidol 72 hours prior to apomorphine at 0.4 mg/kg sc 
on stereotyped behavior. Chronic treatment of haloperidol at 1.25 
mg/kg per day for five days resulted in approximately twice the amount 
of stereotyped behavior fo 11 owing apomorph i ne at 0.4 mg/kg, com pa red 
to vehicle-treated controls (Tables 26-30, Figs. 16-20). Chronic 
morphine at 10 mg/kg per day for five days also produced a 
significantly enhanced stereotyped response ( +117% compared to 
control) to apomorphine (Table 26, Fig. 16). However, when morphine 
was simultaneously administered with ha 1 operi dol, the enhanced effect 
(+117%) was not additive and was essentially the same as the chronic 
haloperidol group (+144%) and the chronic morphine-haloperidol group 
(+150%, Table 25). When naltrexone at 40 mg/kg was chronically 
administered, it had no effect on apomorphine stereotypy compared to 
vehicle controls (Table 27, Fig. 17). Also, naltrexone did not 
attenuate haloperidol-induced enhancement of apomorphine stereotypy 
(Table 27, Fig. 17). Likewise, chronic EKC at 20 mg/kg either alone 
or in combination with haloperidol had no effect in this paradigm 
(Table 28, Fig. 18). 
On the other hand, both chronic cyclazocine and SKF 10,047 
effectively attenuated haloperidol-induced supersensitivity in the 
stereotypy model. Apomorphine (0.4 mg/kg) -induced stereotypy was 
enhanced by 137% in the chronic haloperidol group and only enhanced by 
58% in the cyclazocine (2.5 mg/kg) -haloperidol group when compared to 
the vehicle control group (Table 29, Fig. 19). In comparing the mean 
stereotypy scores (x of veh.-haloperidol = 5.63; x of cyclazocine-
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haloperidol = 3.75), there was a 33% reduction in supersensitivity 
which was statistically significant (Table 29). The combination of 
chronic SKF 10,047 at 40 mg/kg and haloperidol was most effective in 
significantly reducing haloperidol-induced supersensitivity by 61% to 
control levels (Table 30, Fig. 20). 
The effects of chronic (5-day) simultaneous administration of opiate 
agents and haloperidol 72 hours prior to apomorphine at 0.4 mg/kg sc 
in the climbing mouse assay. Chronic morphine at doses from 2.5 to 10 
mg/kg resulted in an enhanced responsiveness (53% to 76%) to 
apomorphine in the climbing assay although this effect was not 
significant (Table 31). However, when morphine was simultaneously 
administered with ha 1 operi do 1, there was no further enhancement of 
apomorphine-induced climbing seen after haloperidol alone (Table 31). 
The concurrent administration of chronic naloxone (5 to 40 mg/kg) and 
haloperidol had no effect on haloperidol-induced CMA-SS (Table 32). 
However, chronic naltrexone at doses from 2.5 to 40 mg/kg slightly 
decreased (11% to 46%) haloperidol-induced CMA-SS although this effect 
was not statistically significant (Table 33). 
The chronic simultaneous administration of EKC at 5 to 20 mg/kg 
and haloperidol resulted in a consistent (although non-significant) 
suppression (40% to 49%) in the enhanced climbing response to 
apomorphine seen after haloperidol alone (Table 34). Five-day 
administration of EKC alone had variable effects on the climbing 
behavior (Table 34). The mixed agonist-antagonist, pentazocine (10 to 
80 mg/kg) had no effect on haloperidol-induced CMA-SS (Table 35) while 
chronic cyclazocine at doses from 0.38 to 3 mg/kg significantly 
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reduced (by 38% to 49%) the enhanced responsiveness of apomorphine 
following chronic haloperidol to control levels (Table 36). On the 
other hand, chronic cyclazocine and vehicle had no effect in this 
paradigm (Table 36). The sigma agonist, SKF 10,047 dose-dependently 
attenuated haloperidol-induced CMA-SS (Table 37). At doses from 5 to 
40 mg/kg, haloperidol-induced CMA-SS was decreased from 33% to 76% 
while chronic SKF 10,047 alone had no effect on apomorphine-induced 
climbing behavior in this paradigm. 
Acute interaction effects of apomorphine (0.4 mg/kg) and either 
naloxone, EKC or SKF 10,047 on climbing behavior in •ice. Naloxone 
alone at 1, 3 and 10 mg/kg did not induce climbing behavior in mice 
(Table 38). However, when naloxone at 3 and 10 mg/kg ip was simul-
taneously administered with apomorphine at 0.4 mg/kg sc, there was a 
slight potentiation in climbing from 25% climbing in the apomorphine 
group to 46% climbing in the apomorphine-plus-naloxone group (Table 
38). EKC alone at 3 and 10 mg/kg 180 minutes after administration, 
produced hyperactivity after an initial depression unlike the 
prolonged stereotyped climbing seen after apomorphine (Table 39). 
This hyperactivity was not similar to either amphetamine or morphine 
hyperactivity in that the mice did not limit their locomotion to 
circling on the bottom of the cage as with amphetamine or exhibit the 
"running fit" of persistant circling accompanied by Straub tail as 
observed with morphine (unpublished observations). EKC-induced 
hyperactivity was characterized by quick, sporadic running up and down 
vertically in the cage and episodes of stereotypic rearing and sniff-
ing. The combination of EKC and apomorphine resulted in a slight 
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increase in climbing behavior compared to apomorphine controls (27% 
climbing compared to 33% to 42%). SKF 10,047 at 10 mg/kg induced a 
climbing response ( +33%) at 90 minutes resembling the deliberate and 
sustained stereotypic climbing seen after apomorphine alone (Table 
40). Mice were initially ataxic for the first 30 minutes after 
administration, then followed stereotyped behavior characterized by 
vocalization, excessive grooming and sniffing, then rearing and 
finally climbing approximately 75 to 90 minutes post administration. 
The combination of SKF 10,047 (1 to 10 mg/kg) and apomorphine produced 
an approximate additive climbing response compared to apomorphine 
controls (Table 40). 
Ethyl ketocyclazocine-induced hyperactivity in mice. Since EKC admi n-
i stration produced hyperactivity after an initial decrease in 
locomotor activity, a time response was run over six hours to deter-
mine the duration of locomotor activity in the wire mesh stick cages. 
EKC was administered at 5 mg/kg sc in mice. Onset of hyperactivity 
occurred at 120 to 150 minutes with peak activity (47%) at 180 to 210 
minutes, followed by a gradual decrease in activity to six hours 
(Table 41). Then EKC was administered at doses from 1.25 to 10 mg/kg 
and the E050 for hyperactivity measured 180 minutes after 
administration was equal to 7.1 mg/kg sc (Table 42). 
Effects of various blocking agents on EKC-induced hyperactivity. The 
following agents had no effect on EKC-induced hyperactivity at 5 mg/kg 
sc: naloxone, bicuculline, yohimbine, clonidine, propranolol, PCPA, 
methysergide and atropine although PCPA at 300 mg/kg antagonized the 
hyperactivity by 46%, it was not statistically significant (Table 43). 
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The following catecholaminergic blockers and depleters significantly 
an-tagonized EKC-induced hyperactivity (Table 43): haloperidol at 1 
mg/kg (-54%), apomorphine at 0.1 mg/kg (-65%), muscimol at 1 mg/kg (-
63%), alpha-methyl-para-tyrosine at 300 mg/kg (-81%), phentolamine at 
10 mg/kg (-47%), prazosin at 2.5 mg/kg (-97%), reserpine at 5 mg/kg (-
74%) and tetrabenazine at 5 and 40 mg/kg (-81% and -90%, 
respectively). 
SKF 10,047-induced climbing behavior in mice. As previously des-
cribed, SKF 10,047-induced a climbing response similar to that of 
apomorphine-induced climbing. SKF 10,047 was administered at 40 mg/kg 
sc and climbing was measured from 30 to 180 minutes after dosing 
(Table 44). Onset of climbing began at 30 minutes with peak effect at 
90 minutes {72%) and then the climbing gradually waned. Then SKF 
10,047 was administered at doses from 3 to 30 mg/kg and the ED50 for 
climbing determined 90 minutes after administration was equal to 14.6 
mg/kg sc (Table 45). 
Effects of various blocking agents on SKF 10,047-induced climbing 
behavior. The following agents had no effect on SKF 10,047-induced 
climbing behavior: naloxone, bicuculline, yohimbine, clonidine, 
propranolol, PCPA, atropine and reserpine (Table 46). The following 
blockers significantly antagonized SKF 10,047-induced climbing activ-
ity (Table 46): haloperidol at 1 mg/kg (-73%), apomorphine at 0.1 
mg/kg (-64%), muscimol at 1 mg/kg (-89%), alpha-methyl-para-tyrosine 
at 300 mg/kg (-97%), phentolamine (-37%) and prazosin at 2.5 mg/kg 
(-90%), methysergide at 10 mg/kg (-66%) and tetrabenazine at 5 and 40 
mg/kg (-75% and -97%, respectively). 
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DISCUSSION 
Just as dopaminergic supersensitivity (DA-SS) is a well-
established behavioral and biochemical phenomenon following dopamine 
receptor blockade by neuroleptics, the fact that endorphinergic agents 
such as morphine and endorphin are capable of inducing DA-SS (Puri and 
Lal, 1973; Gianutsos et al., 1974; Cox et al., 1976; Carlson and 
Almasi, 1978; Baume et al., 1979; Bhargava, 1981; Martin and Takemori, 
1986) is an intriguing consequence of how disruption of endorphinergic 
homeostasis can effect dopamine-dependent behaviors. This di sserta-
tion dealt with how the various exogenous opiate receptor subtype 
agents, namely mu (µ), kappa (K) and sigma (a ) agonists, influenced 
dopaminergic systems, specifically in the development of haloperidol-
induced dopamine receptor supersensitivity. 
It has also become apparent that there are two major dopamine 
receptor subtypes: D-1 receptors involved in the stimulation of 
adenyl ate cyclase activity and D-2 receptors which act independently 
of the enzyme and which, in some tissues, inhibit adenylate cyclase 
activity (Kebabian and Calne, 1979; Sibley et al., 1982; Creese, 
1985). Clinically, effective neuroleptics such as haloperidol, possess 
a nanomolar potency for displacement of tritiated ligand at D-2 
receptor sites and a micromolar potency at D-1 receptor sites (Creese 
et al., 1982). Neuroleptics also antagonize apomorphine-induced behav-
ioral effects which primarily reflect activation of D-2 receptor sites 
(Randrup and Munkvad, 1974; Creese et al., 1983). However, recent 
evidence suggests that dopaminergic behaviors may be mediated through 
D-1 receptors or be expressed by complex functional interactions 
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between D-1 and D-2 receptors in the brain (Mailman et al., 1984; 
Molloy and Waddington, 1984, 1985; Pugh et al., 1985; Barone et al., 
1986; Saller and Salama, 1986). 
Therefore, since apomorphine is a direct dopamine-receptor agonist 
(Ernst, 1967), it served as a pharmacological tool for gauging dopa-
mine receptor (D-2) sensitivity in the behavioral paradigms predictive 
of mesolimbic and striatal dopamine activity, i.e., locomotion, 
stereotypy and climbing behavior (Pijnenberg and Van Rossum, 1973; 
Costall and Naylor, 1975; Kelley et al., 1975; Pijenberg et al., 1976; 
Protais et al., 1976; Costall et al., 1979, 1980). Apomorphine's 
effects on these behaviors were verified in these procedures and 
produced especially reliable and robust effects in stereotypy (ED50 = 
0.80 mg/kg sc; Table 2) and climbing (ED50 = 0.58 mg/kg sc; Table 3), 
while only producing slight enhancement of locomotion (Table 1; Fig. 
6). However, the reason for only slight increases in locomotion is 
due to the fact that the stereotypic components of apomorphine's 
effects (even at relatively low postsynaptic doses) interferes with 
horizontal locomotor activity, i.e., stereotyped behavior was observed 
between 0.3-3.0 mg/kg (Table 2) whereas slight increases in locomotor 
activity occur at 1.5 and 5.0 mg/kg (Table 1). 
It was of interest to determine whether the opiates were capable 
of blocking dopaminergic effects by antagonizing apomorphine-induced 
climbing and stereotyped behavior. Biochemical studies showed 
neuroleptics act at opiate sites (Creese et al., 1976) but opiates do 
not interact at neuroleptic sites (Creese et al., 1976; Puri et al., 
1978). Generally, this was the case in the climbing and stereotypy 
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experiments. Morphine, naloxone, naltrexone, pentazocine and 
cyclazocine had no effect on apomorphine (1.5 mg/kg) -induced climbing 
behavior (Table 12). Although, ethylketocyclazocine (EKC) at 20 mg/kg 
and SKF 10,047 at 40 mg/kg significantly decreased climbing by 52% and 
25%, respectively (Table 12), this may have been due to the initial 
depressive effects of EKC and the ataxia produced by SKF 10,047 which 
rendered the mice unable to climb. In fact, lower doses of these 
compounds had no effect on climbing (Table 12). Likewise, only EKC 
(20 mg/kg) was active in antagonizing apomorphine-induced stereotypy 
(Table 13), further evidence that the side effects of EKC, namely, 
general overt depression and flaccidity were responsible for the 
blockade of these behaviors, not dopamine-receptor blockade. Also, 
SKF 10,047 (40 mg/kg) did not antagonize apomorphine-induced 
stereotypy which showed that although ataxia interfered with climbing, 
it had no effect on stereotypy. Furthermore, in both the acute 
(Tables 17, 21 and 24) and chronic (Tables 28, 30, 34 and 37) 
supersensitivity paradigms, neither EKC nor SKF 10,047 were capable of 
inducing DA-SS. Therefore, the opiate receptor subtype agents do not 
appear to act as dopamine receptor antagonists in the two behavioral 
assays which are predictive for anti psychotic agents, i.e., 
apomorphine-induced climbing and stereotypy. 
On the other hand, might these opiates act either directly or 
indirectly as dopaminergic agents? Inasmuch as dopamine agonists and 
releasers are known to , induce locomotor activity in rodents (Costall 
and Naylor, 1977), it was important to investigate the locomotor 
effects of the opiate subtypes. 
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In the locomotor activity experiments, morphine, EKC, pentazocine, 
cyclazocine and SKF 10,047 all increased locomotion at some time 
during the six hours of testing while the pure antagonists, naloxone 
and naltrexone, had no effect. Opioid-induced hyperactivity has pre-
viously been implicated to be mediated by dopaminergic transmission 
(Buxbaum et al., 1973; Holtzman and Jewett, 1972, 1973; Kuschinsky and 
Hornykiewicz, 1974; Iwamoto, 1981). Morphine(µ), SKF 10,047 (er ), 
pentazocine and cyclazocine (K, a ) each produced immediate increases 
in locomotion which generally lasted from one to three hours (Tables 
4, 9, 10 and 11; Figures 7, 11, 12 and 13). 
Morphine induction of hyperactivity or "morphine mania", as well 
as pentazocine-, cyclazocine- and SKF 10,047-induced hyperactivity 
have been we 11 documented (Re thy et al • , 1971; Holtzman and Jewett, 
1972, 1973; Iwamoto, 1981). However, initial experiments in rats and 
mice (Tepper and Woods, 1978; Iwamoto, 1981) failed to show EKC-
i nduced hyper activity because these experiments lasted for one to two 
hours and hyperactivity was not evident until three hours 
postadministration (Table 8, Fig. 10). The results in this disserta-
tion, along with a recent study (Gwynn and Domino, 1984) where 
locomotion was monitored for 6 hours showed that EKC induced a 
biphasic locomotor effect where an initial decrease in activity was 
followed at approximately 180 minutes by a significant increase in 
locomotion (Table 8, Fig. 10). 
EKC hyperactivity was further investigated for peak effect and 
mechanism of action by utilizing the wire-mesh stick cages. Peak 
activity at 5 mg/kg sc was determined to be between 180 to 210 minutes 
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(Table 41). Various blocking agents at appropriate pretreats were 
combined with EKC at 5 mg/kg sc and hyperactivity was measured at 180 
to 210 minutes (Table 43). EKC hyperactivity was clearly distin-
guishable from the morphine-induced "running fit" or "morphine mania" 
in mice. EKC hyperactivity was relatively insensitive to naloxone 
(Table 43) and EKC induced a sporadic running and episodes of 
stereotyped rearing and sniffing whereas morphine induced a "running 
fit" characterized by persistant circling which was antagonized by 
naloxone (Rethy et al., 1971). EKC hyperactivity was dependent upon 
catecholamine transmission since the synthesis inhibitor a -MPT 
(Spector et al., 1965) and the depleters reserpine (Iverson et al., 
1965) and tetrabenazine (Quinn et al., 1959; Pletscher et al., 1962) 
blocked EKC-induced hyperactivity. Furthermore, the postsynaptic 
dopamine receptor blocker haloperidol, and a presynaptic autoreceptor 
dose of apomorphine (0.1 mg/kg) effectively antagonized the increased 
activity produced by EKC. Also, the GABA agonist muscimol (Beaumont 
et al., 1978) suppressed the EKC-induced hyperactivity suggesting 
GABAergic inhibition of this activity, possibly through the mediation 
of the dopaminergic system. In addition to dopamine mediation of EKC-
induced hyperactivity, norepinephrine transmission at the alpha-1 
receptor (but not alpha-2) appeared important since phentolamine and 
prazosin (but not yohimbine) effectively antagonized EKC-induced loco-
motor activity. However, there was only limited serotonergic media-
tion of this behavior and no cholinergic involvement (Table 43). 
Therefore, the kappa agonist EKC may be acting through the mesolimbic 
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and/or striatal system by increasing synthesis and release of 
catecholamines. 
These experiments also revealed that the sigma agonist SKF 10,047 
(Martin et al., 1976; Pasternak et al., 1981) induced a stereotypic 
behavior in mice which eventually culminated into a climbing response 
similar to that of apomorphine (Dunn et al., 1984). Following SKF 
10,047 (40 mg/kg sc) administration, mice were initially ataxic for 
the first 30 minutes, then exhibited stereotyped behavior character-
ized by vocalization, excessive grooming and sniffing, then rearing 
and finally climbing approximately 75 to 90 minutes postadministration 
(Table 44) with an ED50 for climbing equal to 14.6 mg/kg sc (Table 
45). 
In addition, SKF 10,047 induced an increase in locomotor activity 
beginning at 15 minutes postadministration and lasting for up to five 
hours (Table 11; Fig. 13). This increase in locomotion was previously 
observed in rats (Iwamoto, 1981) and was at least partially attributed 
to dopaminergic activity since this activity was attenuated by 
spiperone (a postsynaptic dopamine receptor antagonist) and 
apomorphine (a presynaptic dopamine inhibitor at 0.1 mg/kg). On the 
other hand, the mu antagonist naltrexone, had no effect on SKF 10,047-
induced 1 ocomot ion except at very high doses (Iwamoto, 1981). These 
results were confirmed in mice in the six-hour locomotion paradigm in 
that haloperidol but not naltrexone effectively antagonized SKF 
10,047-induced locomotion (unpublished observations). 
To further elucidate the mechanism of action responsible for SKF 
10,047 induction of locomotor activity, stereotypy and climbing, 
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interaction experiments were conducted utilizing the climbing mouse 
paradigm since climbing behavior is mediated by both mesolimbic 
(locomotion) and striatal (stereotypy) systems (Protais et al., 1976; 
Costall et al., 1979). SKF 10,047 was administered at 40 mg/kg sc and 
combined with the various blocking agents (at appropriate pretreats) 
and climbing behavior was scored for 30 minutes, 90 minutes post-SKF 
10,047 administration (Table 46). SKF 10,047-induced climbing behav-
ior was not mediated by the opiate system since it was not antagonized 
by naloxone. SKF 10,047-induced climbing behavior was dependent upon 
catecholamine transmission and a direct serotonin receptor inter-
action. Blockade of catecholamine synthesis by a -MPT completely 
antagonized (-97%) SKF 10,047-induced climbing while autoinhibition of 
dopamine systems by apomorphine, GABAergic inhibition by muscimol and 
dopamine-receptor blockade by haloperidol also attenuated this 
behavior. Furthermore, noradrenergic receptor blockade by phentol-
amine, specifically alpha-1 receptor antagonism by prazosin and 
serotonin receptor blockade by methysergide significantly antagonized 
SKF 10,047 climbing behavior. However, this behavior was independent 
of serotonin synthesis and release since PCPA had no effect on SKF 
10 ,047-i nduced climbing. Interestingly, tetrabenazi ne but not reser-
pine blocked this behavior probably due to the dopamine receptor 
blocking properties of tetrabenazine (Reches et al., 1983) and not 
because of neurotransmitter depletion. 
These results suggest that SKF 10,047-induced climbing is the 
result of an activation of catecholamine transmission and of a 
serotonin receptor interaction. The effect of a serotonin mediation 
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of this behavior is somewhat unclear since serotonin and specifically 
the serotonergic raphe projection to the substantia nigra and striatum 
are predominately inhibitory (Grabowska, 1974; Miller et al., 1975; 
Dray et al., 1976), although an excitatory role of serotonin based on 
some selective neuronal excitation cannot be excluded (Dray et al., 
1976). Furthermore, serotonin inhibits dopamine mediated hyperactiv-
ity and stereotypy (Weiner et al., 1975; Pycock et al., 1978). 
However, SKF 10,047 effects may be similar to the 5-HT agonist, 
quipazine, which has been found to potentiate apomorphine-induced 
stereotypy (Pycock et al., 1978), possibly through inhibition of 
dopamine reuptake (Ponzio et al., 1981). Therefore, SKF 10,047-
induced climbing behavior may result from a dopamine reuptake 
inhibition similar to quipazine, a selective serotonergic excitatory 
effect on mesolimbic and/or striatal dopaminergic neurons, as well as 
a direct and/or indirect effect on catecholamine synthesis and 
transmission. 
Although both EKC and SKF 10,047 appear to have some effects on 
dopaminergic systems, might these agents be working indirectly to 
potentiate dopaminergic transmission? In order to ascertain indirect 
effects, these compounds were combined with a low dose of apomorphine 
(0.4 mg/kg) and observed in the climbing mouse paradigm. In each 
case, EKC and SKF 10 ,047 at doses from 1 to 10 mg/kg potent iated 
apomorphine-induced climbing from 23 to 67% (Tables 39 and 40) in an 
approximately additive fashion because each of these compounds a 1 one 
at 3 and 10 mg/kg showed either hyperactivity (EKC) or climbing (SKF 
10 ,047). 
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Since each of these compounds have in common mu antagonist proper-
ties, might this characteristic be at least partially responsible for 
the potent i at ion of dopami nergi c effects? As previously reported, 
na 1 oxone has augmented sever a 1 dopamine-dependent behaviors ( Namba et 
al., 1980; Quack and Welsh, 1981; Adams et al., 1981; Quack and Lucas, 
1981, 1983; Quack et al., 1983; Balsara et al., 1984). Naloxone at 1 
to 10 mg/kg was shown to potentiate apomorphine climbing from 17 to 
83% (Table 38) while having no effect alone on either climbing or 
hyperactivity. These results further substantiate the hypothesis that 
an opiate receptor antagonist may potentiate dopaminergic effects 
through the blockade of opiate receptors on ni grostri ata 1 and 
mesolimbic dopamine neurons, thereby releasing these neurons from the 
tonic inhibition of endogenous opiate production (Celsen and 
Kushinsky, 1974; Loh et al., 1976; Balsara et al., 1984). In 
addition, recent evidence has shown that newly synthesized dopamine 
and norepinephrine and an alpha-1 receptor interaction influence 
naloxone potentiation of apomorphine-induced climbing (Quack et al., 
1984). Therefore, although EKC and SKF 10,047 alone induce hyper-
activity and climbing, respectively, part of the potentiation of 
apomorphine's effect may be due to the blockade of these opiate 
receptors as well as either direct and/or indirect effects of these 
agents on dopaminergic systems. 
Because of the following results suggesting dopami nergi c effects: 
mu, kappa, sigma and kappa, sigma agonists induced locomotor activity; 
sigma agonist-induced stereotypy and climbing; and mu antagonists as 
well as kappa and sigma agonists potentiation of apomorphine effects; 
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a 11 of these protypi cal opiate agents were tested in the acute DA-SS 
climbing paradigm. All of these compounds except morphine effectively 
attenuated acute haloperidol-induced DA-SS (Tables 18-24). It was not 
surprising that compounds which either directly or indirectly augment 
dopaminergic transmission (in the above acute models) would prevent 
the development of haloperidol-induced DA-SS in an acute paradigm, 
since it was previously reported that L-DOPA or apomorphine in 
combination with haloperidol blocked the development of DA-SS 
(Friedhoff et al., 1977; Ezrin-Waters and Seeman, 1978; Christensen 
and Nielsen, 1979; List and Seeman, 1979; Seeger et al., 1981). 
Morphine's lack of effect in attenuating DA-SS may be due to the 
fact that it, unlike all of the other opiates tested, was devoid of mu 
antagonist properties. Quite possibly, at least in the acute model, 
opiate receptor blockade was the initial factor in down regulating the 
development of DA-SS following haloperidol administration. The impor-
tance of opiate receptor antagonism was further substantiated s i nee 
naloxone and naltrexone, which lack overt dopaminergic effects, i.e., 
locomotion, stereotypy, climbing etc., were active in attenuating 
haloperidol-induced DA-SS. Blockade of opiate receptors located pre-
synaptically on dopamine neurons or on opiate neurons synaptically 
connecting with dopamine neurons in the mesol imbic and striatal areas 
(Pollard et al., 1977a, b; 1978; Murrin et al., 1980) may be suffi-
cient to antagonize endorphinergic and enkephalinergic inhibition of 
dopamine release (Celsen and Kushinsky, 1974; Subramanian et al., 
1977; Loh et al., 1976). In other words, more endogenous dopamine 
would be released as a result of occupation of opiate receptors by mu 
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antagonists. The fact that the sigma and/or kappa agonist components 
of SKF 10,047, EKC, cyclazocine and pentazocine may be either directly 
or indirectly facilitating the release of dopamine may be of secondary 
importance to the opiate-receptor blocking properties of these 
compounds (and naloxone and naltrexone) in attenuating the development 
of haloperidol-induced DA-SS. Therefore, would these agents when 
administered chronically with haloperidol, prevent the development of 
DA-SS? 
The consequences of chronic simultaneous administration of the 
opiate agents with haloperidol were assessed in the climbing mouse 
paradigm as well as the stereotypy model since chronic haloperidol 
treatment produced DA-SS in this model (Tables 26-30) although acute 
administration did not induce DA-SS (Table 15). In both models, 
chronic five-day morphine administration resulted in an enhanced 
response to apomorphine (Tables 26 and 31) while having no effect on 
haloperidol-induced DA-SS. These results were similar to earlier 
studies where morphine induced DA-SS in various paradigms (Puri and 
Lal, 1973; Gianutsos et al., 1974; Cox et al., 1976; Carlson and 
Almasi, 1978; Baume et al., 1979; Bhargava, 1980; Martin and Takemori, 
1985). Since morphine does not antagonize dopamine receptors (Creese 
et al., 1976; Puri et al., 1978), morphine-induced DA-SS apparently 
results from an inhibition of dopamine release mediated by the opiate 
system (Celsen and Kuschinsky, 1974; Loh et al., 1976; Subramanian et 
al., 1977). Therefore, chronic inhibition of dopamine release would 
have the same effect as receptor blockade, i.e., a decrease in 
postsynaptic dopaminergic activation. 
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The opiate antagonists, naloxone and naltrexone, when chronically 
administered alone or with haloperidol, had no effect in either 
paradigm (Tables 27, 32 and 33). These results showed that while 
opiate receptor blockade alone was sufficient to down regulate the 
hypersensitivity which developed following acute haloperidol admin-
istration in the climbing paradigm, it did not effectively attenuate 
chronic haloperidol-induced DA-SS in either the climbing or stereotypy 
models. It should be noted that naltrexone showed some slight attenu-
ation of haloperidol-induced DA-SS in the climbing assay (Table 33). 
This may have been due to the longer duration of antagonist activity 
of nal trexone compared to naloxone (Verebey et al., 1976). The kappa 
agonist, mu antagonist EKC, produced similar results in these models. 
Although chronic EKC had no effect on the development of DA-SS in the 
stereotypy paradigm (Table 28), it provided a consistent suppression 
of haloperidol-induced DA-SS in the climbing model (Table 34). It is 
possible that the mesol imbic system (cl imbing-mesol imbic and striatal 
mediation) was more sensitive than the striatal system (stereotypy-
striatal mediation) to these long-acting agents, i.e., naltrexone as 
an antagonist and EKC as an antagonist and a locomotor stimulant after 
three hours. Al though the locomotor effects of EKC appeared to be 
primarily due to dopaminergic activity (Table 43), the dopaminergic 
effects were not as robust as SKF 10,047. 
The sigma agonist, mu antagonist SKF 10,047 produced the most con-
sistent suppression of haloperidol-induced DA-SS in both chronic 
stereotypy and climbing models (Tables 30 and 37). Not only was this 
suppression statistically significant but in each case, the combina-
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tion of SKF 10,047 and haloperidol effectively reduced the development 
of DA-SS to vehicle control levels. The dopaminergic activity of SKF 
10,047 i.e., locomotor effects, stereotypy and climbing, apparently 
was sufficient to down regulate the dopamine-receptor blocking effects 
of haloperidol which lead to the development of DA-SS, similar to L-
DOPA's effect in this paradigm. 
Likewise, the sigma, kappa agonist, mu antagonist cyclazocine also 
effectively suppressed the development r~ haloperidol-induced DA-SS in 
both the chronic stereotypy and climbing models (Tables 29 and 36). 
However, the kappa, sigma agonist, mu antagonist pentazocine, had no 
effect on haloperidol-induced DA-SS in the chronic climbing paradigm 
(Table 35). This may be a result of the fact that cyclazocine has a 
much greater affinity than pentazocine for the sigma receptor (Zukin 
and Zukin, 198lb). Also, in drug discrimination testing, cyclazocine 
but not pentazocine generalized to SKF 10,047 trained rats (Shearman 
and Herz, 1982). These results suggested that cyclazocine had a high 
affinity for and high intrinsic activity at the sigma receptor while 
pentazocine had a much lower affinity for the sigma receptor. 
Therefore, in the chronic DA-SS paradigms, cyclazocine had similar 
effects to SKF 10,047, whereas pentazocine did not. 
These results would suggest that agents with strong sigma effects, 
as well as mu antagonist effects, were able to suppress the 
development of DA-SS in both acute and chronic behavioral paradigms. 
Kappa agents and opiate antagonists were effective in attenuating the 
development of DA-SS in the acute climbing model while showing little 
or no effects in the chronic stereotypy and climbing models. Other 
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than the fact that the attenuation of DA-SS by sigma agonists in 
particular may be due to dopaminergic effects as manifest behaviorally 
by increased locomotion, stereotypy and climbing, there are other 
aspects of opioid pharmacology, some of which remain controversial, 
which might explain some of the results in this dissertation, 
especially opiate influence on dopaminergic systems. 
First and foremost, it was crucial to establish the existence in 
the central nervous system (CNS) of these various opiate receptor 
subtypes, namely, mu, kappa and sigma (and even delta and epilsilon 
for enkephalins and endorphins, respectively) so that the behavioral 
effects could be linked to the brain. Furthermore, any drug which 
attenuates DA-SS must exhibit activity in the mesolimbic and/or 
striatal dopaminergic systems. 
Since Martin's (1976) pioneer study in dogs where he classified 
opiates based on neurophysiological and behavioral evidence as either 
mu, kappa or sigma, some controversy has surrounded the existence of 
these receptors in the CNS. The existence of different mu (morphine) 
and delta (enkephalin) binding sites in the CNS was well established 
(Pert and Snyder, 1973; Snyder, 1978) • Autorad iographi c techniques 
revealed a high concentration of mu receptors in the striatum and high 
levels of delta receptors in the striatum, nucleus accumbens and 
olfactory tubercle (Goodman et al., 1980). The highest concentrations 
of endorphins and enkephalins were located in the striatum (Llorens-
Cortes et al., 1977). Furthermore, approximately one-third of stri-
atal opiate or enkephalin receptors are located on dopaminergic 
neurons while one-half to two-thirds are located on neurons intrinsic 
63 
to or emanating from the striatum (Hong et al., 1977; Pollard et al., 
1977b, 1978; Murrin et al., 1980). An even larger percentage (50-70%) 
of opiate receptors were located presynaptically on dopaminergic 
neurons in the mesolimbic area (Pollard et al., 1977a). 
The discovery of sigma and kappa receptors in the CNS has been 
somewhat controversial. SKF 10,047 is the protoype sigma agonist (with 
mu antagonist properties) which produces psychotomimeti c effects in 
man (Keats and Teford, 1964). Biochemical and autoradiographic stud-
ies have identified sigma receptors in mouse, rat and guinea pig 
brains. Since the intial report of a commonality of the sigma 
opiate/phencyclidine (PCP) receptor (Zukin and Zukin, 198lb), much 
debate has taken place in defense of these receptors being identified 
(Zukin, 1982; Mendelsohn et al., 1985; Sircar et al., 1986) and to the 
contrary, that these receptors are distinct (Su, 1982; Tam, 1983, 
1985; Martin et al., 1984; Gundlach, 1985; Downes et al., 1986). The 
distinction between these two binding sites was based on several 
observations: (3H) PCP binding is decreased in the presence of sodium 
ions but (+)-(3H) SKF 10,047 binding is not; the two binding sites 
have different drug 
affinity and little 
selectivity; the PCP binding sites show low 
stereoselectivity towards SKF 10,047, EKC, 
cyclazocine and pentazocine whereas these drugs are highly 
stereoselective towards the (+)-(3H) SKF 10,047 binding sites; and the 
regional distribution in the CNS of the sigma binding sites differs 
from the PCP binding sites. Moreover, biochemical and autoradio-
graphic techniques have shown that (+)-(3H) SKF 10,047 labels two 
sites, a high affinity site corresponding to the sigma receptor and a 
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low affinity site representing the PCP receptor (Gundlach et al., 
1985; Downes et al., 1986). Therefore, the sigma and PCP receptors are 
probably different receptors which share some similar properties. 
Until recently, the proof of the existence of a central kappa 
receptor site was difficult since kappa drugs interacted with a number 
of receptor sites, i.e., mu (µ), sigma ( a ), enkephalin (c) and kappa 
(K) sites (Kosterlitz and Paterson, 1980; Pasternak, 1980; Snyder and 
Goodman, 1980; Chang et al., 1981; Garzon et al., 1984). Biochemical 
and autoradi ographi c studies showed di st in ct kappa opiate receptors 
were present in the CNS of the guinea pig (Kosterl itz et al., 1981; 
Wood and Charleson, 1982), mouse (Garzon et al., 1984) and human brain 
(Pfeiffer et al., 1982; Maurer et al., 1983). Furthermore, K , a ,µ, 
and c receptors have all been established in the striatum, midbrain 
and frontal cortex (Wolozin et al., 1982). 
Since enkepha 1 i n-conta i ni ng neurons and various opiate receptors 
are present in high concentrations in the basal ganglia and mesolimbic 
system, areas also rich in dopamine (Snyder, 1978), what effects would 
endogenous and exogenous opiates have on dopaminergic transmission? 
In vitro evidence from superfused striatal slices showed that morphine 
(Celsen and Kuschinsky, 1974), enkephalin (Subramanian et al., 1977) 
and s -endorphin (Loh et al., 1976) inhibited K+ stimulated release of 
(3H)-DA. However, in vivo evidence appears to show a species differ-
ence between rats and mice. Both mu and delta agonists elevated 
striatal DA synthesis but not release in the rat striatum (Wood et 
al., 1980; Wood and Richard, 1982), while in the mouse, there was an 
increase in DA synthesis and release (Wood et al., 1980; Wood and 
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Richard, 1982). In the rat, this initial depression of dopaminergic 
transmission following morphine administration was followed by a 
feedback activation which was probably responsible for an increased 
firing rate in the substantia nigra (Iwatsubo and Clouet, 1977). 
Also, direct injection of opiates and opioid peptides into the 
substantia nigra activated dopamine neurons projecting to the caudate 
nucleus (Iwamoto and Way, 1977). Opiate injection into the ventral 
tegmental region induced hyperactivity in the rat due to a release of 
dopamine in the nucleus accumbens (Kelley et al., 1980). Therefore, 
opiates activate both mesolimbic and striatal dopamine neurons. 
However, this appeared to be an indirect effect since ionto-
phoretically applied morphine at the substantia nigra has no effect on 
dopaminergic neuron activity (Pert et al., 1979). 
Morphine-induced hyperactivity appears to be mediated by both 
opiate and catecholamine systems since morphine-induced locomotor 
activity was blocked by naloxone (Rethy et al., 1971; Parker, 1974), 
a-MPT or reserpine (Buxbaum et al., 1973) and presynaptic (auto-
inhibiting) doses of apomorphine (Strombom and Svensson, 1978). 
Further evidence for two independent systems which mediate locomotor 
activity was provided by Pert and Sivit (1977) who showed that 
intraaccumbens morphine-induced locomotor activity was antagonized by 
naloxone but not haloperidol and intraaccumbens apomorphine-induced 
locomotor activity was antagonized by haloperidol but not naloxone. 
Also, other regions besides the mesolimbic system appear to be 
involved in morphine-induced hyperactivity since lesions of the 
nucleus accumbens and ventra 1 tegmenta 1 area attenuated and de 1 ayed, 
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but did not completely abolish morphine-induced locomotor activity 
(Bunney et al., 1984). 
It is unlikely that presynaptic opiate receptors are located on 
dopaminergic neurons in mice since lesion of the nigrostriatal pathway 
in mice did not result in decreased opiate binding in the striatum 
whereas this lesion resulted in decreased opiate binding in the rat 
(Wood and Richard, 1982). Because intranigral morphine induced 
increases in DA metabolites similar to parenteral injection in mice, 
it was suggested that opiate receptors on dopaminergic cell bodies 
and/or afferent nerve fibers innervating these neurons regulate 
nigrostriatal activity (Wood and Richard, 1982). 
In the mouse, the initial increase in DA turnover in the striatum 
following morphine administration (Baume et al., 1979; Wood and 
Richard, 1982) lasting for six to 12 hours (Kuschinsky, 1974; Baume et 
al., 1979) was followed at 24 hours by a significant decrease in HVA 
levels following either a single dose of morphine or for several days 
following chronic morphine administration (Baume et al., 1979). In 
fact, either a single dose of morphine or chronic morphine resulted in 
an enhanced apomorphine-induced climbing response for days following 
treatment similar to haloperidol (Baume et al., 1979; Martin and 
Takemori, 1985, 1986) as well as DA-SS in other models (Puri and Lal, 
1973; Gianutsos et al., 1974; Cox et al., 1976; Carlson and Almasi, 
1978). The diminished activity of DA neurons reflected an increased 
activity of the feedback loop when the postsynaptic receptors became 
hypersensitive to dopamine (Matres et al., 1977). Chronic morphine 
resulted in tolerance to the increase in DA turnover from morphine and 
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cross tolerance to the increase in DA turnover following haloperidol 
administration (Baume et al., 1979). Morphine-induced DA-SS could not 
be attributed to an increase in dopamine receptors similar to that 
seen following haloperidol administration (Burt et al., 1977) since 
chronic morphine either decreased (Puri et al., 1978), slightly 
increased (Baume et al., 1979; Martin and Takemori, 1986) or had no 
effect (Carlson and Seeger, 1982) on 3H-neuroleptic binding. However, 
there may be an increase in affinity, although fewer binding sites 
(Puri et al., 1978). 
The effects of kappa and/or sigma agonists on dopaminergic 
transmission remains somewhat unclear and in need of more thorough 
investigations. Pentazocine has been reported to have either no 
effect on catecholamine turnover (Holtzman and Jewett, 1972) or 
increased the turnover of dopamine in whole brain (Sugre, 1974) and 
striatum (Sugre, 1974; Wood et al., 1980). Likewise, cyclazocine 
slightly lowered brain catecholamine levels (Holtzmann and Jewett, 
1973) while increasing striatal dopamine turnover (Wood et al., 1980; 
Gavend et al., 1981; Snell et al., 1984) and norepinephrine and 
serotonin turnover in the cortex, hypothalamus, midbrain, pons and 
medulla (Gavend et al., 1981). Cyclazocine also inhibited stimulated 
acetylcholine release from striatal slices (Johnson and Snell, 1985). 
The kappa agonists, EKC and ketazocine, showed a slight increase 
in striatal DA metabolite levels and turnover (Wood et al., 1980; 
Snell et al., 1984). However, animals were sacrificed 60 minutes 
following drug administration while stimulant activity of EKC was not 
apparent until three hours postadmi ni stration. If turnover studies 
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were run at this time point, it might be possible that there would be 
higher levels of DA turnover. Furthermore, EKC potently inhibited 
acetylcholine (ACh) release in superfused striatal slices and this 
effect was reversed by haloperidol (Leventer and Johnson, 1984). 
Since ACh release is known to be inhibited by DA, it was suggested 
that EKC-induced inhibition of ACh was mediated via dopaminergic 
neurons (Leventer and Johnson, 1984). 
The sigma agonist, SKF 10,047 produced small increases in striatal 
DOPAC and DA that were resistant to naloxone challenge (Wood et al., 
1980). It must be noted that tissue samples were analyzed at 60 
minutes postadministration and quite possibly more dramatic effects 
may have been seen at 90 minutes after SKF 10,047. In an in vitro 
assay, SKF 10,047 and EKC slightly enhanced the basal efflux of (3H) 
DA from striatal slices (Snell et al., 1984). In addition, SKF 10,047 
inhibited the reuptake of DA while EKC and cyclazocine were extremely 
weak uptake inhibitors (Johnson and Snell, 1985). Similar to EKC, SKF 
10,047 inhibited ACh release (Leventer and Johnson, 1984; Johnson and 
Snell, 1985), with this effect being reversed by haloperidol (Leventer 
and Johnson, 1984). 
In addition to biochemical evidence linking sigma activity to the 
dopamine system, behavioral studies have also shown a sigma-dopamine 
interaction. Since the original observation by Martin et al. (1976) 
that some of the activity of the dopamine agonist apomorphine showed 
certain similarities to those of SKF 10,047, recent behavioral evi-
dence has supported a dopaminergic mediation of sigma-induced 
behavior. In rats, SKF 10,047 and cyclazocine induced dose-related 
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increases in locomotion, sniffing, repetitive head movements, rearing 
and some ataxia (Iwamoto, 1980, 1981; French and Vantini, 1984; 
Contreras et al., 1986; Greenberg and Segal, 1986). SKF 10,047-
induced hyperactivity was attenuated by presynapt i c autoi nhi bit ion of 
dopamine and norepinephrine by apomorphine (0.1 mg/kg) and clonidine 
(0.1 mg/kg), respectively, and by postsynaptic dopamine blockade by 
spiperone (0.15 mg/kg) (Iwamoto, 1980, 1981). Further indication of 
SKF 10,047-induced dopaminergic activity in the midbrain was shown 
when SKF 10,047-induced hyperactivity was prevented by 6-hydroxy-
dopamine (6-0HDA) lesions of both the nucleus accumbens (French and 
Vantini, 1984) and the A-10 region of the ventral tegmental area 
(French, 1986). Also, in the rat circling model (unilateral 6-0HDA 
lesion of the substantia nigra), SKF 10,047 causes ipsilateral turning 
like amphetamine, suggesting indirect activation of the intact 
dopaminergic pathway possibly by inhibition of dopamine reuptake, by 
releasing dopamine or by indirect stimulation of neostriatal pathways 
at the level of the cell body (Iwamoto, 1980). Further support for 
SKF 10,047 indirectly activating dopamine neurons was provided by 
electrophysiological (single-unit recording) evidence which showed 
that intravenously administered SKF 10,047 increased the firing rate 
of dopamine neurons in the ventral tegmental area (A-10) and the 
substantia nigra (A-9) while iontophoretically applied SKF 10,047 had 
no effect on these neurons (Freeman and Bunney, 1984). 
Both biochemically and behaviorally, the sigma opiates may 
indirectly affect dopamine turnover and/or uptake. It is intriguing 
that antipsychotic agents such as haloperidol and other phenothiazines 
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have been shown to inhibit striatal and whole brain binding of (3H) 
SKF 10,047 in vitro in rat and guinea pigs (Su, 1981, 1982; Tam and 
Cook, 1984; Tam, 1985). Also, an in vivo binding assay in mouse brain 
found haloperidol to be the most potent compound to inhibit specific 
(+)-(3H) SKF 10,047 binding with an ID50 of 0.75 mg/kg i.p., followed 
by thioridazine (8.9 mg/kg) and chlorpromazine (19.2 mg/kg) (Ferris et 
al., 1985, 1986). Therefore, in both in vivo and in vitro sigma 
binding assays, haloperidol was the most potent displacer of (3H) SKF 
10,047 followed by the phenothiazines. However, the sigma and dopa-
mine binding sites were found to be different for several reasons: 
Dopamine and dopamine agonists did not bind to the SKF 10,047 binding 
site; there was reversed stereoselectivity for butaclamol binding to 
the sigma and dopamine sites; and there was no direct relationship 
between the affinity of antipsychotic drugs for the sigma site and for 
the (3H) spiperone binding site (Tam, 1983; Tam and Cook, 1984). 
However, an intricate relationship between haloperidol and SKF 10,047 
was shown in whole guinea pig brain in binding assays when the order 
of drug potency for opiates and antipschotics in displacing these (3H) 
ligands was similar (Tam and Cook, 1984). 
(3H) Haloperidol bound to two distinct receptors, namely a 
Therefore, it was pro-dopamine D-2 binding site and the sigma site. 
posed that some antipsychotic agents may act therapeutically by 
antagonizing both dopamine and sigma receptors. Furthermore, an 
endogenous 1 igand referred to as 11 sigmaphin 11 has been identified to 
directly interact with sigma receptors (Su et al., 1986). It was 
proposed that the ideal antipsychotic drug might be a specific sigma 
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antagonist, devoid of dopamine receptor antagonism and, therefore, 
more likely not to cause the undesirable extrapyramidal side effects 
or tardive dyskinesias. Likewise, since there appears to be a dynamic 
interrelationship between the sigma and dopamine systems, it is not 
surprising that an agent with sigma properties could interact in some 
way to either down regulate or compensate for the development of 
dopaminergic supersensitivity following haloperidol administration. 
In 1 i ght of what has previously been reported as well as the 
results of this dissertation, it would appear that the sigma agonist, 
SKF 10,047 has at least indirect dopamine agonist properties in the 
mesolimbic and striatal areas. This, in combination with its mu 
antagonist property which also potentiates dopamine-dependent 
behaviors, would appear to sufficiently stimulate release and augment 
dopaminergic transmission in the mesolimbic and striatal systems to 
compensate for and down regulate the development of DA-SS fo 11 owing 
haloperidol treatment. Cyclazocine, which is more of a sigma rather 
than kappa agonist (Zukin and Zukin, 198lb), also has dopaminergic 
effects capable of attenuating haloperidol-induced DA-SS. Kappa 
effects on dopaminergic transmission are somewhat unclear at this time 
but following an initial period of sedation, dopaminergic activity is 
enhanced, but not to the extent of a sigma agoni st. Enhancement of 
dopaminergic transmission by these opiate agents was partially 
responsible for the attenuation of haloperidol-induced DA-SS but it is 
also important to note recent results concerning haloperidol 's effect 
on endorphinergic transmission and how this effect may mediate the 
development of DA-SS. 
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Although this dissertation did not directly study endogenous opi-
ates, enkephalins and endorphins seem to play a role in the modulation 
of neuroleptic effects and the eventual development of DA-SS. Chronic 
administration of haloperidol has been shown to increase enkephal in 
content in the striatum (Hong et al., 1978; Tang et al., 1983; Chou et 
al., 1984; Blanc et al., 1985) and the nucleus accumbens (Hong et al., 
1978) due to an increase in peptide synthesis (Hong et al., 1979). 
Recently, it was found that haloperidol increased the biosynthesis of 
the mRNA for preproenkephalin which led to an increase in enkephalin 
synthesis (Tang et al., 1983; Blanc et al., 1985) and possibly release 
(Tang et al., 1980; Blanc et al., 1985). The effects of enkephalin on 
dopaminergic activity remain controversial. Enkephalin has been 
reported to have either no effect on striatal dopamine release (Loh et 
al., 1976), or inhibit both striatal (Subramanian et al., 1977) and 
retinal (Oubocovich and Weiner, 1983) dopamine release. The 
inhibition of dopamine release was naloxone reversible (Subramanian et 
al., 1977; Oubocovich and Weiner, 1983) since naloxone blocked the 
binding of enkephalins to endogenous opiate receptors (Pert and 
Snyder, 1973). Naloxone alone either had no effect on dopamine 
release (Loh et al., 1976; Subramanian et al., 1977; Dubocovich and 
Weiner, 1983) or has caused increases in striatal dopamine 
concentration (Costa et al., 1978). 
Acute and chronic haloperidol administration also resulted in an 
increased release of immunoreactive s -endorphin (s -endorphin is the 
predominant peptide) in the blood and in the striatum (Holt and 
Bergmann, 1982). However, unlike the tolerance to striatal dopamine 
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turnover which occurs rapidly following haloperidol administration 
(Lerner et al., 1977), there was no tolerance to the increase in 8 -
endorphin following haloperidol treatments (Holt and Bergmann, 1982). 
Although, Arbilla and Langer (1978) reported that 8-endorphin had no 
effect on dopamine release in the striatum, others have found 8 -
endorphin inhibited striatal dopamine release (Celsen and Kuschinsky, 
1974; Loh et al., 1976) and increased dopamine reuptake (George and 
Van Loon, 1982) in the striatum. These effects were naloxone 
reversible. Interestingly, 8 -endorphin secretion can be inhibited by 
dopamine and dopamine receptor agonists (Vale et al., 1979). 
Therefore, 8-endorphi n-i nduced decrease of stria ta l dopamine rel ease 
and increased reuptake decreased dopaminergic transmission. Hence, it 
was not surprising that behaviorally, 8-endorphin-induced DA-SS 
(Bhargava, 1981) and chronic stress which increases the concentration 
of endogenous opiates (Amir et al., 1980) produced DA-SS as measured 
by enhanced apomorphine-induced climbing (Cabib et al., 1984). 
Furthermore, stress-induced DA-SS was prevented by chronic treatment 
with the opiate antagonist naltrexone (Cabib et al., 1984). It has 
become increasingly evident that the development of dopaminergic 
supersens itivity is a consequence of dopamine receptor blockade as 
well as an endorphinergic imbalance which further effects dopamine 
systems. 
The results of this dissertation and some of the recent results of 
other groups has led to intriguing possibilities concerning opiate 
modulation of dopaminergic supersensitivity. Under normal physio-
logical conditions, the effects of both endogenous opiates and opiate 
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antagonists on the inhibition of dopamine release and disinhibition of 
dopamine release, respectively, is small and difficult to detect. 
However, enhanced dopaminergic responsiveness during DA-SS, resulting 
from either chronic antipsychotic treatment or from chronic endogenous 
or exogenous opiate agonists, magnifies the effects of enkephalins, 
endorphins and mu antagonists on dopaminergic transmission. 
Therefore, chronic haloperidol administration not only blocks dopamine 
receptors rendering them supersensitive but also may modulate or 
augment DA-SS through continual increased endorphin and enkephalin 
synthesis and release which inhibits dopamine release and increases 
re uptake. Concomitant admi ni st rat ion of opiate antagonists may dis-
inhi bit endogenous opiate influence on dopaminergic transmission by 
increasing dopamine release and blocking reuptake, thereby increasing 
the amount of synaptic dopamine. However, this antagonism alone may 
be insufficient to compensate for or overcome dopamine receptor 
blockade to attenuate DA-SS during chronic neuroleptic therapy. 
Furthermore, if dopaminergic transmission is stimulated and opiate 
receptors blocked, DA-SS can be attenuated. 
L-Dopa and other dopamine agonists have been shown to attenuate 
haloperidol-induced DA-SS (Friedhoff et al., 1977; Christensen and 
Nielsen, 1979; List and Seeman, 1979; Allen et al., 1980; Seeger et 
al., 1981; Reches et al., 1982). These dopamine agonists, by in-
creasing the amount of dopamine at the receptor and increasing 
dopamine receptor stimulation, compensate for the haloperidol receptor 
blockade (Friedhoff et al., 1977; Christensen and Nielsen, 1979; List 
and Seeman, 1979; All en et a 1., 1980; Seeger et a 1., 1981; Rec hes et 
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al., 1982). But also, dopamine and dopamine agonists inhibit 13 -
endorphin secretion (Vale et al., 1979), thus releasing dopaminergic 
neurons from endorphinergic inhibition. Therefore, at least theoreti-
cally, greater or more effective attenuation of haloperidol-induced 
DA-SS can be achieved by not only increasing dopamine release during 
receptor blockade but by antagonizing opiate receptors thereby thor-
oughly negating any endogenous opiate inhibition of dopaminergic 
transmission. Since there is no tolerance to the increased secretion 
of endogenous opiates during haloperidol treatment (Holt and Bergman, 
1982), it is important to block the opiate receptor and thus dopamine 
modulation by endogenous opiates. SKF 10,047 and cycl azoc i ne effec-
tively attenuate haloperidol-induced DA-SS through an apparent 
increase in dopaminergic transmission as well as opiate receptor 
blockade. However, the psychotomimeti c effects of sigma agoni sts in 
normal patients (Keats and Telford, 1964) may prevent the use of these 
drugs in schizophrenics unless there was a paradoxical effect in 
psychotic patients (similar to the paradoxical effect of amphetamine 
in hyperactive children). 
The possibility of opiate agents modulating the development of 
dopaminergic supersensitivity is intriguing. Human studies in schizo-
phrenic patients who received neuroleptics have shown increased 13 -
endorphin levels in plasma (Emrich et al., 1980) and in cerebrospinal 
fluid (Terrenius et al., 1976; Domschke et al., 1979; Lindstrom et 
al., 1980). This coupled with the fact that naloxone had no deleteri-
ous effect and may possibly improve some symptoms of schizophrenia 
(Verebey et al., 1978; Watson et al., 1978; Pickar et al., 1982; Lo et 
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al., 1983; Blum et al., 1984) adds strength to the hypothesis that 
schizophrenia may be due to an imbalance in endorphinergic as well as 
dopaminergic homeostasis. The results of this dissertation add to the 
intriguing possibility that opiate agents may help to fine-tune 
dopaminergic imbalance in the treatment of schizophrenics. Hopefully, 
additional preclinical and clinical research in this area will lead to 
a better understanding of schizophrenia and a better prognosis for a 
schizophrenic to lead a more normal and satisfying life. 
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CONCLUSIONS 
Hypothesis 1. 
Opiates are not dopa•ine receptor antagonists and therefore, will not 
attenuate apomorphine-induced climbing and stereotyped behavor in 
•ice. 
Ethylketocyclazocine (EKC) and SKF 10,047 inhibited apomorphine-
induced climbing because of motor deficits, sedation and ataxia, 
respectively. Only EKC inhibited apomorphine-induced stereotypy due 
to initial motor deficits and sedation. Therefore, these compounds 
were not 
be ha vi ors 
dopamine 
were only 
antagonists, 
antagonized 
insofar as apomorphi ne-i nduced 
at debilitating doses which 
incapacitated mice. In addition, the mixed kappa, sigma agonists, 
pentazocine and cyclazocine, as well as morphine, naloxone and 
naltrexone did not antagonize these behaviors. 
Hypothesis 2. 
Opiates which stimulate catecholamine neuronal activity will cause 
either increased locomotor activity (indicative of mesolimbic 
activity), stereotypy (indicative of striatal activity) or climbing 
behavior (indicative of mesolimbic and/or striatal activity) in mice. 
Morphine, SKF 10,047, pentazocine and cyclazocine produced 
increases in locomotor activity suggesting increased dopaminergic 
activity, while naloxone and naltrexone had no effect on locomotion. 
EKC induced a biphasic effect of sedation followed by an increase in 
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locomotor activity at three hours postadministration. SKF 10,047 not 
only increased locomotor activity but also induced stereotypy and 
climbing behavior. Kappa-induced EKC hyperactivity was dependent upon 
catecholamine synthesis and transmission since a-MPT, reserpine, 
tetrabenazine, haloperidol, apomorphine (at 0.1 mg/kg, a presynaptic 
autoreceptor dose), muscimol and prazosin blocked EKC-induced 
locomotor activity. Sigma-induced SKF 10,047 climbing was dependent 
on catecholamine transmission and a direct serotonin receptor 
interaction since a-MPT, tetrabenazine, haloperidol, apomorphine (0.1 
mg/kg), muscimol, prazosin and methysergide antagonized this behavior. 
Both EKC-induced hyperactivity and SKF 10,047-induced climbing were 
not antagonized by naloxone. In addition, EKC, SKF 10,047 and 
naloxone potentiated apomorphine-induced climbing behavior. 
Hypothesis 3. 
The acute and/or chronic simultaneous ad•inistration of the opiate 
receptor subtype agents and haloperidol will attenuate the development 
of dopa•inergic supersensitivity as measured by apomorphine-induced 
climbing and stereotyped behavior in mice. 
Enhanced responsiveness to apomorphine following the acute 
administration of haloperidol 72 hours prior to testing was only 
observed in the apomorphine-induced climbing mouse assay. In the 
acute climbing paradigm, haloperidol-induced dopaminergic 
supersensitivity (DA-SS) was dose-dependently attenuated by SKF 
10,047, EKC, cyclazocine, pentazocine, naloxone and naltrexone, all of 
these compounds possessing mu antagonistic properties, with morphine 
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inactive. Chronic five-day administration of haloperidol-induced DA-SS 
was observed in the apomorphine-induced climbing and stereotypy 
paradigms, but not in the locomotor activity model. In the chronic 
climbing and stereotypy models, only the concomitant administration of 
the sigma agents, either SKF 10,047 or cyclazocine and haloperidol 
attenuated the development of DA-SS, while morphine alone produced DA-
SS. These results suggest differential modulation of DA-SS in the 
acute vs. chronic paradigms. Furthermore, sigma agonists were most 
effective in attenuating haloperidol-induced DA-SS. 
Fig. 1 
Fig. 2 
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Fig. 4 
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Fig. 9 
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Figure legends 
Oopaminergic structures in the nigrostriatal and meso-
1 imbic systems in the mouse brain. 
Agonist and antagonist interaction of prototypical opiate 
agents at mu, kappa and sigma receptor sites. 
Chemical structures of morphine, naloxone and naltrexone. 
Chemical structures of the benzomorphans cyclazocine, 
pentazocine, SKF 10,047 and ethylketocyclazocine. 
Antinociceptive and locomotor activity of the prototypical 
opiate agents. 
The effects of apomorphine at 0.5, 1,5 and 5.0 mg/kg sc on 
locomotor activity over two hours in mice. Locomotor 
activity units for each group based on four pairs of mice 
which were acclimated for one hour prior to dosing. 
The effects of morphine at 2 .5, 5 and 10 mg/kg sc on 
locomotor activity over six hours in mice. Locomotor 
activity units for each group based on four pairs of mice 
which were acclimated for one hour prior to dosing. 
The effects of na 1 oxone at 10, 20 and 40 mg/kg sc on 
locomotor activity over six hours in mice. Locomotor 
activity units for each group based on four pairs of mice 
which were acclimated for one hour prior to dosing. 
The effects of na ltrexone at 10, 20 and 40 mg/kg sc on 
locomotor activity over six hours in mice. Locomotor 
activity units for each group based on four pairs of mice 
which were acclimated for one hour prior to dosing. 
Fig. 10 
Fig. 11 
Fig. 12 
Fig. 13 
Fig. 14 
Fig. 15 
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The effects of ethylketocyclazocine at 5, 10 and 20 mg/kg 
sc on locomotor activity over six hours in mice. 
Locomotor activity units for each group based on four 
pairs of mice which were acclimated for one hour prior to 
dosing. 
The effects of pentazoci ne at 20, 40 and 80 mg/kg sc on 
locomotor activity over six hours in mice. Locomotor 
activity units for each group based on four pairs of mice 
which were acclimated for one hour prior to dosing. 
The effects of cyclazocine at 2.5, 5 and 10 mg/kg sc on 
locomotor activity over six hours in mice. Locomotor 
activity units for each group based on four pairs of mice 
which were acclimated for one hour prior to dosing. 
The effects of SKF 10,047 at 10, 20 and 40 mg/kg sc on 
locomotor activity over six hours in mice. Locomotor 
activity units for each group based on four pairs of mice 
which were acclimated for one hour prior to dosing. 
The effects of acute administration of haloperidol at 1.25 
mg/kg ip 72 hours prior to apomorphine at 0.4 mg/kg sc on 
locomotor activity over two hours in mice. Locomotor 
activity units for each group based on eight pairs of mice 
which were acclimated for one hour prior to dosing. 
The effects of chronic (5-days) administration of 
haloperidol at 1.25 mg/kg ip 72 hours prior to apomorphine 
at 0.4 mg/kg sc on locomotor activity over two hours in 
mice. Locomotor activity units for each group based on 
Fig. 16 
Fig. 17 
Fig. 18 
Fig. 19 
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eight pairs of mice which were acclimated for one hour 
prior to dosing. 
The effects of chronic (5-days) simultaneous 
administration of morphine at 10 mg/kg SC and/or 
ha 1 operi do 1 at 1.25 mg/kg ip, 72 hours prior to 
apomorphine at 0.4 mg/kg sc on stereotyped behavior in 
mice. Stereotypy scores for each group based on eight 
mice (maximum score for each mouse = 6) which were 
acclimated for one hour prior to dosing. 
The effects of chronic (5-days) simultaneous 
administration of naltrexone at 40 mg/kg sc and/or 
haloperidol at 1.25 mg/kg ip, 72 hours prior to 
apomorphine at 0.4 mg/kg sc on stereotyped behavior in 
mice. Stereotypy scores for each group based on eight 
mice (maximum score for each mouse = 6) which were 
acclimated for one hour prior to dosing. 
The effects of chronic (5-days) simultaneous 
administration of ethylketocyclazocine (EKC) at 20 mg/kg 
sc and/or haloperidol at 1.25 mg/kg ip, 72 hours prior to 
apomorphine at 0.4 mg/kg sc on stereotyped behavior in 
mice. Stereotypy scores for each group based on eight 
mice (maximum score for each mouse = 6) which were 
acclimated for one hour prior to dosing. 
The effects of chronic (5-days) simultaneous 
administration of cyclazocine at 2.5 mg/kg sc and/or 
haloperidol at 1.25 mg/kg ip, 72 hours prior to 
Fig. 20 
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apomorphine at 0.4 mg/kg sc on stereotyped behavior in 
mice. Stereotypy scores for each group based on eight 
mice (maximum score for each mouse = 6) which were 
acclimated for one hour prior to dosing. 
The effects of chronic (5-days) simultaneous 
administration of SKF 10,047 at 40 mg/kg sc and/or 
ha 1 operi do 1 at 1.25 mg/kg i p, 72 hours prior to 
apomorphine at 0.4 mg/kg sc on stereotyped behavior in 
mice. Stereotypy scores for each group based on eight 
mice (maximum score for each mouse = 6) which were 
acclimated for one hour prior to dosing. 
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F;gure 1 
NIGROSTRIATAL SYSTEM 
caudate nucleus/putanen zona compac ta of 
substantia nigra 
nucleus accumbens 
tuberculum 
ol factor1um 
interpenducular nucleus of the 
ventral tegmental region 
MESOLIMBIC SYSTEM 
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Figure 2 
Opiate Receptor Subtypes 
Prototypical Agonists, Antagonists and Mixed Agonist-Antagonists 
Compound 
_J!_ I( a 
Morphine Ag.1 
Naloxone, Naltrexone Ant. Ant. Ant. 
Ketocyclazocine, Ethylketocyclazocine Ant. Ag. 
Pentazocine Ant. Ag. Ag. 
Cyclazocine Ant. Ag. Ag. 
N-allyl-normetazocine (SKF 10,047) Ant. Ag. 
lAg. = agonist, Ant. = antagonist, - = no activity 
Morphine 
Naloxone 
Figure 3 
Chemical Structures of 
Morphine and its Antagonists 
Naltrexone 
86 
N-CH2-<J 
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Figure 4 
Chemical Structures of Benzomorphans 
HO 
~ R fu E2 
Cyclazocine (K, 0) CH3 CH2~ H 
Pentazocine (K 9 0) CH3 CH2CH=C(CH3)2 H 
SKF 10,047 ( 0) CH3 CH2CH=CH2 H 
Ethylketocyclazocine (K) CH3CH2 CH2-<J =O 
.. 
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Figure 5 
Opiate Receptor Subtypes 
Antinociceptive Activity - Behavioral Excitation Activity in Mice 
Compound (receptor subtype) 
Morphine ( ii agonist) 
Naloxone, naltrexone (ii, I(. o antagonist) 
Ketocyclazocine, ethylketocyclazocine 
{ I( agonist, ii antagonist) 
Pentazocine { K, o agonist; ii antagonist) 
Cyclazocine { K, o agonist; ii antagonist) 
N-allyl-normetazocine ( o agonist, 
ii antagonist) 
Antinociceptive 
Activity 
+++1 
+++ 
++ 
+ 
Behavioral 
Excitation 
Activity 
t 
- {"') 
t 
t 
t 
1 + = positive activity; - = no activity; t = increase; .i. = decrease 
2 Initial decrease {.i.) followed by increase {t) {Dunn, 1984). 
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Dose 
~m9£k9 sc) 0-15' 
Control 46.5 + 1.4 
0.5 46.9 .!. 0.9 
1.5 48.0 .! 0.5 
5.0 48. l .! 1.5 
TABLE 1 
Effects of Apomorphine on Locomotor Activity 
Mean Activity Counts .! S.E.a 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 
40.5 + 4.0 32.4 .! 6.0 25.8 .! 6.9 24.6 .! 7.0 24.4 .! 4.3 
37.1 .! 3.0 24.4 .! 3.1 21.3 .! 3.1 24.6 .! 3.2 14.9 .! 3.2 
47.1_!0.7 45 .1 .! 1.2 33.1 .! 2.7 21.1 .! 3.1 17.8 .! 3.3 
47.6 .! 2.1 46.8 .! 2.6 44.0 .! 2.3 39.9 .! 2.8 32.8 .! 4.6 
2. 60' Intervals over 2 Hours 
Dose 
(mg/kg sc} 
Control 
0.5 
1.5 
5.0 
60' 
77 .o .! 6.8 
75.7 .! 2.9 
87 .8 .! 1.7 
93.5 .! 4.1 
120' 
53.5 .! 7.4 
44.5 .! 2.6 
52.3 .! 4.3 
62.0 .! 6.7 
aMean and standard error of the square root of the activity counts of 16 pairs of mice. 
•p <0.05; One-way ANOVA 1 Ounnet's multiple comparison 
90'-105' 
29.4 .! 3.7 
12.0 .! 4.0 
30.0 .! 3.5 
22.3 .! 4.8 
105'-120' 
21.0 + 5.1 
25.5 .! 4.4 
29.6 .! 3.6 
23.0 .! 4.0 
>-' 
0 
+::> 
Dose 
_(mg/kg_ill 0-15' 
Control 2170 + 133 
0.5 2195 + 79 
1.5 2308 + 45 
5.0 2345 + 144 
TABLE la 
Effects of Apomorphine on Locomotor Activity 
Mean Activity Counts ! S.E.a 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 
1751 + 261 1289 + 331 1001 + 324 944 + 352 732 + 214 
1427 + 197 670 + 149 514 + 158 688 + 143 298 + 89 
2242 + 66 1797 + 178 1148 ! 192 507 + 127 383 + 151 
2297 + 205 2244 + 262 1966 + 212 1655 + 225 1225 + 272 
2. 60' Intervals over 2 Hours 
Dose 
(mg/kg sc} 60' 120' 
Control 6211 + 999 3261 ! 791 
0.5 4805 + 367 2043 ! 228 
1.5 7732 ! 301 2863 + 446 
5.0 8851 + 800 4176 + 868 
aMean and standard error of the activity counts of 16 pairs of mice. 
90'-105' 
961 + 222 
261 + 135 
988 + 203 
660 + 252 
105 I -120 I 
624 + 245 
797 + 214 
975 + 198 
636 + 198 
....... 
0 
(.}'1 
106 
TABLE 2 
Apomorphine-Induced Stereotyped Behavior in Mice 
Apomorphine 
Dose Stere~typy Score 
(mg/kg sc} n x ±SE % of Stereotypya 
0 8 0.00 + 0.00 
0.3 8 1.38 + 0.26 23 
1.0 8 3.25 + 0.16 54 
3.0 8 5.38 + 0.18 90 
a % of stereotypy based on maximum score = 6 
% stereotypy= i of Dose Group x 100 Max. score 
ED50 (95% confidence limits} 
0.80 (0.76-0.84) 
107 
TABLE 3 
Apomorphine-lnduced Climbing Behavior in Hice 
Apomorphine 
Dose Climbing Score ED50 {mglkg sc) n x ±SE % of Climbinga {95% confidence limits) 
0 8 0.13 .! 0.13 
0.3 8 11 0.75 .! 0.41 
0.58 (0.55-0.61) 
1.0 8 5.25 .! 0.37 87 
3.0 8 5.75 .! 0.16 96 
a% of climbing based on maximum score = 6 
% climbing = (x of Dose Group) - (x of Control) x 100 
(Max. score) - (x of Control) 
Dose 
(ing[k_[~ 
Control 
2.5 
5 
10 
Dose 
(mg/kg sc} 
Control 
2'. 5 
5 
10 
0-15' 15'-30' 
TABLE 4 
Effects of Morphine on Locomotor Activity 
Mean Activity Counts .:!. S.E.a 
1. 15' Intervals over 2 Hours 
30'-45' 45'-60' 60'-75' 75'-90' 90'-105 I 
48.l + 10.4 39.0 ..: 15.8 33.6 .:!. 9.6 25.7 .:!. 7.1 14.9 + 7.3 30.2 .:!:. 13.9 24.6 + 4.0 
41.5..: 4.8 46.0..: 17.9 48.2 .:!:. 4.6 48.6 .:!:. 4.9* 45.6 + 5.7* 48.8 .:!:. 4.0 43 • 6 ! 1. 9* 
48. 7 ..: 1.8 52.6 .:!. 0.4 53.7 .:!:. 1.3 52.8 .:!:. 0.4* 51.8 ! 0.8* 49.4 ! 2.0 47.2 !. 5.5* 
48.7 + 3.8 54.2 !. 3.6 55.9 + 0.6* 53.5 ! 0.7* 51.l + 0.1* 49.8 ! 0.3 50.6 .:!:. 0.1* 
2. 60' Intervals over 6 Hours 
60' 120' 
.!fill:. 240' 12Q.:. 
75 .3 .:!:. 21.5 50.0 !. 9.9 58.9 ! 26.7 60.4 ! 9.7 47 .6 .:!:. 1.8 
92.3 .:!:. 9.5 89.5 ! 6.3* 48.1!1.9 66.5 ! 8.5 31.2 ! 6.8 
104.0 .:!:. 2.0 98.1 .:!:. 6.5* 64.7 .:!:. 6.3 49.0 + 14.2 34.4 .:!:. 21.7 
106.3 + 4.2 100.7 .:!:. 0.5* 92.6 ! 7.1 55.8 .:!:. 9.1 37.2 .:!:. 5.8 
JMean and standard error of the square root of the activity counts of 4 pairs of mice. 
*P <0.05; One-way ANOVA. Ounnet's multiple comparison 
105'-120' 
24.3 ! 2.8 
40.1 + 4.8* 
47.4 ! 5.0* 
50.0 + 0.7* 
360' 
49. 7 + 21.4 
73.9 + 4.5 
44.3 + 7.2 
28.2 + 0.8 
..... 
0 
ex:> 
TABLE 4a 
Effects of Morphine on Locomotor Activity 
Mean Activity Counts .:!:. S.E.a 
1. 15' Intervals over 2 Hours 
Dose 
(mg/kg sc) 0-15 1 15 1 -30 1 30 1 -45 1 45 1 -60 1 60 1 -75 1 75 1 -90 1 90' -105 I 
Control 2426 + 1002 1772 + 1229 1223 + 648 708 + 362 275 .:!:. 216 1105 + 838 622 + 198 
2.5 1746 + 401 2139 + 427 2347 + 442 2385 + 478 2112 + 523 2401 + 386 1900 + 168 
5 2379 + 176 2772 .:!:. 45 2889 + 140 2790 + 44 2689 + 83 2440 + 199 2260 + 519 
10 2386 + 369 2954 + 384 3121 + 61 2865 .:!:. 79 2615 + 4 2477 + 30 2558 + 2 
2. 60 1 Intervals over 6 Hours 
Dose 
(mg/kg sc) 60 1 120 1 180 1 240 1 300 1 
Control 6128 + 3242 2601 .:!:. 992 4186 .:!:. 3146 3744 + 1175 2265 .:!:. 167 
2.5 8616 + 1748 8047 .:!:. 1129 2318 ! 178 4487 + 1124 1022 + 426 
5 10829 + 406 9658 + 1278 4225 + 819 2605 + 1395 1653 .:!:. 1491 
10 11324 + 895 10150 .:!: 96 8629 + 1308 3197 + 1020 1414 ! 430 
aMean and standard error of the activity counts of 4 pairs of mice. 
105 1 -120 1 
599 + 136 
1634 + 388 
2270 + 476 
2501 + 68 
360 1 
2923 + 2122 
5481 + 668 
2018 .:!:. 634 
796 + 46 
....... 
0 
I.Cl 
Dose 
{mg/kg sc) 
Control 
10 
20 
40 
Dose 
(mg/kg sc) 
Control 
10 
20 
40 
0-15' 
45.1 + 1.0 
52.7 .:!: 0.2* 
58.0 .:!: 1. 7* 
51.B + 2 .4* 
60' 
TABLE 5 
Effects of Morphine on locomotor Activity 
Mean Activity Counts .:!: S.E.a 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 
33.4 .:!: 5.1 32.9 .:!: 7.7 8.0 ! 2.0 10.2+7.l 
52.6 ! 0.4* 52 .3 ! 1. 7* 51.6 + 1.5* 51. 7 ! 1.3* 
64 .6 + 1.6* 58.8 ! 0.5* 54 .3 + 1.8* 54 .2 + 1.0* 
57 .2 ! 1.2* 53.0 ! 0.5* 50.5 + 1.9* 50.9_:!:3.l* 
2. 60' Intervals over 6 Hours 
120' 180' 240' 
75'-90' 90'-105' 
10.5 + 0.3 20.4 + 13.7 
50.4 ! 1.8* 55.0 + 4.3* 
54.2 + 0.9* 52.0 + 0.4* 
49.4 ! 3.8* 49.1 + 4.0 
300' 
6ti.2 + 0.4 39.7 ! 2.4 46.2 ! 10.8 41.5 ! 12.5 35.0 ! 2.1 
1094.7 ! 1.6* 104 .o ! 1.5* 99.1 ! 5 .O* 70.3 ! 6.5 47.7 ! 5.2 
118.1 ! 0.6* 106.0 ! 1.3* 98.0 + 2.0* 84.6 + 5.0* 58.1 ! 0.3 
106.4 + 1.7* 99.7 + 7.3* 98.4 ! 2.4* 95.5 + 2.1* 49.8 ! 14.2 
aMean and standard error of the square root of the activity counts 
*P <0.05; One-way ANOVA. Dunnet's multiple comparison 
of 4 pairs of mice. 
105'-120' 
23.4 ! 13.0 
50.5 + 1.4* 
51.5 + 0.4* 
49.8 + 3.8 
360' 
49.4 + 17.3 
40.2 ! 9.8 
42.1 + 6.1 
39.4 + 1.2 
~ 
~ 
0 
Dose 
~mglkg sc) 0-15' 
Control 2030 + 87 
10 2778 + 18 
20 3362 + 195 
40 2690 + 246 
Dose 
(mg/kg sc) 60' 
TABLE Sa 
Effects of Morphine on Locomotor Activity 
Mean Activity Counts .! S.E.a 
1. 15' lnterva 1 s over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 
1139 + 337 1142 + 506 67 + 31 154 + 144 
2769 + 38 2742 + 173 2673 + 150 2679 .! 129 
4177 + 206 3456 + 60 2948 + 191 2935 + 104 
3273 + 138 2809 + 55 2553 + 187 2600 + 312 
2. 60' Intervals over 6 Hours 
120' 180' 240' 
75'-90' 90'-105' 
llO + 5.5 603 + 558 
2551 + 177 3039 + 473 
2947 .! 93 2701 + 43 
2456 + 371 2430 + 391 
300' 
Control 4378 + 51 1583 .! 190 2248 + 1000 1879 + 1038 1230 + 149 
10 10960 + 343 10820 .! 309 9845 .! 987 4985 + 907 2299 .! 493 
20 13943 + 150 ll240 + 278 9613 .! 396 7189 + 843 3379 + 39 
40 11324 + 350 9984 .! 1452 9704 .! 475 9131 + 547 2677 .! 1413 
3 Mean and standard error of the activity counts of 4 pairs of mice. 
105'-120' 
717 + 610 
2551 + 142 
2657 + 38 
2499 + 377 
360' 
2742 + 1710 
1712 + 791 
1808 + 511 
1552 + 96 
...... 
I-' 
I-' 
Dose 
(mg/kg sc) 
Control 
10 
20 
40 
Dose 
(mg/kg sc) 
Control 
10 
20 
40 
0-15' 
51.2 + 5.2 
45.9 + 0.6 
47.9 + 2.9 
TABLE 6 
Effects of Naloxone on Locomotor Activity 
Mean Activity Counts ! S.E.a 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 
35.3 ! 1.8 17.3 ! 7.2 35.0 ! 17.2 24.4 ! 20.4 
32. 9 .!. 1. 7 18.7 .!. 4.4 15.4 .!. 3.2 30.8 .!. 5.3 
30.1 .!. 8.4 17.4 .!. 3.3 24.5 + 6.9 23.l + 9.5 
75'-90' 90'-105' 
24.5 .!. 4.4 21.9 .!. 4.1 
36.4 .!. 1.8 21.4 .!. 1.9 
31.8 + 4.5 28.3 + 16.4 
40.9 ! 3.2 32.0 .!. 5.1 28.6 + 2.7 26.5 .!. 0.7 20.7 .!. 5.7 23.4,!ll.7 24.4 .!. 12.6 
2. 60' Intervals over 6 Hours 
60' 120' 180' 240' 300' 
74.6 + 14.1 47.9 .!. 13.1 47.0 .!. 18.7 66.7 + 27.8 44.6 .!. 3.9 
61.7,!0.l 59.2 .!. 9.4 45.5 .!. 1.1 59.4 .!. 5.7 53.5 .!. 8.5 
64.4 + 9.6 51.9 .!. 8.4 28.6 .!. 7.0 55.7 + 12.7 47.3 .!. 12.3 
65.2 .!. 3.1 51.5,!4.l 64 .5 + 10.0 42. 7 + 4 .3 39.0 + 12.1 
aMean and standard error of the square root of the activity counts of 4 pairs of mice. 
*P <0.05; One-way ANOVA, Dunnet's multiple comparison 
105'-120' 
16.0 .!. 9.3 
24.6 + 14.9 
15.0 + 0.4 
25.1 + 11.8 
360' 
56.2 + 25.l 
63.l + 8.7 
47.6 + 14.3 
55.8 + 2.4 
I-' 
I-' 
N 
Dose 
(mg/kg sc) 
Control 
10 
20 
40 
Dose 
(mg/kg __ sc_) 
Control 
10 
20 
40 
0-15' 
2653 + 533 
2105 + 53 
2303 + 274 
1682 + 259 
60' 
TABLE 6a 
Effects of Naloxone on Locomotor Activity 
Mean Activity Counts ..! S.E.a 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 
1249 + 127 350 + 248 1518 ..! 1199 1008 + 992 
1088 + 114 368 + 163 247 + 99 1375 + 323 
976 + 506 315 + 115 647 + 337 624 + 438 
1051 + 329 824 + 153 703 + 36 460 + 237 
2. 60' Intervals over 6 Hours 
120' 180' 240' 
75'-90' 90' -105' 
620 + 215 496 + 178 
1330 + 133 460 + 79 
1034 + 285 1066 + 925 
685 + 547 756 + 615 
300' 
5769 ..! 2107 2465 + 1251 2553 + 1754 5218 + 3704 2004 + 345 
3807 + 4 3589 + 1108 2070 + 103 3564 + 678 2930 + 910 
4243 ..! 1234 2950 + 1659 864 ..! 398 3261 + 1418 2394 + 1167 
4259 + 400 2670 + 423 4264 + 1287 1846 + 367 1663 + 942 
ilMeiln and standard error of the activity counts of 4 pairs of mice. 
105'-120' 
341 + 297 
825 + 731 
226 + 11 
770 + 591 
360' 
3785 + 2816 
4060 + 1099 
2473 + 1362 
3115 + 268 
....... 
...... 
w 
Dose 
(mg/kg scJ 
Control 
10 
20 
40 
Dose 
(mg/kg sc) 
Control 
10 
20 ' 
40 
0-15 1 15 1 -30 1 
TABLE 7 
Effects of Naltrexone on Locomotor Activity 
Mean Activity Counts .:!. S.E.a 
1. 15 1 Intervals over 2 Hours 
30'-45' 45'-60 1 60'-75' 75'-90' 90'-105 t 
51.1.!,7.7 44.2 + 5.8 34.8 .:!. 6.0 19.9 .:!. 1.0 23.9 .:!. 1.9 25.1 .:!. 19.6 38.3 .:!. 7.8 
49.6 + 4.2 43.2 + 6.7 26.2 + 4.3 29.1 + 0.2 22 .o + 10.1 27.8 .:!. 5.1 37.5 .:!. 5.9 
51.2 + 3.1 29.6 + 8.5 22.8 .:!. 0.6 26.3 + 11.0 14.7 + 1.4 22.0 .:!. 8.4 15.2 .:!. 6.0* 
47.9 + 0.7 47.4 + 0.7 38.4 .:!. 2.8 35.2 .:!. 0.7 36.3 .:!. 1.7 38.4 .:!. 0.5 39.2 .:!. 1.5 
2. 60' lnterva 1 s over 6 Hours 
60 1 120 1 180 1 240 1 300 1 
78.7 .:!. 10.7 60.0 .:!. 16.3 63.l .:!. 7.7 40.7 + 13.3 58.5 .:!. 2.1 
76.6 .:!. 8.0 65.4 .:!. 0.7 56.3 .:!. 0.9 53.5 .:!. 7.6 70.9 .:!. 2.4 
69.3 + 10.3 36.3 .!. 13.2 44.1 .:!. 26.8 60.9 .:!. 7.6 35.3 .:!. 7.7 
85. 2 .:!. 1. 6 76.5 .:!. 1.4 66.4 .:!. 3.7 48.0 + 1.8 62.8 .!. 21.0 
aMean and standard error of the square root of the activity counts of 4 pairs of mice. 
*P <0.05; One-way ANOVA. Dunnet's multiple comparison 
105'-120' 
27.0 + 5.3 
37.7 .:!. 4.9 
19.0 .:!. 9.8 
39.1 .:!. 0.3 
360 1 
42 .6 + 1. 7 
48.4 + 3.8 
60.5 + 14 .4 
61.4 + 5.0 
I-' 
I-' 
+>-
Dose 
(mg/~~tl 0-15' 
Control 2669 ! 786 
10 2480 + 419 
20 2634 + 318 
40 2297 + 70 
Dose 
(mg/kg scJ 60' 
TABLE 7a 
Effects of Naltrexone on Locomotor Activity 
Hean Activity Counts ! S.E.a 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 
1988 + 514 1247 + 414 398 ! 39 573 + 92 
1908 + 576 703 + 223 845 + 10 587 + 444 
950 + 505 519 + 27 812 + 576 217 + 39 
2245 + 69 1481 + 216 1238 + 50 1320 + 119 
2. 60' Intervals over 6 Hours 
120' 180' 240' 
75'-90' 90'-105' 
1011 + 980 1526 + 595 
798 + 283 1441 + 439 
553 + 367 267 + 181 
1472 + 42 1537 + 115 
300' 
Control 6302 + 1674 3863 + 1955 4041 + 973 1831 + 1080 3422 ! 243 
10 5936 + 1228 4272 + 93 3171 ! 101 2915 + 811 5036 + 338 
20 4914 + 1426 1491 ! 958 2660 + 2360 3761 + 924 1302 + 542 
40 7260 + 266 5853 + 217 4429 + 489 2304 + 173 4386 ! 2644 
aMean and standard error of the activity counts of 4 pairs of mice. 
105'-120' 
755 + 286 
1447 + 371 
455 + 370 
1525 + 24 
360' 
1815 + 143 
2353 + 369 
3865 + 1746 
3791 + 609 
....... 
I-' 
U1 
Dose 
tmg/kg sc) 
Control 
5 
10 
20 
Dose 
(mg/kg sc) 
Control 
5 
10 
20 
0-15' 
52.1 + 4.4 
1. 7 + 1. 7* 
2.2 ..!. 2.2* 
4.7 + 1.5* 
60' 
TABLE 8 
Effects of Ethylketocyclazocine on Locomotor Acti~ity 
Mean Activity Counts ..!. S.E.a 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 
40.2 + 0.6 24.0 + 1.5 21.6 ..!. 4.8 34.9 ..!. 9.6 27.9 + 8.1 
0.7 ..!. 0.7* 6.4 + 1.0* 19.1 ..!. 11.0 18.2 ..!. 2.3 27.8 + 6.2 
1.8 ..!. 1.8* 2.2 + 2.2* 2.3 + 2.3 7.8 ..!. 0.1* 2.3 ..!. 0.9* 
1.8 + 1.8* 2.2 ..!. 2.2* 2.3 ..!. 2.2 2.1 + 2.1* 1.5 ..!. 1.5* 
2. 60' Intervals over 6 Hours 
90' -105' 
20.6 ..!. 14.3 
28.2 + 4.4 
8.8 ..!. 3.1 
2.7 ..!. 2.7 
120' 180' 240' 300' 
73.4 + 5.3 53.4 ..!. 3.6 54.3 ..!. 10.4 44.6 + 10.9 38.3 ..!. 0.8 
20.5 ..!. 10.7* 47.2 ..!. 7.0 79.3 ..!. 14.5 82 .6 ..!. 1. 7 79.6 ..!. 1.8* 
4.2 + 4.2* 20.2 ..!. 4.3* 36.l + 5.8 64.5 + 8.3 72.4 ..!. 18.5 
7.0 + 0.8* 5.8 + 3.0* 17.0 ..!. 7.1 37.6 + 18.2 49.0 + 7.0 
3 Mean and standard error of the square root of the activity counts of 4 pairs of mice. 
*P <0.05; One-way ANOVA, Dunnet's multiple comparison 
105'-120' 
9.0 + 0.3 
17.8 + 0.4 
14.6 + 7.6 
3.8 + 1.0 
360' 
40.5 + 2.0 
73.6 + 3.8 
73.6 + 13.9 
58.7 + 10.2 
...... 
...... 
°' 
TABLE 8a 
Effects of Ethylketocyclazocine on Locomotor Activity 
Mean Activity Counts ! S.E.a 
1. 15' Intervals over 2 Hours 
Dose 
(mg/kg sc) 0-15' 15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 90'-105' 
Control 2734 + 453 1615 + 44 577 ± 69 487 + 205 1308 ! 667 844 + 453 630 + 590 
5 6 + 6 1 + 1 42 + 13 486 ! 419 335 ! 83 809 + 345 814 + 246 
10 10 ! 10 7 + 7 10 + 10 11 ! 11 62 + 1 6 + 4 87 + 54 
20 25 + 14 7 + 7 10 + 10 10 + 10 9 ! 9 5 + 5 14 + 14 
2. 60' Intervals over 6 Hours 
Dose 
(mg/kg sc) 60' 120' 180' 240' 300' 
Control 5412 + 722 2863 + 381 3058 ! 1125 2105 ! 973 1548 ! 63 
5 535 ! 439 2273 ! 660 6502 ! 2302 6830 ! 281 6344 ! 279 
10 36 + 36 426 ! 172 1340 ! 417 4227 + 1066 5588 + 2684 
20 50 + 11 43 + 34 339 + 241 1747 + 1366 2449 + 683 
aMean and standard error of the activity counts of 4 pairs of mice. 
105'-120' 
81 + 5 
316 + 13 
272 + 222 
16 + 7 
360' 
1642 + 165 
5434 + 564 
5605 + 2043 
3552 + 1193 
....... 
....... 
-......J 
Dose 
~mg/kg sc} 
Control 
20 
40 
80 
Dose 
(mg/kg sc) 
Control 
20 
40 
80 
TABLE 9 
Effects of Pentazocine on Locomotor Activity 
Mean Activity Counts .:!: S.E.a 
1. 15' Intervals over 2 Hours 
0-15' 15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 90'-105' 
50.l .:!: 7.1 42.1 .:!: 0.6 24.2 + 5.9 18.6 .:!: 9.6 17.4 .:!: 3.9 14.6 .:!: 5.4 32.0 .:!: 16.0 
47.0 + 2.1 46.7 .:!: 1.4 46.9 + 0.0* 49.9 .:!: 9.3* 51. 9 .:!: 6.0* 50.5 .:!: 9.9* 43.3 .:!: 2.2 
55.3 + 2.7 50.3 .:!:. 3.9 46.8 .:!: 2.2* 47.3 .:!: 4.1 48.5 .:!: 2.9* 46.6 .:!: 3.3* 47.7+1.0 
49.6 + 4.2 43.3 + 7.0 45.3 .:!: 2.9* 46.0 .:!: 4.4 42.9 .:!: 4.7* 40.9 .:!: 7.3 36.7 + 8.2 
2. 60' Intervals over 6 Hours 
60' 120' 180' 240' 300' 
73.2 + 5.0 51.8 + 11.8 54.4 .:!: 19.0 43.7 .:!:. 15.6 53.1 .:!: 2.1 
95.6 .:!: 5.2* 88.2 .:!: 8.8 52 .2 .:!: 1. 7 65.4 .:!: 0.0 48.5 .:!: 3.1 
100.l + 6.4* 92.3 .:!: 3.1* 76.8 .:!: 1.3 43.6 .:!: 10.3 35.5 .:!: 7.5* 
92. 7 + 1. 9* 76.1 .:!: 13.4 64.5 + 9.6 51.9 + 7.9 26.6 + 0.3* 
ilMean and standard error of the square root of the activity counts of 4 pairs of mice. 
*P <0.05; One-way ANOVA, Dunnet's multiple comparison 
105'-120' 
31.2 + 2.8 
24.1 + 5.2 
41.4 + 1.5 
30.3 + 7.2 
360' 
41.5.:!:16.7 
89.5 + 13.0* 
46.6 + 8.2 
48.1 + 6.8 
....... 
....... 
~ 
Dose 
(mg/kg sc) 
Control 
20 
40 
80 
Dose 
(mg/kg sc) 
Control 
20 
40 
80 
TABLE 9a 
Effects of Pentazocine on Locomotor Activity 
Mean Activity Counts _:!: S.E.a 
1. 15' Intervals over 2 Hours 
0-15' 15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 90'-105' 
2558 + 708 1770 + 53 619 + 284 440 + 359 319 + 137 242 ! 158 1284 + 1027 
2214 + 195 2182 + 129 2200 + 0 2577 ! 931 2732 + 622 2646 + 1001 1881 + 186 
3060 + 298 2550 + 397 2196 ! 207 2257 + 384 2357 + 282 2180 + 310 2297 + 97 
2476 + 415 1922 + 608 2057 + 26 2133 + 401 1860 ! 402 1727 + 596 1415 + 599 
2. 60' Intervals over 6 Hours 
60' 120' 180' 240' 300' 
5387 + 729 2824 + 1226 3321 ! 2070 2155 + 1366 2831 + 263 
9172 + 996 7865 ! 1560 2723 + 178 4278 + 2 2366 ! 305 
10062 + 1286 8533 ! 563 5896 !. 192 2004 + 898 1314 !. 533 
8587 + 355 5971 ! 2036 4245 + 1234 2754 + 821 710 + 18 
aMean and standard error of the activity counts of 4 pairs of mice. 
105'-120' 
980 + 177 
607 + 250 
1718 + 126 
970 + 438 
360' 
1998 + 1386 
8178 + 2322 
2243 + 763 
2356 + 655 
I-' 
I-' 
\.0 
Oose 
(mg/kg sc) 
Control 
2.5 
5 
10 
Dose 
(mg/kg sc} 
Control 
2.5 
5 
10 
TABLE 10 
Effects of Cyclazocine on Locomotor Activity 
Mean Activity Counts .! S.E.a 
1. 15' Intervals over 2 Hours 
0-15' 15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 90'-105' 
53.9 + 9.5 51.3_!7.7 36.1 + 10.0 29.9 .! 7.2 26.2 .! 16.3 11. 7 .! 6.5 13.4 .! 6.1 
58.4 + 2.6 59.8 .! 1.0 63.0 + 4.2'* 56.5 .! 3.9'* 43.7 .! 9.2 38.CJ .! 10.5 43.7 .! 5.2'* 
57.7 .! 2.0 60.7 .! 2.2 61.8_! 4.2'* 60.2 .! 0.3'* 46.2 .! 4.3 29.6 .! 5.2 28.6 + 6.3 
55.4 + 0.1 58.7 .! 3.8 57 .2 .! 1.9 62 .6 .! 1.1 '* 64.2 + 0.3* 53.5 .! 3.6'* 42.4 .! 3.1'* 
2. 60' Intervals over 6 Hours 
60' 120' 180' 240' 300' 
88.1 + 16.8 48.7 .! 4.7 36.3 + 4.7 52 .1 .! 11.2 37.5 .! 2.6 
119.0 .! 5.8 80.6 .! 18.1 77 .1 .! 3.7'* 40.0 .! 11.2 54.6 .! 8.8 
120.3 .! 4.3 67.2 .! 2.4 54.8 .! 0.6 43.0 .! 5.6 36.2 .! 18.8 
117.1 .! 3.3 100.3 .! 5.3'* 54 .9 .! 11.4 37.5 .! 6.0 32 .1 .! 11.2 
aMean and standard error of the square root of the activity counts of 4 pairs of mice. 
'*P <0.05i One-way ANOVA. Ounnet's multiple comparison 
105'-120' 
31. 7 .! 6.1 
33.4 .! 12.6 
24.6 .! 2.5 
35.5 .! 5.4 
360' 
45.0 .! 6.4 
36.5 .! 11. 9 
48.7 .! 3.6 
30.1 + 2.1 
....... 
N 
0 
Dose 
~mglkg sc} 
Control 
2.5 
5 
10 
Dose 
(mg/kg sc) 
Control 
2.5 
5 
10 
0-15' 
2997 + 1021 
3416 + 298 
3333 + 226 
3073 + 16 
60' 
TABLE lOa 
Effects of Cyclazocine on Locomotor Activity 
Mean Activity Counts ~ S.E.a 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 
2694 ~ 794 1402 + 720 948 + 430 954 + 854 
3576 + 114 3989 + 524 3203 + 440 1989 + 799 
3690 + 268 3830 + 513 3626 + 34 2154 + 392 
3462 + 449 3280 + 211 3915 + 136 4120 + 42 
2. 60' Intervals over 6 Hours 
120' 180' 240' 
75'-90' 90 1 -105 I 
180 + 153 216 + 163 
1624 + 830 1936 + 450 
901 + 307 860 + 362 
2870 + 385 1806 + 262 
300' 
8041 + 2965 2392 + 458 1342 ~ 339 2839 + 1161 1410 + 195 
14183 + 1376 6825 + 2914 5960 ~ 564 1723 + 894 3056 + 958 
14479 + 1042 4526 + 325 3005 ~ 65 1878 + 477 1666 + 1361 
13729 + 781 10085 + 1072 3142 ~ 1252 1439 + 449 1157 + 720 
aMeJn and standard error of the activity counts of 4 pairs of mice. 
105'-120' 
1042 + 386 
1277 + 844 
612 + 122 
1290 + 382 
360' 
2063 + 576 
1470 + 865 
2385 + 349 
910 + 128 
........ 
N 
........ 
Dose 
tmgL kg sc l 
Control 
10 
20 
40 
Dose 
(mg/kg sc) 
Control 
10 
20 
40 
TABLE 11 
Effects of SKF 10,047 on Locomotor Activity 
Mean Activity Counts ! S.E.a 
1. 15' Interva 1 s over 2 Hours 
0-15' 15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 90'-105' 
42 .1 ! 17. 0 47.3 ! 10.3 44.6 ! 5.9 46.9 ! 10.8 25.3 ! 14.8 13.8 ! 1.9 28.6 ! 0.7 
56.2 + 0.9 59.0 ! 0.8 56.8 + 1.6 54.9 + 0.2 45.8 + 4.9 46.7 ! 3.7* 41.7 + 4.7* 
55.7 + 0.7 59.8 + 0.6 62.8 ! 0.9* 58.2 + 1.8 49.6 .! 8.9 50.5 .! 6.3* 52.0 + 4.0* 
53.7 + 0.7 56.6 + 1.7 58.4 .! 3.0* 58.8 .! 2.7 56.2 .! 3.9 51.1 .! 4.1* 45.3 .! 0.6* 
2. 60' Intervals over 6 Hours 
60' 120' 180' 240' 300' 
91.0 + 21.6 54.1 .! 13.7 55.9 .! 19.3 35.1 .! 4.1 55.8 .! 13.3 
113.5 + 0.9 88.5 + 1. 9 65 .2 .! 1.1 47 .9 .! 21.3 70.6 .! 4.1 
118.4 + 1.1 99.8 .! 12.8* 77.9_!15.l 52.7 .! 12.9 38.1 .! 19.1 
113.9 .! 4.1 100.4 .! 1.1* 73.6 .! 12.2 47.5 + 4.0 44 .4 .! 1.8 
aMean and standard error of the square root of the activity counts of 4 pairs of mice. 
*P <0.05; One-way ANOVA, Dunnet's multiple comparison 
105'-120' 
33. 3 ! 11.1 
41.8 + 0.5 
47.3 .! 6.6 
46.8 + 6.1 
~ 
so.a + 13.9 
54.6 + 9.5 
50.8 + 1.5 
25.2 + 3.1 
I-' 
N 
N 
TABLE lla 
Effects of SKF 10,047 on Locomotor Activity 
Mean Activity Counts ! S.E.a 
1. 15' Intervals over 2 Hours 
Dose 
(mg/kg sc) 0-15' 15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 90'-105' 
Contra l 2059 + 1432 2347 + 972 2024 + 525 2314 + 1008 861 + 750 194 + 52 820 + 41 
10 3163 + 97 3482 + 99 3228 + 180 3012 + 17 2125 + 444 2194 + 343 1760 + 390 
20 3108 + 78 3578 + 73 3945 + 109 3386 ! 209 2538 + 880 2587 + 637 2722 + 419 
40 2888+ 74 3206 + 188 3423 + .353 3466 + 321 3169 + 433 2632 + 421 2048 + 55 
2. 60' Intervals over 6 Hours 
Dose 
(mg/kg sc) 60' 120' 180' 240' 300' 
Control 8743 + 3938 3108 ! 1478 3495 ! 2160 1248 + 285 3287 + 1483 
10 12885 + 199 7828 + 331 4246 + 147 2747 ! 2038 5007 + 576 
20 14015 + 251 10125 ! 2563 6304 + 2358 2941 + 1356 1817 + 1453 
40 12983 + 936 10080 + 228 5572 + 1796 2270 + 378 1977 + 157 
ilMean and standard error of the activity counts of 4 pairs of mice. 
105'-120' 
1235 + 738 
1761 + 41 
2279 + 626 
2231 + 571 
360' 
2678 + 1381 
2981 + 122 
2579 + 151 
644 + 156 
...... 
N 
w 
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TABLE 12 
The Effects of Acute Administration of Opiate Agonists, 
Antagonists, and Mixed Agonist-Antagonists on 
Apomorphine-Induced Climbing in Micea 
Dose i Change 
Treatment {mglkgl Comeared to Control ~b 
VehicleC 
Morphine 2.0 +7 
8.0 -6 
Naloxone 5.0 +2 
20.0 +2 
Naltrexone 5·.o -6 
20.0 -21 
Ethylketocyclazocined 5.0 -18 
20.0 -52 * 
Pentazocine 20.0 -4 
80.0 -2 
Cyclazocine 1.25 +7 
5.0 +4 
SKF 10,047d 10.0 -9 
40.0 -25 * 
aorugs administered (n=8) ip 30 min. prior to apomorphine at 1.5 mg/kg sc. 
bone-way ANOVA, Duncan's multiple-range test; *P <0.05 
CRange of means over five experiments (5.5-6.0). 
dGeneral depressive effects including ataxia and flaccidity were 
observed at each dose. 
TABLE 13 
Effects of SKF 10,047 and EKC on 
Apomorphine-Induced Stereotypya 
Dose Ster~otypy Score i Change 
Treatment {mglkg i E!} x ± S.E. from Control 
Vehicle 5.63 + 0.26 
SKF 10,047 40.0 5.00 + 0.50 -11 
EKCC 20.0 1.50 + 0.98 -73 
aAcute pretreatment 30 minutes prior to apomorphine at 1.5 mg/kg sc 
(n=8} 
bone-way ANOVA, Duncan's multiple-range test; •p <0.05; significant 
difference compared to vehicle control. 
CGeneral depressive effects were observed. 
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~b 
* 
Treatment 
Vehicle 
TABLE 14 
Effects of Acute Haloperidol Treatment on 
Apomorphine (0.4 mg/kg) -Induced Locomotor Activitya 
Mean Activity Counts ! S.E.b 
1. 15' Intervals over 2 Hours 
0-15' 15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 90'-105' 105'-120' 
53.5 + 1.1 49.3 ! 2.5 29.9 ! 6.6 25.6 ! 2.4 26.8 ! 5.9 32.8 ! 8.1 26.0 + 7.3 34.6 + 4.8 
llaloperidol 48.6 ! 2.4 50.3 ! 1.9 38.7 ! 5.7 34.7 ! 4.5 20.2 .! 7.0 20.0 .! 5.8 27.0 .! 10.7 26.4 + 3.1 
2. 60' Intervals over 2 Hours 
60' 120' 
I Change 
i ±SE 
I Change 
Treatment x ± SE from Control from Control 
Vehicle 83.3 .! 5.0 
- 63.8 .! 6.4 
Ha 1 operi do l 87.6 .:!: 6.0 +5 52.8 .! 5.0 -17 
aHaloperidol administered at 1.25 mg/kg ip followed by a 72-hr. drug-free period, then apomorphine at 0.4 
mg/kg SC. 
hMean and standard error of the square root of the activity counts of 8 pairs of mice. 
*P <0.05; "t" test >--' 
N 
(J'\ 
Treatment 
Vehicle 
Haloperidol 
0-15' 
2861 + 115 
2377 + 236 
TABLE 14a 
Effects of Acute Haloperidol Treatment on 
Apomorphine (0.4 mg/kg) -Induced Locomotor Activitya 
Mean Activity Counts + S.E.b 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 
2447 + 232 1024 + 458 675 + 122 823 + 352 1273 + 467 
2539 + 185 1595 + 471 1264 + 351 558 + 351 504 + 234 
2. 60 1 Intervals over 2 Hours 
60' 120' 
90'-105' 
835 + 373 
1072 + 582 
.! SE 
S Change 
- + 
S Change 
Treatment x from Control x - SE from Contro 1 
Vehicle 7007 .! 849 
-
4196 + 732 
Haloperidol 7774 + 1063 +11 2860 + 511 
-32 
105 1 -120 I 
1266 + 351 
726 + 174 
a llaloperidol administered at 1.25 mg/kg ip/day for five days followed by a 72-hr. drug-free period, then 
apomorphine at 0.4 mg/kg sc. 
b Medn and standard error of the activity counts of 8 pairs of mice. 
I-' 
N 
'-I 
TABLE 15 
Apomorphine-Induced Stereotyped Behavior 
Effects of Haloperidol (1.25 mg/kg) 72 Hours Pretreatment 
Apomorphine 
Dose Stere~typy Score % I Change 
(mg/kg sc) Treatment n x ± SE Stereotypya Compared to Control 
0.4 Vehicle 8 2.63 :!: 0.38 44 
Haloperidol 8 2.88 .!. 0.55 48 +10 
0.8 Vehicle 8 3.38 .!. 0.38 56 
Haloperidol 8 4.13 :!: 0.30 69 +22 
a % of stereotypy based on maximum score = 6. 
% stereotypy = x of Dose Group x 100 
Max. score 
b "t" test 
~b 
.._. 
N 
co 
Treatment 
Vehicle 
Ha 1 operi do 1 
TABLE 16 
Haloperidol-Induced Supersensitivity 
in the Climbing Hice Assaya 
Dose Climbing Score 
{mg/kg ip) n i ± SE 
24 2.1 !: 0.3 
1.25 24 4.8 !: 0.3 
i 
Change 
+129 
aAcute injection of haloperidol 72 hours prior to apomorphine at 0.4 
mg/kg SC. 
bntn test, *P c0.001 
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lli..:.b 
* 
TABLE 17 
Climbing Mice Supersensitivitya 
Simultaneous Administration of Vehicle and Opiate Agonists, 
Antagonists and Mixed Agonist-Antagonists 
Treatment 
Vehicle-VehicleC 
Vehicle-Morphine 
Vehicle-Naloxone 
Vehicle-Naltrexone 
Vehicle-EKC 
Vehicle-Pentazocine 
Vehicle-Cyclazocine 
Vehicle-SKF 10,047 
Dose 
(mg/kg) 
2 
8 
5 
20 
5 
20 
5 
20 
20 
80 
1.25 
5 
10 
40 
% Change 
Compared to Control 
+79 
-20 
+27 
-32 
-20 
-4 
+13 
+5 
+86 
0 
-7 
0 
-13 
-53 
a Acute simultaneous administration, 72-hr. pretreat, then apomorphine 
at 0.4 mg/kg sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test. 
c Range of means over four experiments (1.8-2.8). 
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TABLE 18 
Climbing Hice Supersensitivitya 
Simultaneous Administration of Haloperidol and Opiate Agonists, 
Antagonists and Mixed Agonist-Antagonists 
Dose 
131 
Treatment {mgLkg) 
I Change 
Compared to Control ~b 
Haloperidol-VehicleC 1.25 
Haloperidol-Morphine 2 
8 
Haloperidol-Naloxone 5 
20 
Haloperidol-Naltrexone 5 
20 
Haloperidol-EKC 5 
20 
Haloperidol-Pentazocine 20 
80 
Haloperidol-Cyclazocine 1.25 
5 
Haloperidol-SKF 10,047 10 
40 
+11 
-29 
-9 
-44 
-50 
-51 
-3 
-56 
+11 
-42 
-53 
-64 
-54 
-75 
* 
* 
* 
* 
* 
* 
* 
* 
a Acute simultaneous administration, 72-hr. pretreat, then apomorphine 
at 0.4 mg/kg sc (n=B per group). 
b One-way ANOVA, Duncan's multiple-range test; *P <0.05 
c Range of means over four experiments (4.3-5.6) 
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TABLE 19 
Climbing Hice Supersensitivity 
Simultaneous Administration of Haloperidol and Naloxonea 
Vehicle and Na 1 oxone 
% Change 
Dose Clim~ing Score Compared 
Treatment (mg/kg) x ±SE to Control ~b 
Vehicle-Vehicle 2.00 + 0.42 
Vehicle-Naloxone 5.0 2.13 + 0.40 +7 
10.0 2 • 00 .:t 0 • 71 0 
20.0 2.88 + 0.64 +44 
40.0 1.38 + 0.73 -31 
Haloperidol and Na l oxone 
% Change 
Dose Climbing Score Compared 
Treatment (mg/kg) x ± SE to Control ~b 
Haloperidol-Vehicle 1.25 4.00 .:t 0.76 
Haloperidol-Naloxone 5.0 2.50 + 0.54 -37 
10.0 2.29 + 0.78 -43 
20.0 1.63 .:t 0.26 -59 * 
40.0 1.50 + 0.42 -62 * 
a Acute simultaneous administration, haloperidol ip - naloxone sc, 72-hr 
pretreat, then apomorphine at 0.4 mg/kg sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test, *P <0.05 
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TABLE 20 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol and Naltrexonea 
Vehicle and Na 1 trexone 
i Change 
Dose Climbing Score Compared 
Treatment {mglkg} x ± SE to Control ~b 
Vehicle-Vehicle 2.38 + 0.53 
Vehicle-Naltrexone 2.5 1. 75 + 0.41 -26 
5.0 2.13 + 0.40 -11 
10.0 1. 75 + 0.37 -26 
20.0 1.38 + 0.50 -40 
Haloperidol and Naltrexone 
i Change 
Dose Climbing Score Compared 
Treatment {mglkg} x ± SE to Control ~b 
Haloperidol-Vehicle 1.25 4.00 + 0.46 
Haloperidol-Naltrexone 2.5 2.63 + 0.53 -34 
5.0 2.63 + 0.71 -34 
10.0 2.13 + 0.42 -47 * 
20.0 1.63 + 0.42 -59 * 
a Acute simultaneous administration, haloperidol ip - naltrexone sc, 72-hr 
pretreat, then apomorphine at 0.4 mg/kg sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test, *P <0.05 
TABLE 21 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol and EKca 
Vehicle and EKC 
% Change 
Dose Climbing Score Compared 
Treatment (mg[kg) x ± SE to Control 
Vehicle-Vehicle 1.25 + 0.49 
Vehicle-EKC 2.5 1.38 + 0.53 +10 
5.0 1.25 + 0.45 0 
10.0 1.38 .:!: 0.53 +10 
20.0 1. 75 + 0.56 +50 
Haloperidol and EKC 
% Change 
Dose Climbing Score Compared 
Treatment (mg[ kg) x ± SE to Control 
Haloperidol-Vehicle 1.25 2.88 + 0.52 
Haloperidol-EKC 2.5 2.38 + 0.38 -17 
5.0 1.88 + 0.81 -35 
10.0 2.25 .:!: 0.68 -22 
20.0 1.25 + 0.86 -57 
a Acute simultaneous administration, haloperidol ip - EKC sc, 72-hr 
pretreat, then apomorphine at 0.4 mg/kg sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test, *P <0.05 
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~b 
~b 
* 
* 
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TABLE 22 
Climbing Hice Supersensitivity 
Simultaneous Administration of Haloperidol and Pentazocinea 
Vehicle and Pentazocine 
i Change 
Dose Climbing Score Compared 
Treatment (mg/kg) x ±SE to Control lli.:.b 
Vehicle-Vehicle 1.63 + 0.65 
Vehicle-Pentazocine 10.0 1.63 + 0.53 0 
20.0 2.13 + 0.58 +31 
40.0 1.88 + 0.58 +15 
80.0 1.88 + o. 77 +15 
Ha 1 operi do 1 and Pentazocine 
i Change 
Dose Cl im~i ng Score Compared 
Treatment (mg/kg) x ± SE to Control lli.:.b 
Haloperidol-Vehicle 1.25 3.50 + 0.80 
Haloperidol-Pentazocine 10.0 4.50 + 0.50 +29 
20.0 2.50 + 0.89 -29 
40.0 2.25 + 0.80 -56 * 
80.0 2.00 .! 0.57 -63 * 
a Acute simultaneous administration, haloperidol ip - pentazocine sc, 72-hr 
pretreat, then apomorphine at 0.4 mg/kg sc (n=S per group). 
b One-way ANOVA, Duncan's multiple-range test, *P <0.05 
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TABLE 23 
Climbing Hice Supersensitivity 
Simultaneous Administration of Haloperidol and Cyclazocinea 
Vehicle and Cyclazocine 
i Change 
Dose Climbing Score Compared 
Treatment {mglkg) i ±SE to Control .lli:.b 
Vehicle-Vehicle 1.88 + o. 74 
Vehicle-Cyclazocine 0.625 2.25 .! 0.49 +20 
1.25 2.00 .! 0.50 +6 
2.5 1.88 + 0.58 0 
5.0 2.00 + 0.68 +6 
Hal operi do l and Cyclazocine 
% Change 
Dose Climbing Score Compared 
Treatment {mglkg) i ± SE to Control .lli:.b 
Haloperidol-Vehicle 1.25 3.88 .! 0.35 
Haloperidol-Cyclazocine 0.625 4.00 +l.07 +3 
1.25 2.63 + 0.60 -32 
2.5 2.00 + 0.85 -48 * 
5.0 1.75 + 0.59 -55 * 
a Acute simultaneous administration, haloperidol ip - cyclazocine sc, 72-hr 
pretreat, then apomorphine at 0.4 mg/kg sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test, *P <0.05 
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TABLE 24 
Climbing Mice Supersensitivity 
Simultaneous Administration of Haloperidol and SKF 10,047a 
Vehicle and SKF 10,047 
% Change 
Dose Climbing Score Compared 
Treatment {mglkg} x ± SE to Control ~b 
Vehicle-Vehicle 1.88 !. 0.48 
Vehicle-SKF 10,047 5.0 2.00 + 0.60 +6 
10.0 1.38 !. 0.38 -27 
20.0 1.63 + 0.63 -13 
40.0 1. 75 + 1.00 -7 
Haloperidol and SKF 10,047 
% Change 
Dose Clim~ing Score Compared 
Treatment {mglkg} x ± SE to Control ~b 
Haloperidol-Vehicle 1.25 3.50 !. 0.57 
Haloperidol-SKF 10,047 5.0 2.13 + 0.91 -39 
10.0 1.63 + 0.57 -53 * 
20.0 1.75 + 0.41 -50 
40.0 0.88 + 0.48 -75 * 
a Acute simultaneous administration, haloperidol ip - SKF 10,047 sc, 72-hr 
pretreat, then apomorphine at 0.4 mg/kg sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test, *P <0.05 
Treatment 
Vehicle 
TABLE 25 
Effects of Chronic Haloper1dol Treatment on 
Apomorphine (0.4 mg/kg) -Induced Locomotor Act1v1tya 
Mean Activity Counts .:!:. S.E.b 
1. 15' Intervals over 2 Hours 
0-15' 15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 90'-105' 105'-120' 
53.3 + 1.9 44.9 .:!:. 2.3 28.6 .:!:. 4.9 26.3 .:!:. 2.5 35.7 .:!:. 5.7 23.4 .:!:. 7.7 31.6 .:!:. 12.2 49.8 .:!:. 4.5 
llaloperidol 51.4 .:!:. 1.8 52.7 .:!:. 0.7* 41.4 .:!:. 2.5 37.4 .:!:. 5.2 44.1.:!:.1.7 46.4 .:!:. 2.7* 35.2 .:!:. 7.9 24.9 + 4.8* 
2. 60' Intervals over 2 Hours 
60' ~ 
x ± SE 
I Change 
i ±SE 
I Change 
Treatment from Control from Control 
Vehicle 80.3 .:!:. 3.1 - 76.5 .:!:. 8.7 
Halop~ridol 92.7 .:!:. 4.2 +15 78.2 .:!:. 6.6 +2 
a11aloperidol administered at 1.25 mg/kg ip per day for five days followed by a 72-hr. drug-free period. then 
apornorphine at 0.4 mg/kg sc. 
bMean and standard error of the square root of the activity counts of 8 pairs of mice. 
*P <0.05. "t" test 
I-' 
w 
co 
Treatment 
Vehicle 
llaloperidol 
0-15' 
2852 + 203 
2654 + 183 
TABLE 25a 
Effects of Chronic Haloperidol Treatment on 
Apomorphine (0.4 mg/kg) -Induced Locomotor Activitya 
Mean Activity Counts .! S.E.b 
1. 15' Intervals over 2 Hours 
15'-30' 30'-45' 45'-60' 60'-75' 75'-90' 
2036 + 197 887 + 321 708 + 129 1372 + 357 723 + 426 
2782 + 74 1729 + 210 1479 + 391 1955 + 145 2175 + 145 
2. 60' Intervals over 2 Hours 
60' llQ.'.. 
90'-105 I 
1439 + 752 
1428 + 522 
S Change i Change 
Treatment x .! SE from Cont ro 1 - + x - SE from Control 
Vehicle 6483 .! 485 
-
6070 + 1405 
Haloperidol 8644 .! 786 +33 6248 + 1060 +3 
105'-120' 
2536 + 416 
690 + 281 
a Haloperidol administered at 1.25 mg/kg ip per day for five days followed by a 72-hr. drug-free period, then 
.ipomorphine at 0.4 mg/kg sc. 
b Mean and standard error of the activity counts of 8 pairs of mice. 
...... 
w 
l.O 
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TABLE 26 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-0ay Administration of 
Morphine (10 mg/kg sc) and Haloperidol (1.25 mg/kg ip)a 
Stereotypy Score I Change 
Treatment x ± SE from Control ~b 
Vehicle-Vehicle 2.25 + 0.37 
Vehicle-Haloperidol 5.50 .!. 0.27 +144 
Morphine-Vehicle 4.88 + 0.44 +117 
Morphine-Haloperidol 5.63 + 0.26 +150 
a Five days simultaneous administration, haloperidol ip - morphine sc 
followed by a 72-hr. drug-free period, then apomorphine at 0.4 mg/kg 
sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test; *P <0.05 
* 
* 
* 
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TABLE 27 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of 
Naltrexone (40 mg/kg sc) and Haloperidol (1.25 mg/kg ip)a 
Stereotypy Score % Change 
~b Treatment x ± SE from Control 
Vehicle-Vehicle 2.13 + 0.44 
Vehicle-Haloperidol 5.13 + 0.40 +140 * 
Naltrexone-Vehicle 2.63 + 0.53 +23 
Naltrexone-Haloperidol 5.25 + 0.31 +146 * 
a Five days simultaneous administration, haloperidol ip - naltrexone sc 
followed by a 72-hr. drug-free period, then apomorphine at 0.4 mg/kg 
sc (n=S per group}. 
b One-way ANOVA, Duncan's multiple-range test; *P <0.05 
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TABLE 28 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of 
EKC (20 mg/kg sc) and Haloperidol (1.25 mg/kg ip}a 
Stere~typy Score % Change 
iUl..:.b Treatment x ±SE from Control 
Vehicle-Vehicle 2.75 + 0.53 
Vehicle-Haloperidol 5.25 + 0.37 +91 
EKC-Vehicle 2.88 + 0.13 +5 
EKC-Haloperidol 5.13 + 0.40 +87 
a Five days simultaneous administration, haloperidol ip - EKC sc 
followed by a 72-hr. drug-free period, then apomorphine at 0.4 mg/kg 
sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test; *P <0.05 
* 
* 
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TABLE 29 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of 
Cyclazocine (2.5 mg/kg sc) and Haloperidol (1.25 mg/kg ip)a 
Stereotypy Score % Change 
~b Treatment x ± SE from Control 
Vehicle-Vehicle 2.38 + 0.26 
Vehicle-Haloperidol 5.63 + 0.18 +137 * 
Cyclazocine-Vehicle 2.63 .:t 0.38 +11 
Cyclazocine-Haloperidol 3.75 + 0.31 +58 •C 
a Five days simultaneous administration, haloperidol ip - cyclazocine sc 
followed by a 72-hr. drug-free period, then apomorphine at 0.4 mg/kg 
sc (n=8 per group). 
b One-way ANOVA, Duncan's multiple-range test; *P <0.05 
c Significantly different from vehicle-haloperidol group and vehicle-
vehicle group. 
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TABLE 30 
Apomorphine-Induced Stereotyped Behavior 
Effects of 5-Day Administration of 
SKF 10,047 (40 mg/kg sc) and Haloperidol (1.25 mg/kg ip)a 
Stereotypy Score % Change 
i!Jhb Treatment x ±SE from Control 
Vehicle-Vehicle 1.88 + 0.35 
Vehicle-Haloperidol 4.88 + 0.48 +160 * 
SKF 10,047-Vehicle 1.13 + 0.40 -40 
SKF 10,047-Haloperidol 1.88 + 0.55 0 
a Five days simultaneous administration, haloperidol ip - SKF 10,047 sc 
followed by a 72-hr. drug-free period, then apomorphine at 0.4 mg/kg 
sc (n=8 per group}. 
b One-way ANOVA, Duncan's multiple-range test; *P <0.05 
TABLE 31 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of 
Morphine and Haloperidola 
Vehicle and Morphine 
Dose 
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Treatment {mgLkg) 
Climbing Score 
x ±SE 
% Change 
Compared to Control ~b 
Vehicle-Vehicle 2.13 + 0.52 
Vehicle-Morphine 2.5 3.75 + 0.88 +76 
5.0 3.63 + 0.50 +70 
10.0 3.25 + 0.37 +53 
Haloperidol and Morphine 
Dose Climbing Score 
Treatment {mglkg) x ± SE 
% Change 
Compared to Control ~b 
Haloperidol-Vehicle 1.25 5.38 + 0.80 
Haloperidol-Morphine 2.5 5.50 + 0.38 +2 
5.0 5.38 + 0.50 0 
10.0 5.25 + 0.49 -4 
a Five days simultaneous administration, haloperidol ip - morphine sc, 
followed by a 72-hour drug-free period, then apomorphine at 0.4 mg/kg 
sc, n=8 per group. 
b One-way ANOVA, Duncan's multiple-range test 
TABLE 32 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of 
Naloxone and Haloperidola 
Vehicle and Naloxone 
Dose 
146 
Treatment 
Climbing Score S Change 
(mg/kg) x ± SE Compared to Control ~b 
Vehicle-Vehicle 2.63 .! 0.60 
Vehicle-Naloxone 5.0 2.50 .! 0.42 
10.0 2.75 + 0.80 
20.0 2.88 + 0.69 
40.0 2.25 + 0.67 
Haloperidol and Naloxone 
Dose Climbing _ Score 
Treatment {mglkg) x ± SE 
Haloperidol-Vehicle 1.25 6.13· + 0.35 
Haloperidol-Naloxone 5.0 5.50 .! 0.57 
10.0 5.88 + 0.40 
20.0 6.13 + 0.48 
40.0 5.13 + 0.52 
-5 
+5 
+10 
+14 
S Change 
Compared to Control ~b 
-10 
-4 
0 
-16 
a Five days simultaneous administration, haloperidol ip - naloxone sc, 
followed by a 72-hour drug-free period, then apomorphine at 0.4 mg/kg 
sc, n=S per group. 
b One-way ANOVA, Duncan's multiple-range test 
TABLE 33 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of 
Naltrexone and Haloperidola 
Vehicle and Naltrexone 
Dose Climbing Score i Change 
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Treatment {mg[kg} x ± SE Compared to Control lli:_b 
Vehicle-Vehicle 
Vehicle-Naltrexone 
Treatment 
Haloperidol-Vehicle 
Haloperidol-Naltrexone 
1.50 + 0.38 
2.5 1.63 + 0.32 
5.0 1.38 + 0.53 
10.0 2.13 + 0.58 
20.0 1.63 + o. 91 
40.0 2.00 .:': 0.76 
Ha 1 operi do 1 and Naltrexone 
Dose Climbing Score 
(mg[kg} x .± SE 
1.25 4.63 + 0.75 
2.5 4.13 + 0.48 
5.0 3.38 + 0.60 
10.0 2.50 + 0.63 
20.0 3.00 + 0.78 
40.0 3.50 + 0.57 
+9 
-8 
+42 
+9 
+33 
% Change 
Compared to Control lli:.b 
-11 
-27 
-46 
-35 
-24 
a Five days simultaneous administration, haloperidol ip - naltrexone sc, 
followed by a 72-hour drug-free period, then apomorphine at 0.4 mg/kg 
sc, n=8 per group. 
b One-way ANOVA, Duncan's multiple-range test 
TABLE 34 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of 
EKC and Haloperidola 
Vehicle and EKC 
Dose 
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Climbing Score % Change 
{mg£ kg) x ±SE Compared to Control ~b Treatment 
Vehicle-Vehicle 2.00 + 0.76 
Vehicle-EKC 2.5 1.13 + 0.40 -43 
5.0 1.88 .:!: o. 74 -6 
10.0 4.00 + 0.82 +100 
20.0 2.13 + 0.58 +7 
Haloperidol and EKC 
Dose Climbing Score 
Treatment {mg£ kg) x ±SE 
% Change 
Compared to Control ~b 
Haloperidol-Vehicle 1.25 4.38 + 0.57 
Ha 1 operi do 1-EKC 2.5 4.50 + 0.60 +3 
5.0 2.63 + 0.94 -40 
10.0 2.25 + 0.45 -49 
20.0 2.50 + 0.71 -43 
a Five days simultaneous administration, haloperidol ip - EKC sc, 
followed by a 72-hour drug-free period, then apomorphine at 0.4 mg/kg 
sc, n=8 per group. 
b One-way ANOVA, Duncan's multiple-range test 
TABLE 35 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of 
Pentazocine and Haloperidola 
Vehicle and Pentazocine 
I Change 
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Treatment 
Dose 
{mg/kg} 
Climbing Score 
x ± SE Compared to Control ~b 
Vehicle-Vehicle 2.13 + 0.40 
Vehicle-Pentazocine 10.0 2.13 + 0.79 0 
20.0 1.25 + 0.37 -41 
40.0 1.87 + 0.64 -12 
80.0 1.75 + 0.45 -18 
Haloperidol and Pentazocine 
Dose Climbing Score I Change 
Treatment {mg[kg} x. ±SE Compared to Control 
Haloperidol-Vehicle 1.25 5.25 + 0.62 
Haloperidol-Pentazocine 10.0 5.62 + 0.50 +7 
20.0 6.00 + 0.38 +14 
40.0 5.50 + 0.65 +5 
80.0 4.75 + 0.70 -10 
a Five days simultaneous administration, haloperidol ip - pentazocine 
sc, followed by a 72-hour drug-free period, then apomorphine at 0.4 
mg/kg sc, n=8 per group. 
b One-way ANOVA, Duncan's multiple-range test 
~b 
TABLE 36 
Climbing Mice Supersensitivity 
Chronic Simultaneous Administration of 
Cyclazocine and Haloperidola 
Vehicle and Cyclazocine 
% Change 
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Treatment 
Dose 
(mg/kg) 
Climbing Score 
x ± SE Compared to Control i!..9..:.b 
Vehicle-Vehicle 3.12 + 0.67 
Vehicle-Cyclazocine 0.38 3.12 + 0.64 0 
0.75 3.12 + 0.69 0 
1.5 3.38 + 0.73 +8 
3.0 2.63 + 0.53 -16 
Haloperidol and Cyclazocine 
Dose Climbing Score % Change 
Treatment (mg/kg) x ·±SE Compared to Control 
Haloperidol-Vehicle 1.25 5.88 + 0.48 
Haloperidol-Cyclazocine 0.38 3.63 + 0.37 -38 
0.75 3.38 + 0.80 -43 
1.5 3.00 + 0.71 -49 
3.0 3.12 .! 1.09 -47 
a Five days simultaneous administration, haloperidol ip - cyclazocine 
sc, followed by a 72-hour drug-free period, then apomorphine at 0.4 
mg/kg sc, n=8 per group. 
b One-way ANOVA, Duncan'~ multiple-range test; *P <0.05 
i!..9..:.b 
* 
* 
TABLE 37 
Climbing Hice Supersensitivity 
Chronic Simultaneous Administration of 
SKF 10,047 and Haloperidola 
Vehicle and SKF 10,047 
Dose Climbing Score % Change 
Treatment (mg/kg) i ± SE Compared to Control 
Vehicle-Vehicle 2.38 + 0.60 
Vehicle-SKF 10,047 5.0 2.50 + 0.38 +5 
10.0 1.75 + 0.62 -26 
20.0 2.75 + 0.67 +16 
40.0 2.14 + 0.80 -10 
Haloperidol and SKF 10,047 
Dose Climbing Score % Change 
Treatment {mglkgl i :t SE Compared to Control 
Haloperidol-Vehicle 1.25 5.25 + 0.70 
Haloperidol-SKF 10,047 5.0 3.50 + 0.57 -33 
10.0 3.12 + 0.69 -40 
20.0 2.38 + 0.91 -55 
40.0 1.25 + 0.37 -76 
151 
~b 
~b 
* 
* 
a Five days simultaneous administration, haloperidol ip - SKF 10,047 sc, 
followed by a 72-hour drug-free period, then apomorphine at 0.4 mg/kg 
sc, n=8 per group. 
b One-way ANOVA, Duncan's multiple-range test; *P <0.05 
TABLE 38 
The Effects of Naloxone on 
Apomorphine-lnduced Climbing Behavior 
Dose S of Climbing Score % Change 
Tredtmenta {mg/kg i p) n x ± SE Total Climbingb Potentiation of Climbingc 
Vehicle + Naloxone 0 8 0.00 + 0.00 0 
1 8 0.00 + 0.00 0 
3 8 0.00 + 0.00 0 
10 8 0.13 .! 0.13 2 
Apomorphine + Naloxone 0 8 1.50 + 0.42 25 
1 8 1.75 .! 0.37 29 +17 
3 8 2.75 .! 0.41 46 +83 
10 8 2.75 + 0.25 46 +75 
J Apomorphine (0.4 mg/kg sc) and naloxone administered simultaneously O' prior to testing. 
hi Climbing based on maximum score= 6 
. . _ x of Dose Group X 100 Z Cl1mb1ng - Max. score 
c '.l'. Change Potentiation of Climbing= (Apo.+ Nal.) - (Veh. + Nal.) x 100 
(Apo. + Veh. ) 
I-' 
CJl 
N 
TABLE 39 
The Effects of Ethylketocyclazocine on 
Apomorphine-lnduced Climbing Behavior 
S of Dose Climbing Score S Change 
Treatment a {mg/kg i~) n x ± SE Total C11mb1ngb Potent1ation of Climbingc 
Vehicle + EKC 0 8 0.00 .:!:. 0.00 0 
1 8 0.00 .:!:. 0.00 0 
3 8 2.38 + 0.92 4od 
10 8 1.63 + 0.73 27d 
Apomorphine + EKC 0 8 1.63 .:!:. 0.63 27 
1 8 2.50 .:!:. 0.68 42 +17 
3 8 2.38 + 0.26 40 0 
10 8 2.00 + 0.50 33 +23 
a EKC administered 180' prior to testing; Apomorphine (0.4 mg/kg sc) administered O' prior to testing. 
b % Climbing based on maximum score = 6 
~ Cl. b" : x of Dose Group X 100 ~ im lng Max. score 
c % Change Potentiation of Climbing = (Apo. + EKC) - (Veh. + EKC) x 100 
(Apo. + Veh.) 
d Hyperactivity rather than characteristic prolonged climbing seen after apomorphine. I-' 
U1 
w 
TABLE 40 
The Effects of SKF 10,047 on 
Apomorphine-Induced Climbing Behavior 
Dose Climbing Score % of % Change 
Treatment a {mg/kg iQ) n x ±SE Total Cli111b_1_rlgb P()~ent 1 at ion of C 1 imb i ngC 
Vehicle + SKF 10,047 0 8 0.13 + 0.13 2 
1 8 0.25 .!. 0.25 4 
3 8 0.50 + 0.27 8 
10 8 2.00 + 0.76 33d 
Apomorphine + SKF 10,047 0 8 1.50 .!. 0.42 25 
1 8 2.25 .!. 0.45 38 +33 
3 8 2.50 .!. 0.38 42 +33 
10 B 3.00 .!. 0.19 50 +67 
a SKF 10,047 administered 90' prior to testing; Apomorphine (0.4 mg/kg sc) administered O' prior 
to testing. 
b % Climbing based on maximum score = 6 
% Cl . b ' = x of Dose Group X 100 lm lng Max. score 
c % Change Potentiation of Climbing = ~ + SKF 10,047} - (Veh. + SKF 10,047) x 100 (Apo. + Veh.) 
d Prolonged climbing similar to apomorphine-induced climbing. 
...... 
<..n 
+>-
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TABLE 41 
Induction of Hyperactivity in Mice 
by Ethylketocyclazocine at 5 mg/kg sc 
Pretreat (min.) 
30 
60 
90 
120 
150 
180 
210 
240 
270 
300 
330 
360 
Hyperactivity Scorea 
i ± SE 
0.00 + 0.00 
0.00 + 0.00 
0.00 + 0.00 
0.38 + 0.26 
1.13 + 0.64 
1.88 + 0.58 
1.88 + 0.48 
0.75 + 0.53 
1.00 + 0.65 
0.88 + 0.40 
0.75 + 0.53 
0.38 + 0.38 
a Hyperactivity measured in stick cages; n=8. 
b % of hyperactivity based on maximum score = 4 
% hyperactivity = x of Pretreat Group X 100 
Max. score 
% of HyPeractivityb 
0 
0 
0 
10 
28 
47 
47 
19 
25 
22 
19 
10 
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TABLE 42 
Ethylketocyclazocine-lnduced Hyperactivity in Mice 
Dose a 
(mg/kg sc) 
Hyperactivity Scoreb ED50 
i ± SE % of Hyperact ivityc 95% Confidence Limits 
0 0.25 + 0.16 
1.25 1.88 + 0.93 28 
2.5 i.oo + a.so 13 7.1 
{6.0-8.7) mg/kg SC 
5.0 2.50 + 0.75 44 
10.0 3.25 + 0.85 57 
a 180 1 pretreat; n=8. 
b Hyperactivity measured in stick cages. 
c % of hyperactivity based on maximum score = 6. 
% hyperactivity= {x of Dose Group) - {x of Vehicle Group) x 100 (Max. score) - (x of Vehicle Group} 
TABLE 43 
Ethylketocyclazocine-Induced Hyperactivity in Micea 
Effects of Various Blocking Agents 
Dose % Change 
Com~ound {mglkg i~) Pre treat Com~ared to Controlb 
Naloxone 10.0 10' -8 
100.0 10' -17 
Haloperidol 1.0 180' -54 
Apomorphine 0.1 5' -65 
Muscimol 1.0 30' -63 
Bicucl 1 ine 1.0 30' 0 
a-MPT 300.0 4 hrs. -81 
Phentolamine 10.0 60' -47 
Prazosin 2.5 30' -97 
Yohimbine 5.0 30' 0 
Clonidine 0.025 30' -35 
Propranolol 2.5 30' +20 
PCPA 300.0 72 hrs~ -46 
Methysergide 10.0 30' +7 
Atropine 5.0 30' -5 
Reserpine 5.0 17 hrs. -74 
TBZ 5.0 60' -81 
40.0 60' -90 
a EKC at 5 mg/kg sc; 180' pretreat; Hyperactivity measured in stick 
cages. 
b Control = EKC +vehicle; range of control means for 4 separate 
experiments--3.0-3.9; maximum score = 6; n=B. 
% Change from corresponding control score. 
c One-way ANOVA, Duncan's multiple-range test; *P <0.05 
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TABLE 44 
Induction of Climbing Behavior in Mice 
by SKF 10,047 at 40 mg/kg sc 
Climbing Scorea 
Pretreat (min.) x ±SE 
30 1.38 + 0.42 
60 2.75 + 0.31 
90 2.88 + 0.48 
120 2.50 + 0.57 
150 2.38 + 0.46 
180 1.75 + 0.53 
a n=8 
b % of climbing based on maximum score = 4. 
% climbing = x of Pretreat Group x 100 
Max. score 
158 
% of Climbingb 
35 
69 
72 
63 
60 
44 
159 
TABLE 45 
SKF 10,047 -Induced Climbing in Mice 
Dose a Climbing Score 
{mg/kg sc) i ± SE % of Climbingb 
0 0.00 :. 0.00 
3 0.50 + 0.38 +8 
10 1.88 + 0.58 +31 
30 4.50 + 0. 71 +75 
a 90' pretreat; n=8. 
b % of climbing based on maximum score = 6. 
% climbing = x of Dose Group x 100 
Max. score 
ED50 
95% Confidence Limits 
14.6 
(12.8-16.8) mg/kg SC 
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TABLE 46 
SKF 10,047-Induced Cage Climbing in Hicea 
Effects of Various Blocking Agents 
Dose i Change 
Com2ound {mglkg i(!} Pre treat Com2ared to Controlb 
Naloxone 10.0 10' -8 
100.0 10' -12 
Haloperidol 1.0 180' -73 
Apomorphine 0.1 5' -64 
Muscimol 1.0 30' -89 
Bicuclline 1.0 30' -9 
a-MPT 300.0 4 hrs. -97 
Phentolamine 10.0 60' -37 
Prazosin 2.5 30' -90 
Yohimbine 5.0 30' -12 
Clonidine 0.025 30' -8 
Propranolol 2.5 30' +9 
PCPA 300.0 72 hrs. +25 
Methysergide 10.0 30' -66 
Atropine 5.0 30' +48 
Reserpine 5.0 17 hrs. -11 
TBZ 5.0 60' -75 
40.0 60' -97 
a SKF 10,047 at 40 mg/kg sc; 90' pretreat. 
b Control = SKF 10,047 + vehicle; range of control means for 4 separ3te 
experiments--3.9-5.0; maximum score = 6; n=8. 
% Change from corresponding control score. 
c One-way ANOVA, Duncan's multiple-range test; *P <0.05 
* 
* 
* 
* 
* 
* 
* 
* 
* 
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